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p53 protein is a tumour suppressor that is frequently mutated in human cancers, 
resulting in a protein with altered biochemical functions. The Interactome of the wild-
type and mutant p53 revolves around core interactions with components of the 
transcriptional machinery and/or the chaperone-assisted degradation machinery. The 
balance between these two Interactomes regulates the activity of p53. In this study 
53F270A 	R175H and wild-type (wt) p53 were used as a panel to dissect how 
oligomeric protein conformation affects p53 ubiquitination and binding of other 
proteins to p53. p53F270A  is hyperubiquitinated in cells as determined by p53-
immunoprecipitation and immunoblotting with an anti-ubiquitin antibody. Using a 
mass-spectrometric approach, eukaryotic elongation factor la (eefl a) was identified as 
binding specifically to hyperubiquitinated p53'270". In this study, using a one-strep 
tagged approach, the interactome of p53 was extended by defining stable cellular 
binding proteins to wild-type and mutant p53. The system faithfully recapitulates the 
enhanced ubiquitination pattern of the unfolded oncogenic forms of p53. Further, 
mutually exclusive binding partners were identified for wt and mutant p53: the wild-
type protein interacted predominantly with MDM2; whilst the mutant interacted 
selectively with Heat shock protein 70 (Hsp70) and the TCP-1 beta chaperonin. Upon 
analyzing the effects of stresses on the p53-interactomes, we identified a Nutlin and 17-
(Allylamino)- 1 7-demethoxy-geldanamycin (1 7-AAG)-induced binding to a novel 
spliced form of HSP90 lacking the N-terminus (HSP90AN). Ionizing radiation did not 
induce the formation of a p53: HSP90AN complex. By contrast, the oncogenic and 
hyperubiquitinated mutant p53 was constitutively bound to HSP90AN. These data 
expand on the Interactome of p53 and identify eefla and HSP90AN as novel 
components of signalling pathways that control p53 homeostasis. 
xix 
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I .0 The DNA Damage Checkpoint Cascade 
Throughout evolution, organisms have evolved a complex network of 
checkpoints that act concertedly to maintain genomic stability 1,  2 Activation of 
checkpoints by DNA damage ultimately interface with cell cycle regulators and lead to 
several downstream effects including cell cycle arrest, DNA repair, apoptosis and 
cellular senescence, thus preventing the proliferation of damaged cells - a hallmark of 
cancer. The cascade of events in checkpoint pathways requires the cooperation of 
proteins broadly characterised as sensors, transducers and effectors. (Figure 1)' 2  DNA 
lesions include single and double stranded breaks, and changes in higher order 
structures of chromatin 3 . For reasons of brevity the proteins that will be discussed in 
the following literature review are the checkpoint kinase 2 (CHK2) and p53 transducer, 
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Figure 1 1 Conceptual Organization of 
the essential components and outcomes 
of checkpoint responses.' 
Figure 1.1 adapted from Iliakis, G., et al., DNA damage checkpoint control in cells exposed to ionizing 
radiation. Oncogene, 2003. 22(37): p. 5834-47. 
1 
1.1 CHK2 tumour suppressor protein - structure related to function 
CHK2 is a 543 amino acid, nuclear serine/threonine, stable kinase that is expressed 
throughout the cell cycle . CHK2 has been conserved through eukaryotic evolution 
as a pivotal protein in checkpoint signal cascades. CHK2 is the human homologue of 
the yeast checkpoint kinases Cdsl (Schizosaccharomyces pombe) and Rad53 
(Saccharomyces cerevisiae) 
The CHK2 protein (Figure 1.2) consists of three distinct functional domains; a 
serine-glutamine (SQ)/threonine-glutamine (TQ) cluster domain (amino acid residues 
19-69); a forkhead associated domain (FT-IA amino acid residues 112-175) and a 
Ser/Thr kinase domain (amino acid residues 220-486). The SQ/TQ domain contains five 
SQ and two TQ motifs, which satisfy the primary substrate motif for ataxia-
telangiectasia mutated (ATM) which is a protein that interacts with DNA damage 
sensor proteins and acts upstream of CHK2. 
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Figure 1.211  Schematic view showing functional domains of human CHK2. SQITQ, a regulatory domain 
containing multiple (ATM/ATR)-recognition sites; FHA a forkhead associated domain required for 
CHK2 homodimerization and other protein-protein interactions. Positions of tumour associated mutations 
are indicated (top) Red boxes highlight three mutations associated associated with familial cancer; 
1 lOOdelC is the most frequent mutation found both in sporadic and familial cancer. 
Figure 1.2 Bartek J, Lukas J. ChkJ and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 
2003 May; 3(5):421-9. 
2 
1.1.1 CHK2 activation in response to DNA damage 
CHK2 is inactive in the absence of genotoxic stress but is activated in the 
presence of DNA double stranded breaks (DsBs). As depicted in Figure 1.3 activation 
of CHK2 occurs via the ATM dependent phosphorylation of CHK2 on Thr68. Following 
phosphorylation at Thr68, two CHK2 molecules dimerize at the FHA domains leading to 
trans activation of other CHK2 proteins via phosphorlyation at Thr383/Thr387. CHK2 
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Figure 1.31" Autoactivation of CHK2 is responsible for the rapid relay of the signal down the checkpoint 
signalling pathway. 
Figure 1.3 Schwarz, J.K., C. M. Lovly, and H. Piwnica-Worms, Regulation of the Chk2 protein kinase 
by oligomerization-mediated cis- and trans-phosphorylation. Mol Cancer Res, 2003. 1(8): p. 
598-609. 
1. 1.2 CHK2 propagation of signal at various stages of the cell cycle 
Activation of CHK2 leads several downstream effects such as DNA replication 
and cell cycle progression, chromatin restructuring, and apoptosis. The downstream 
targets of CHK2 include cell cycle phosphatases Cdc25C and Cdc25A 7 8 breast cancer 
1, early onset protein (BRCA1) 9 and the transcription factors E2F1 
10, 
p53 and p21 
waf/cipl II 12 Live-cell imaging of CHK2 in human cells exposed to DNA damage 
revealed immediate redistribution of the activated CHK2 throughout the nucleus 
supporting the role of CHK2 as a checkpoint signal amplifier 5 . Figure 1.4 illustrates the 
checkpoint signalling pathway in the G1-phase of the cell cycle. In this phase key 
regulatory steps determine whether a cell will progress into G/S. These regulatory steps 
fall under the control of two key kinases, cyclin dependent kinase 4 (Cdk4) and cyclin 
dependent kinase 2 (Cdk2), in association with Cyclin D and cyclin E. 
DNA Da age 
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SOII 
~~M DM 2 	11 
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Activation 	 Degradation 
Progression in phase 
Figure. 	1.4w 	GI- 
checkpoint signalling 
cascade 
Figure 1.4: adapted from: Iliakis, G., et al., DNA damage checkpoint control in cells exposed to ionizing 
radiation. Oncogene, 2003. 22(37): p. 5834-47. 
11  
These proteins phosphorylate target proteins, such as CDC45 that ultimately lead to the 
progression into the S-phase of the cell cycle. Cyclin E-Cdk2 is therefore a regulator of 
cell cycle progression into the S-phase and is an important target of two distinct 
checkpoint cascade processes. The first, prompt pathway is the ubiquitinlproteasome 
mediated degradation of CDC25A which maintains Cyclin E-CDK2 locked in the 
inactive state. This is occurs through phosphorylation of CDC25A at Ser'23 by CHK2 
and checkpoint kinase 1 (CHK1). Once CDC25A is inactivated, Cyclin E-CDK2 cannot 
be activated since the former protein cannot remove inhibitory phosphates positioned at 
'4 and Tyr 15. 2 Thr 	 The second, delayed pathway, involves the stabilisation and activation 
of the transcription factor p53. This leads to the transcription of a large number of 
genes. P21 waf/cipl  is one of the genes to be transcribed, and this protein inhibits Cyclin E-
CDK2. In nonirradiated cells, p53 is kept at low levels via the interaction with murine 
double minute 2 (MDM2) which through a negative feedback loop targets p53 for 
ubiquitination and proteasome mediated degradation. The MDM2 oncoprotein is a 
RING (really interesting new gene)-finger-type ubiquitin ligase that ubiquitinates both 
itself and p53, through its binding to the N-terminus of p53 leading to the ubiquitination 
of the latter (cf Sections 1.5). 1  Following DNA damage, phosphorylation of p53 at 
5cr'5 by ATM and ATM and RAD3 -related kinase (ATR), and Scr2° by a broad range of 
calcium calmodulin kinase superfamily members, including CHK2, CHK1, Death 
Associated protein kinase-1 (DAPK-1), death associated protein kinase-3 (DAPK-3), 
DAPK-related-kinase-1 (DRAK-1), and 5'AMP-activated protein kinase (AMPK), leads 
13 to the disruption of the p53-MDM2 interaction 
Although most of the cells in an adult organism are in the GI phase, damage to DNA in 
the S-phase leads to the severe genomic abnormalities if not properly dealt with 
2 
5 
Indeed, radio-resistant DNA synthesis is a phenotypic feature of cells derived from 
patients with ataxia-telangiectasia (AT), AT-like disorder and Nijmegen breakage 
syndrome 1 . Two main pathways operate as checkpoint cascades in the S-phase. The 
first, the ATM-CHK2-CDC25A path, and operates in the same fashion as described in 
the G1-checkpoint. The other pathway involves the MRE11-RAD50-NBS-1 complex. 
ATM phosphorylates NBS1 on Ser343 resulting in the activation of the intra-S 
checkpoint. The protein structural maintenance of chromosomes-i (SMC 1) is also 
phosphorylated by ATM in an NBS-dependent manner and this leads to the activation 
of the intra-S checkpoint. 
The key target protein in the G2/M checkpoint cascade is the Cdc2 kinase. 
Together with its partner cyclin B this protein promotes the progression of the cell into 
mitosis. Analogous to the regulation of the Cyclin E-CDK2 in the GI phase the 
inhibitory phosphates are present on Tyr 15  and Thr'4. These phosphates are added by 
Wee  (Tyr '5)and MYT1 (Thr'4) 14 15 16 In a manner similar to the checkpoint in the GI 
phase, ATM phosphorylates CHK2 at Thr68, which in turn blocks CDC25C by 
phosphorylation at Ser216. CDC25C is responsible for the removal of the inhibitory 
phosphates on CDC2-cyclin B. Once CDC25C is phosphorylated it interacts with the 
14-3-3 protein resulting in sequestration to the cytoplasm, loss of activity in the nucleus 
and halt in the cell cycle. 
n. 
1.2 p53 structure and function 
The p53 tumour suppressor gene encodes a 393-amino acid, DNA binding, 
nuclear phosphoprotein which functions as a transcription factor that is activated in 
response to genotoxic and non-genotoxic cellular stress. Examples of cellular stresses 
that lead to p53 activation include agents that create single or double-strand breaks in 
DNA (y - or UV radiations, free radical damage, inhibitors of topoisomerases), 
mutagens that form bulky DNA adducts (aflatoxins, benzo(a)pyrene, alkylating agents) 
or agents that block elongation by RNA polymerases. In addition, damage to the mitotic 
spindle, ribonucleotide depletion, hypoxia, heat shock and exposure to nitric oxide can 
also induce p53. Induction follows a different time-course, depending upon the nature 
and intensity of the stress 17, 18,  19 20 
p53 is a modular protein (Figure 1.5) with five functional domains, namely an 
N-terminal transactivation domain (TAD), a poly-proline conformational element 
domain (PRD), a core sequence-specific DNA-binding domain, a tetramerisation 




Figure 1.5 Schematic view showing functional domains of p53 and binding sites of regulatory proteins 
p300, MDM2 and CHK2 
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1.2.1 p53 N-terminus 
The TAD is a classical acidic activation domain, which is known to be potent at 
activating transcription and allows the recruitment of the basal transcription machinery 
including the TATA binding protein (TBP) and the TBP-associated factor 1131 
(TAFII31) components of TFIID 22  The N-terminal conserved BOX-I domain (amino 
acid residues 13-23) of p53 found within the TAD encompasses approximately 15 
amino acids and has evolved as a multiprotein binding domain, resulting in an 
interaction with a set of acetyltransferases, ubiquitin ligases and protein kinases 
13  The 
BOX-I domain contains the LXXLL-motif (where X is any amino acid), transactivation 
domain and provides a binding site for other regulatory proteins, including the 
transcriptional co-activators, p300 and its homolog CREB binding protein (CBP) 
23,  24,  
as well as components of the DNA repair machinery, including subunit p62 of the dual 
function transcription/repair factor TFIIH 25 26 The BOX-I domain also contains the 
FXXWXXXL consensus binding site that is required for MDM2-mediated inhibition of 
p53 and will be further discussed in Section 1.5. 
The PRD of p53 (amino acid residues 63-97) contains five evolutionary 
conserved PxxP motifs (where x is any amino acid) 27 Phosphorylation within the 
BOX-I at ser15 and ser20 and the adjacent Thr'8 enables binding of the prolyl isomerase 
Pll'.l to induce cis-trans prolyl isomerizations within the PRD. This leads to 
stabilization of p300 docking and promotes DNA-dependent acetylation of p53 
28  it is 
important to note that phosphorylation at Thr'8 has the most striking effect on blocking 
MDM2 binding 29  while phosphorylation at Ser20 has no effect on MDM2 binding 
30 
8 
1.2.2 p53 core DNA-binding-domain 
The core DNA-binding-domain (DBD) of p53 (amino acid residues 102-292) is 
responsible for the binding of p53 to specific gene promoters. The arrangement of the 
promoter sequence suggests that p53 binds DNA as a tetramer 
31  X-ray crystallography 
of the p53 DBD in complex with consensus DNA solved at 2.2 A demonstrated that the 
DBD consists of three molecules contained in an asymmetric unit that acts as a scaffold 
for three-loop based elements. One of the three core domains is bound to a DNA 
consensus site, the second to a non-consensus region of DNA, and the third molecule 
makes no significant contact with DNA, thus representing a DNA-free state of the 
coredomain. The main structural feature of the core domain is an immunoglobulin-like 
central 13-sandwich of two antiparallel 13-sheets, which provides the basic scaffold for 
the DNA-binding surface (Figure 1.6). This surface is formed by two large loops (L2 
comprising residues 164-194, which is interrupted by a short helix, and L3 comprising 
residues 237-250) that are stabilized by a zinc ion, and a loop—sheet—helix motif (loop 
Li, 13-strands S2 and S20, the end of the extended 13-strand SlO, and the C-terminal 
helix H2) 32, 	Loops Li, L2 and L3 correspond to the most highly evolutionary 
conserved domains, being encoded by the sequences BOX II-V, thereby highlighting 
their importance in p53 function. 
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Figure 1.6" Ribbon diagram of the structure of DNA-bound p53 core domain 
1.2.3 p53 C-terminus 
The C-terminus of p53 (amino acid residues 300-393) consists of a tetramerisation 
domain (amino acid residues 323-356) and a basic regulatory domain (amino acid 
residues 360-393) which are connected by a flexible linker (amino acid residues 300- 
318) 	The crystal structure of the tetramerisation domain resolved at 1.7 A revealed a 
highly symmetrical structure composed of a dimer with each monomer composed of a 
turn, a f3-strand, a second turn and an a-helix. The monomers interact with each other 
across an antiparallel 13-sheet and an antiparallel helix-helix interface to form the dimer. 
Two of these dimers associate across a second and distinct parallel helix-helix interface 
to form the tetramer 34 
Figure 1.6 Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer 
mutants. Oncogene. 2007 Apr 2;26(15):2226-42. 
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The basic regulatory domain controls the active/inactive state of p53 by allosteric 
regulation of the DNA binding domain. The C-terminal region interacts with the core 
domain to induce a conformational shift that prevents DNA binding 
35 36, and this can 
be regulated by post-translation modification of the C-terminus, such as 
phosphorylation, or binding to regulators, such as 14-3-3 proteins 	The C-terminus 
exclusively binds non-specifically to ssDNA, RNA and DNA mismatches 
38 39 as well 
as to reannealing ssDNA and RNA complementary strands 
40, 41 
The C-terminus of p53 also hase three nuclear localization signals (NLS), which have 
been mapped to amino acid residues 316-325, 369-375 and 379-384 and have been 
termed NLS1, NLS2 and NLS3 respectively 42 . Interestingly, a nuclear export signal 
(NES) (amino acid residues 340-351) cooperates with the p53 N-terminal NES for p53 
nuclear export '. 
1.3 p53 mutations 
"The history of p53 is a chaotic voyage from the world of oncogenes to the world of 
tumour suppressor genes, while retaining a certain degree of individuality (Lane and 
Benchimol, 1990). Apart from artefactual problems related to involuntary cloning of 
mutant p53, this ambiguity is also due to our propensity to over categorize in order to 
satisfy our Cartesian and oversimplistic view of science." 
- T Soussi p53 alterations in human cancer: more questions than answers Oncogene 
(2007)26,2145-2156 
It is important to stress that wild-type p53 cannot be pigeon holed into a single 
category of tumour suppressor gene and concomitantly, mutant p53 should be 
considered in context with its interacting proteins namely the 'mutant p53 
megacomplex'. The properties of the 'mutant p53 megacomplex' are defined by the 
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heterogenous loss of activity, dominant-negative activity (antimorphic) and gain of 
function (GOF) (neomorphic) '. Almost 80% of p53 gene mutations are missense 
mutations resulting in the synthesis of a stable protein lacking specific DNA-binding 
activity and accumulating in the nucleus of tumour cells 	The observation of high 
incidence of missense mutations in the p53 gene strongly supports the view of the 
oncogenic activity of mutant p53 in malignant transformation since selection of 
missense mutation hotspots could have two consequences. Firstly, a dominant negative 
45 
effect by heteroligomerization with wild-type p53 expressed in the second allele 	and 
secondly, a specific GOF of mutant p53 46  In the latter scenario, some mutants are 
capable of transactivating target genes such as MDR1, EGFR, c-MYC, PCNA, IGF-II 
or VEGF which are not transactivated by the wild-type p53 protein and the resultant 
GOF properties are associated with growth-promoting phenotypes as well as resistance 
to anti-cancer drugs '. Interestingly, in a recent work by Di-Agostino and co-workers 
has shown that mutant p53 physically interacts with the transcription factor NF-Y, 
whose DNA-binding consensus sequences are present in the regulatory regions of many 
key genes involved in the regulation of the cell cycle such as cyclin A, cyclin Bi, Cdkl 
and Cdc25C 48  
Somatic p53 mutations have been described in all types of cancers with a 
variable prevalence depending on the type of cancer 
20 
p53  is mutated in 75% of 
invasive cancers of the mouth, oesophagus and bronchi, particularly in smokers who are 
exposed to mutagens, and the mutation is often detectable in early, pre-neoplastic 
lesions. In colon and other lower-digestive tract cancers p53 mutations are less common 
in at early stages (polyps or adenomas) but become highly prevalent at the adenoma-
carcinoma transition. In breast cancers, mutations are detected in about 25% of the 
12 
cases, but it has been suggested that inactivation of p53 may occur by other mechanisms 
in a proportion of the cases. Cancers in which p53 mutations are infrequent include 
cancers of the cervix, testicular cancers, neuroblastoma and malignant melanomas, in 
which the overall p53 mutation prevalence is less than 5% 
20  In the latter types of 
cancers, the p53 pathway may be functionally inactivated by viral or cellular oncogenes. 
For example, in cervical cancers, the viral antigen E6 of the oncogenic types of Human 
Papilloma Virus binds to the wild-type p53 protein and induces its rapid degradation, 
thus effectively bypassing the need of an inactivating mutation to remove p53 protein 
function 49 
80% of the missense mutations of p53 are located within the DNA-binding 
domain (DBD). The N-terminus and C-terminus of p53 are rarely targeted by mutations 
(less than 2% of all mutations) 20  The spectrum of p53 mutation can be explained by 
the observation that the DBD, which is encoded by 600 nucleotides, is very fragile and 
each residue in this region has been found to have been the target of at least one 
mutation in cancer 	However, 30% of the mutations fall at five hot spot codons (175, 
245, 248 273 and 282). Four of these residues correspond to arginine residues (175, 
245, 248, 273, and 282) and are involved in protein-DNA interactions, either by direct 
contact with DNA (residues 248 and 273) or by stabilization of the DNA-binding 
surface (residues 175 and 282) 32• 
13 
1.4 The Ubiquitin/Proteasome pathway 
In the 1980's, pioneering work by Hershko and co-workers found that energy, in 
the form of ATP, is needed to modify proteolytic substrates with ubiquitin, a highly 
conserved 76 amino acid polypeptide that is joined to a substrate lysine side chain 
through an isopeptide bond to ubiquitin' s C terminus 50, 	Ubiquitination occurs 
through sequential steps catalyzed by activating (El), conjugating (E2), and ligase (E3) 
enzymes (Figure 1.7) 52  . El activates ubiquitin by using ATP to synthesize ubiquitin C-
terminal adenylate, which then serves as an enzyme bound substrate for the formation of 
an El-ubiquitin thiol ester 53 . The latter ubiquitin is passed to an E2 cysteine residue and 
from there, in an E3-dependent manner, to the substrate 52 
A 
B 0 	 CI 






Figure 1.7' Components and mechanisms in the ubiquitin proteasome pathway (A) Overview of pathway 
showing how ATP is used in its conjugative (top) and degradative (bottom) phases. (B) El calysed 
reaction. Step 1, ubiquitin adenylate formation; Step 2 second round of adenylate formation to yield fully 
loaded enzyme. (C) Ubiquitin conjugation cascade involving El, E2 and E3 enzymes. 
VI  Figure 1.7 Pickart CM. Back to the future with ubiquitin. Nat Struct Mol Biol. 2007 Oct;14(10):885-
887. 
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E3 ligases fall into two groups: those that utilize a covalent mechanism, namely 
Homologous to E6AP C-Terminus-domain (HECT-domain-E3s) and those that do not, 
including but not exclusively RING-domain-E3s. The mammalian RING-domain family 
is very large and it is likely that a substantial fraction of its members are E3s. Some 
consist of just one subunit 	whereas others are multiprotein complexes in which each 
subunit is a member of a distinct protein family, with the RING subunit acting to recruit 
the E2 55 . RING domain E3s act as bridging factors that bring the E2 enzyme with its 
activated ubiquitin into the vicinity of the substrate. It is however unclear how RING 
E3s bring about the exact structural placement of reactants, given the tens of angstroms 
that are inferred to separate the bound E2 and substrate molecules based on data derived 
from X-ray crystallography 56,  57 
Following polyubiquitination of the proteolytic substrate, the 26S proteasome, a 
2.5 MDa complex, uses energy derived from ATP hydrolysis to unfold the substrate 
polypeptide chain and translocate it into an interior chamber 
58  Once inside this 
chamber, the substrate is hydrolysed by a nucleophilic mechanism to produce small 
peptides. Ubiquitin is recycled by release from the substrate prior to degradation by 
deubiquitinating enzymes 51  . The 26S proteasome (Figure 1.8) is made up of the 20S 
core particle (CP) and the 19S regulatory particle (RP). The core particle contains the 
proteases that can be degrade proteins to small peptides. It consists of 28 subunits - 14 
a. and 14 f3 proteins which form 4 stacked rings of 7 subunits each 2 a. rings and 2 3 
rings. The rings sandwich the 13  rings to form a cylindrical structure. In this way a 
central channel is formed with three chambers: two antechambers on either side of a 
central chamber. This central chamber is lined with at least three active sites whose 
combined specificities can hydrolyse almost all peptide bonds. Access to these active 
15 
sites is controlled by the a subunits which form the antechambers and can exhibit closed 
or open conformations. The protein to be degraded passes through this pore and the 
proteases degrade it to 6-9 amino-acid peptide products which are released and recycled 
Figure 1.8 Schematic view of 26S proteasome 
1.4.1 Proteasome inhibitors 
Ever since the discovery of the proteasome as a key player in protein turnover, 
several studies have been undertaken involving the use of small molecular inhibitors. 
These fall under the catagories of Peptide Aldehydes, Lactacystin, Peptide 
Epoxyketones, Cyclic Peptides, Peptide Boronates, Peptide Vinyl Sulfones (VS). For 
reasons of brevity, only the inhibitors used in this study shall be discussed, namely, 
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MG132 
MG132 (Z-Leu-Leu-Leu-Al) and AdaAhx3Leu3VS that belong to the Peptide 
Aldehydes and Peptide VS categories respectively. MG132 is one of the standard tools 
used to modulate proteasome activity. The inhibitor's aldehyde moiety presumably 
forms a hemiacetal linkage with a catalytic threonine residue. Although this linkage is 
covalent, it can be hydrolysed under physiological making MG132 reversible, 
competitive inhibitors. A major drawback of MG132 is its propensity to cross-react with 
other proteolytic activities, primarily cysteine proteases 	AdaAhx3Leu3VS is an 
irreversible proteasome inibitor that covalently modifies the catalytic subunits through 
Michael reaction of the threonine hydroxyl with the VS moiety, resulting in the 
formation of a physiologically stable 3-sulfonyl ether linkage 
60  The nature of the 
peptide portion attached to the electrophylic trap, directs most of the activity of 
AdaAhx3Leu3VS towards the proteasome rather than cysteine proteasome inhibitors, 




Figure 1.9 Structures of 26S proteasome inhibitors MG 132 and AdaAhx3Leu3VS 
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1.5 The p53:MDM2 interaction 
Following the discovery of the MDM2 gene, compelling evidence has emerged 
that MDM2 has a physiological role in controlling p53. MDM2-null mouse embryos die 
after early implantation but are fully rescued if they are co-deficient for p53. 
61  
Principally, MDM2 is an E3 ligase and promotes degradation through a ubiquitin-
dependent pathway on nuclear and cytoplasmic 26 proteasomes. 
62  The ability of 
MDM2 to inactivate p53 relies on a direct interaction between the two proteins. The N-
terminal portion of MDM2 contains the p53-binding domain. MDM2 also contains a 
central acidic region capable of interaction with ribosomal protein L5 
63  as well as the 
ARF tumour suppressor protein. MDM2 contains a C-terminal ring finger domain and a 
zinc finger located downstream of the acidic region. There are also structural 
requirements for the p53 protein for MDM2-dependent p53 degradation. Deletion 
analysis has established that the last 30 amino acid residues of p53 are important for 
MDM2-dependent degradation. 64  Lysines within the C-terminal part of p53 might 
therefore be targets for modification by ubiquitination. Mutation of 6 lysine residues 
within the C-terminus of p53 to arginine (at amino acid residues 370, 372, 373, 381, 382 
and 386) termed 6 KR, was found to confer increased resistance of the mutant p53 
protein to MDM2-mediated degradation. Nonetheless significant residual MDM2-
dependent ubiquitination of the 6KR mutant was observable both in vitro and in vivo. 
65 
Another structural requirement for optimal p53 ubiquitination relates to p53 
oligomerization. Amino acids 333-353 in the tetramerisation domain are crucial for 
Mdm2 binding and Mdm2-dependent degradation. 66 The hydrophobic side of the 
amphipatic p53 a-helix, which is formed by amino acid residues 19-26 (with Phe19, 
Trp23 and Leu26  making contact), fits deeply into the hydrophobic cleft of MDM2. The 
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MDM2 cleft is formed by the amino acid residues 26-108 and consists of two 
structurally similar portions that fold up into a deep groove lined by 14 hydrophobic and 
aromatic residues. (Figure 7) 
Figure 1.l0. MDM2 cleft containing the p53 peptide sequence represented in yellow. 
Apart from the p53 N-terminal binding site for MDM2, the latter also binds a 
secondary conformationally flexible loop within the Si 0 n-sheet in the central DNA-
binding BOX-V domain of p53. The BOX-V region has therefore been defined as a key 
ubiquitination signal for MDM2, which is driven by a dual-site docking mechanism by 
MDM2 on the p53 tetramer 67  The interaction between the N-termini of p53 and 
MDM2 seems to promote a conformational change in MDM2. This stabilizes the 
interaction between the MDM2 acid-domain and the ubiquitination signal located in the 
above mentioned secondary site within the DNA binding domain of the p53 tetramer 
resulting in enhanced ubiquitination 68  These studies thereby highlight the importance 
of p53 conformational status in MDM2-dependent ubiquitination. Interestingly, the 
BOX-V domain of p53 forms a docking site for the calmodulin kinase superfamily 
VU 
 Figure 1.10 Kussie, P.H., et al., Structure of the MDM2 oncoprotein bound to the p53 tumor 
suppressor transactivation domain. Science, 1996. 274(5289): p. 948-53. 
Wei 
which include CHK2, CHK 1, DAPK- 1, DAPK-3, DRAK- 1, and AMPK. It therefore 
appears that the BOX-V interface is a conformationally flexible multiprotein binding 
domain with a potential for cross-talk through competition for the same BOX-V 
interface: CHK1/DAPK-1 and MDM2 resulting in p53 activation and degradation 
respectively 13 
1.5.1 The MDM2-ARF and MDM2-L5-L1 1-L23 ribosomal complex interaction 
The p1 4ARF (ARF) protein is the alternate product of the [NK4A tumour 
suppressor locus. ARF binds to the ring finger domain of MDM2, which houses the E3 
ligase activity thereby acting as a direct inhibitor of the E3 activity of MDM2 69  Studies 
suggest that ARF binds to MDM2 and sequesters it into the nucleolus, away from p53 
that remains in the nucleoplasm 70 71 
A recent study 72  suggests that overexpressed ribosomal proteins L5, Li 1 and L23 can 
inhibit MDM2 function and activate p53. In response to ribosomal biogenesis stress by 
actinomycin D, the same authors suggest that these ribosomal proteins can also form a 
quaternary complex with MDM2, probably working in concert to negate the MDM2 
feedback regulation of p53. The finding that the quadruple complex is markedly 
reduced in the presence of p53 suggests that these ribosomal proteins may compete with 
p53 for binding to MDM2 (Figure 8). Since all three ribosomal proteins can inhibit 
MDM2-mediated ubiquitination, it is likely that they execute inhibitory effects by 
sterically hindering the transfer of the ubiquitin moiety from E2 to p53 - in other words 
blocking the E3 ligase activity of MDM2. 
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Figure 1.1 1" .Inhibition of E3 ligase activity of MDM2 by quadruplex formation of ribosomal proteins 
L5, L  I and L23 with MDM2 
1. 5.2 SUMO protein modification of p53 
SUMO (small ubiquitin-related modifier) family proteins are structurally and 
mechanistically related to ubiquitin in that they are posttranslationally attached to other 
proteins. Like ubiquitin, SUMO is covalently linked to its substrates via amide 
(isopeptide) bonds formed between its C-terminal glycine residue and the i.--amino 
group of internal lysine residues. The enzymes involved in the reversible conjugation of 
SUMO are analagous to those mediating the ubiquitin conjugation. 73  In contrast to 
most ubiquitination functions, sumolation appears to affect the ability of the modified 
protein to interact with other cellular components. 
Modification of proteins by SUMO-1 requires the activity of the SUMO-activating 
enzyme El and the SUMO-conjugating enzyme hUbc9. M.Gotissa and co-workers 
74 
have shown that p53 transcriptional activity is enhanced by SUMO-1 or hUbc9 
overexpression, indicating that both factors are rate limiting in the conjugation process. 
Viii Figure 1.11 Dai, M.S. and H. Lu, Inhibition of MDM2-mediated p53 ubiquitination and degradation 
by ribosomal protein L5. J Biol Chem, 2004. 279(43): P.  44475-82. 
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Indeed co-expression of SUMO-1 and hUbc9 increases the amount of sumolated p53. A 
potential outcome of the sumolation of p53 might be the direct alteration of the growth-
suppressive properties of p53. This outcome might arise via several mechanisms 
including allosteric regulation, interference with the ubiquitinlproteasome-mediated 
degradation, and changes in subcellular distribution. 
1. 5.3 NEDD8 conjugation of p53 via MDM2 
Among the ubiquitin-like family, NEDD8 is most homologous to ubiquitin. 
NEDD8 like SUMO and ubiquitin, is transferred to substrates by El and E2 enzymes. 
Unlike the ubiquitin El enzyme, which is a single polypeptide, the NEDD8 El enzyme 
is a heterodimer composed of the amyloid precursor protein binding protein (APP-BP 1) 
and Uba3 protein. The E2 conjugating enzyme for NEDD8 is the Ube-12 E2-like 
protein 	Recently Xirodimas and co-workers 77 demonstrated that the MDM2 RING 
finger E3-ubiquitin ligase is NEDDylated and promotes conjugation of NEDD8 to p53. 
The critical Cys462 in the ring finger domain of the protein, which is required for the E3 
ubiquitin ligase activity of MDM2, is also required for MDM2-dependent 
NEDDylation. The same authors indicate that three lysine residues at the C-terminus of 
p53 are required for MDM2-mediated NEDDylation, namely 1ys370, 1ys372 and 1ys373. 
Mutation of these three lysines resulted in an increased transcriptional activity 
compared to wild—type p53 in H1299 cells, suggesting that NEDDylation of p53 
inhibits its function. 
MDM2 can therefore be envisaged as a gatekeeper protein with independent regulation 
of ubiquitin and NEDD8 mediated conjugation of p53. 
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1.6 Molecular Chaperones 
The finding that up to 30% of newly synthesised proteins never reach their 
native state (termed defective ribosomal products, DRiPs 
78)  highlights the importance 
of the relationship between the three-dimentional structure of proteins and biological 
activity. Maintaining the three-dimensional, native structure is a delicate process that is 
under constant threat of unfolding as a consequence of chemical equilibrium and 
cellular stress . Misfolded proteins have a tendency to form aggregates thus posing a 
major threat to cell function and viability due to non-specific protein:protein 
interactions. Organisms have therefore evolved systems that actively maintain and 
control protein structure, and involve both molecular chaperones and energy-dependent 
degradation 80  Molecular chaperones are defined by their ability to bind non-native 
proteins. These specialized proteins have evolved to participate in the folding of newly 
translated and damaged polypeptides, in the transport of proteins across cellular 
membranes and in the assembly of protein complexes 
81,  82,  83 These folding events are 
regulated by interactions between chaperones and ancillary proteins, the co-chaperones, 
which in general assist in cycling unfolded substrate proteins on and off the active 
chaperone complex 84 85 Signalling proteins and apoptosis regulators are among the 
most important substrates of molecular chaperones 
86 87 Another important feature of 
chaperones that has been recently discovered revolves around their active participation 
in protein degradation 88 89 an activity that, once again, depends on the ability of 
chaperones to selectively associate with non-native proteins. The ability of molecular 
chaperones to direct the substrate to a folding pathway or to the degradation machinery 
(e.g. by the ubiquitin-proteasome system) has been termed 'The Protein Triage 
Hypothesis'90. In agreement with their essential functions, chaperones are ubiquitously 
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expressed in high abundance and are found in all cellular compartments of the 
eukaryotic cells (except for peroxisomes). Moreover, cells induce chaperone 
concentration as a response to diverse stresses, when proteins when proteins require 
protection and stabilization [ii]. It is, therefore, not surprise that many chaperones are 
heat shock proteins (Hsps). There are four families of cytoplasmic chaperones, namely, 
the Hsp70s, the Hsp90s, the small heat shock proteins and the chaperonins. 
1.6.1 The Hsp7O family 
Members of this family are highly conserved throughout the prokaryotic and 
eukaryotic phylogeny and are typically in the range of 70 kDa in size. The I-Isp70 
proteins bind to misfolded proteins during translation or after stress-mediated protein 
damage 91  The Hsp70s contain three functional domains, namely an amino-terminal 
ATPase domain, a central peptide-binding cleft and a carboxyl terminus that seems to 
form a lid over the peptide-binding cleft 92,  (Figure 1.12). Hsp70s recognize short 
segments of the protein substrate, which are composed of clusters of hydrophobic amino 
acids flanked by basic residues which are frequently found in exposed sequences of 
non-native proteins 	Hsp70 proteins apparently prevent protein aggregation and 
promote proper folding by shielding hydrophobic segments of the protein substrate 
which are recognized by the central peptide-binding (CPB) domain of Hsp70 proteins. 
An X-ray crystallographic approach of the CPB of a bacterial Hsp70 revealed a 
structure composed of two 13-sheets that together with connecting loops form a cleft to 
accommodate extended peptides of about seven amino acids in length 	The adjacent 
C-terminal domain of Hsp70 folds back over the 13-sandwich, suggesting that the 
domain may function as a lid in permitting entry and release of protein substrates 
4 . 
Im 
ATP binding and hydrolysis by the amino-terminal ATPase domain of Hsp70 induce 
conformational changes of the carboxyl-terminus, which lead to lid opening and closure 
which ultimately, allows stable holding of the protein substrate 92  Co-chaperones of the 
Hsp40 family stimulate ATP hydrolysis, thereby promoting substrate binding whereas 
the carboxyl terminus of Hsp70-interacting protein (CHIP) attenuates ATP hydrolysis 
thereby inhibiting substrate binding 95. Also, nucleotide exchange on Hsp70 is under the 
control of co-chaperones Hip, which slows down nucleotide exchange 96  and Bcl-2- 
97 98 associated athanogene 1 (BAG- 1), which assists substrate unloading from Hsp70 
	
Hsp4O 	CHIP 




BAG proteins 	Hip 
Figure 1.12 Schematic view of the Hsp70 chaperone cycle. ATP = ATPase domain, P = Peptide binding 
domain, C = carboxy-terminal domain 
1. 6.2 The Hsp90 family 
The members of this family are typically in the 90 kDa range and exhibit several 
features in common with Hsp70 chaperones in that both possess ATPase activity and 
are regulated by cycling of ATP binding and hydrolysis, and both are further regulated 
by ancillary co-chaperones. In contrast to Hsp70, however, Hsp90 is not generally 
involved in the folding of nascent polypeptide chains, but plays a key role in the 
regulation of signal transduction networks. Hsp90 binds to substrates at a late stage in 
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the folding pathway, and aids the activation of the latter prior to ligand binding or 
associations with other factors. In fact, Hsp90 accepts non-native, but partially folded 
conformations from Hsp70 for further processing '. A chaperone-binding motif found 
in several Hsp70 and Hsp90 cofactors is characterized by a tandem arrangement of three 
degenerate 34 amino acid repeats (tetratricopeptide repeats, TPRs) 85  The transfer of the 
substrate from Hsp70 to Hsp90 requires the Hsp70/Hsp9O organizing protein (Hop), 
which possesses multiple, non-overlapping TPR domains for Hsp70 and Hsp90 thereby 
acting as a coupling factor between the two chaperones during the regulation of signal 
transduction pathways 85 99 100 In each domain, three tandem TPRs align with an 
adjacent a-helix to form a groove that accommodates conserved peptide motifs present 
at the C-terminus of Hsp70 and Hsp90 101 . Similar to Hsp70, CHIP binds Hsp90 
preventing the cooperation of the chaperone with other cofactors required for productive 
chaperone function 102  Other interactors that regulate Hsp90 function include p23 and 
different cyclophillins [iii]. Since Hsp90 substrate proteins are involved in regulating 
cell proliferation and cell death, significant research is currently been undertaken to 
inhibit the Hsp90 chaperone function therapeutically. 
1. 6.3 Chaperonins 
The chaperonins are defined by a barrel-shaped, double-ring structure 
84 92 
Members of this family include bacterial GroEL, mitochondrial and chloroplast Hsp60, 
and the Tri-CCT complex localized in the eukaryotic cytoplasm. A central cavity is 
formed in the ring-structure, where non-native proteins are contained via hydrophobic 
interactions. Conformational changes of the chaperonin subunits, induced through ATP 
hydrolysis, change the inner lining of the cavity from a hydrophobic to a hydrophilic 
061 
nature 103, 104,  105 , resulting in the release of the unfolded protein into the central cavity 
were folding proceeds in protected environment 106 
Figure 1 .I3" Sliced chaperonin complex from Escherichia coli. Misfolded proteins are refolded inside the 
cavity formed by this 21 protein complex. The blue and yellow rings (GroEL) each consist of 7 copies of 
the same protein, while the red cap (GroES) is composed of 7 copies of a different protein. The two rings 
of GroEL exhibit different conformations 
1. 6.4 CHIP - a key factor in protein triage 
Ballinger and co-workers initially identified CHIP by screening human TPR-
containing proteins. The N-terminus of CHIP contains three TPRs which, together with 
an adjacent, highly charged ct-helix, form an adaptor for Hsp70 or Hsp90 chaperones . 
Furthermore, the C terminus of CHIP contains a U-box that confers E3 ligase activity. 
Therefore, the modular structure of CHIP may thus enable the cofactor to link molecular 
chaperones directly to the degradation machinery. In support of this concept, CHIP was 
IX  Figure 1 .13 http://www.rbvi.ucsf.edu/chimera/lmageGallery/entries/1aon/ 1 aon.html 
27 
recently shown to promote the degradation of chaperone substrates by the 
ubiquitinlproteasome system. Among these substrates are glucocorticoid hormone 
receptor (GR) 102,  cystic fibrosis transmembrane conductance regulator (CFTR) 107  and 
p53 
108 109 
Since CHIP associates with molecular chaperones, the latter can therefore be seen as an 
integral part of the ubiquitin ligase complex. Through its ability to recognize non-native 
proteins and specific client proteins, the chaperone apparently selects substrates for 
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Figure 1. 14x Schematic view of protein triage. Molecular chaperones Hsp70/Hsp9O interact with either 
ancillary co-chaperones for the folding of the substrate or CHIP for degradation of mislfolded proteins 
via the 26S proteasome 
X  Hohfeld J, Cyr DM, Patterson C. From the cradle to the grave: molecular chaperones that may choose 
between folding and degradation. EMIBO Rep. 2001 Oct;2( 10): 885-90. 
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1.7 Mass Spectrometry 
Mass spectrometry (MS) is an analytical technique used to measure the mass of 
individual molecules and atoms expressed as their mass-charge (m/z) ratio. All mass 
spectrometers consist of three basic parts: an ion source, a mass analyzer, and a detector 
system. The first essential step in MS analysis, which occurs in the ion source, is the 
conversion of the neutral analyte molecules into gas-phase ionic species, for 
downstream manipulation and detection. Furthermore, the excess energy during the 
ionization event leads to fragmentation of small molecules which provides additional 
structural information. The mass analyzer separates these molecular ions and their 
charged fragments according to their mlz ratio. Finally, the ion current due to these 
mass-separated ions is detected by a suitable detector and displayed in the form of a 
mass spectrum. To prevent collisions and interactions between different ion species, 
each of these steps is carried out under high vacuum. The following sections provide a 
brief outline of the soft ionization sources and mass analyzers used in this study. 
1.7.1 Ionization methods 
1.7.1.1 Matrix-assisted laser desorption/ionization (MALDI) 
In MALDI, the sample is mixed with a suitable matrix, and bombarded with a 
high energy particle beam to produce, just above the point of impact, a high 
concentration of the gas-phase neutral and ionic species. By depositing a large amount 
of energy into the analyte molecule on a timescale that is fast compared with the 
vibrational time period, vaporization generally occurs before thermal decomposition 
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begins. In early mass spectrometry lasers were applied directly to the sample. The 
infrared laser (e.g. ND/YAG (neodynium/yttrium aluminum garnet; 1.06 pm), pulsed 
CO2 laser (10.6 tm) and UV lasers (frequency-quadrupled Nd/YAG laser that emits 
light at 266 run) were used. In this direct mode of laser application, termed 
laser/desorption ionization (LDI), the extent of energy transfer often leads to excessive 
thermal decomposition of the sample. Furthermore, not all compounds absorb radiation 
at the laser wavelength. Consequentially, the LDI mode is applicable to a limited 
number of compounds, usually those with a molecular mass < 1000 Da. Karas and 
Hikkenkamp, and Tanaka and co-workers, reported the development of MALDI in 1988 
110 which revolutionized the study of large biomolecules by mass spectrometry. In 
principle, the sample is mixed with surplus matrix material that absorbs at the 
wavelength of the laser radiation which occurs in short pulses 10-20 ns duration and 
approximately 106  W/cm2 irradiance power [iv]. Since the matrix absorbs at the 
wavelength of the laser irradiation, a large amount of energy is absorbed efficiently by 
the matrix, and subsequently transferred to the sample in a controlled manner, hence 
resulting in the co-desorption of sample and matrix. In addition to absorbing the laser 
energy via electronic or vibrational excitation, a useful matrix should provide a number 
of different functions. Firstly, it should disperse the analyte molecules by dilution 
within the preparation, thus minimizing analyte aggregation. Secondly, disintegration of 
the condensed phase has to take place with concomitant analyte ionization (via gas-
phase proton-transfer reactions) and without excessive destructive heating of the 
embedded analyte molecules 111 . Three different models have been proposed to explain 
desorption of the matrix-sample from the crystal surface: (1) quasithermal evaporation 
as a result of increased molecular motion, (2) expulsion of upper lattice layers, and (3) 
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an increase in the hydrodynamic pressure due to rapidly expanding molecules in the 
crystal lattice [v]. The widely accepted view for analyte molecule ionization following 
desorption is that following their desorption as neutrals, the sample molecules are 
ionized by acid-base proton transfer reactions with the protonated matrix ions in a dense 
phase just above the surface of the matrix UI  The MALDI mass spectra of proteins and 
peptides typically contain signals due to singly protonated target molecules and their 
oligomeric ions (e.g [M+H], [2M+H]). In addition, Na and K adducts are also a 
common feature of MALDI spectra of peptides or proteins. 
Analyte/matrix spot 
I 	III 
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Figure 1.15 Schematic diagram of MALDI 
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1.7.1.2 Electrospray Ionization 
Electrospray Ionization (ESI) is a type of atmospheric pressure ionization (API) 
which is a means of analysing non-volatile samples without first converting them to the 
gaseous phase [vi]. As seen in the schematic diagram of a typical ESI source, the 
capillary tube continuously delivers organic solvent (mobile phase from HPLC) 
containing the dissolved sample. A potential difference of 3-4 kV between the tip of the 
capillary and the walls of the surrounding atmospheric pressure region produces an 
electrostatic field sufficiently strong to disperse the emerging solution in a fine mist of 
charged droplets. The ions are transported from the atmospheric pressure region to the 
high-vacuum region of the mass-analyser via a low-pressure transport region. Prior to 
entering the mass analyzer, all sample ions are stripped off the solvent molecules. 
Hence, ESI incorporates three processes, namely, droplet formation, droplet shrinkage, 
and gaseous ion formation. The electrostatic force exerted on the eluate from the 
capillary causes it to emerge from the tip in the shape of a "Taylor cone" 
112  A thin 
liquid extends from this cone which breaks up in a fine mist. There are two views 
concerning the formation of gas-phase ions from the charged droplets, namely, the 
charge residue model (CRM) and the desorption model (1DM). In CRM, as the droplets 
shrink in size due to solvent evaporation, the charge density on their surface increases 
until it reaches the Rayleigh instability limit. Once this point is reached, repulsive 
Coulombic forces exceed the droplet surface tension and cause droplets to break into 
smaller and highly charged droplets. This process is repeated until the droplet contains 
only one solute molecule and as the remaining solvent evaporates, the analyte is 
dispersed into ambient gas retaining some of the charge on the droplets 
h13•  In 1DM the 
sequence of events related to solvent evaporation and droplet shrinkage is repeated, but 
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instead of proceeding to droplets so small to contain one solute molecule, at an 
intermediate droplet size the electric field due to the surface charge density is 
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Figure 1.16 Schematic representation of an electrospray ion source 
1. 7.2 Mass analyzers 
1.7.2.1 Time of flight mass spectrometer 
The time of flight (TOF) mass spectrometer is one of the simplest mass-
analyzing devices and describes the method used to measure the time it takes for a 
particle, object of stream to reach a detector while traveling over a known distance. In 
TOFMS ions are separated on the basis of their velocity differences 
114  The charged 
ions generated at the ion source are dispersed in time by allowing it to drift in a field-
free region of a long flight tube (Figure). As seen in the equation below, after 
acceleration to a constant kinetic energy (equal to zV, where z is the charge on the ion 
and V the accelerating potential), ions travel at velocities, v, that are an inverse function 






I 	......................Equation 1.1 
M 
Lighter ions travel faster and reach the detector placed at the end of the flight tube 
earlier than do the heavier ones. Therefore, mass analysis of ions that enter the flight 
tube can be accomplished by determining their time of arrival given by: 
1/2 
t = L -_ L(-m 	 Equation 1.2 
V 	2zV) 
In order to convert the time spectrum into a mass spectrum, the instrument is mass 
calibrated by measuring the flight times of two different known mass ions [viii]. 
Recent success to TOFMS can be attributed to its coupling to the MALDI ion source. In 
the past, however, poor mass resolution was one of the major limitations of TOFMS. 
The determining factor that restricted resolution in early TOFMS instruments was the 
kinetic lack of homogeneity within the ion beam resulting in higher-initial-energy ions 
arriving at the detector sooner than do the same-mass lower initial energy ions. 
Resolution can be improved in MALDI-TOF by allowing the initial burst of ions and 
neutrals produced by the laser pulse to equilibrate and dissipate before the ions are 
accelerated into the flight tube. This is referred to as "time-lag focusing" for ionization 
of a gas and "delayed extraction" for desorption ionization 
115  The kinetic energy 
distribution in the direction of ion flight can be corrected by using a reflectron. This 
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device is an electrostatic mirror that consists of a series of electrical lenses, each with 
progressively increasing repelling potential, and reflects the ion beam back to the 
detector. The more energetic ions travel deeper into the reflectron, and take a slightly 
longer path to the detector. Less energetic ions of the same charge and mass travel a 
shorter distance into the reflectron and take a shorter path to the detector. The detector is 
placed at the focal point where ions of different energies but same mass focused by the 
reflectron strike the detector at the same time 116 







Figure 1.17 Schematic representation of a reflectron time-of-flight mass spectrometer 
1.7.2.2 Quadrupole ion trap mass spectrometer 
Quadrupole ion trap (QIT) mass spectrometers are made up of three hyperbolic 
electrodes, consisting of a ring central electrode and two end-cap electrodes each with a 
hyperbolic cross-section, which form the core of the instrument. One of the end-cap 
electrodes has a small opening through which a gated electron beam can enter the trap 
for in-situ ionization of the analyte, while the other end-cap electrode has several 
perforations through which ions escape for external detection. QITMSs are dynamic 
mass analyzers that use an oscillating electric potential applied to the ring electrode, 
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called the "fundamental rf', to focus ions to the centre of the trap. This is accomplished 
by creating a parabolic potential, shaped like a saddle 117,  inside the trapping volume. 
Ultimately a population of trapped ions is therefore observed to occupy only the space 
near the centre of the trap due to the focusing effect of the electric fields. The trapped 
ions precess in the trapping field in the trapping field with a frequency that is dependent 
on their m/z ratio. By increasing the magnitude of the rf voltage and the frequency of 
the rf signal, ions of higher m/z become sequentially unstable in the axial direction and 
ultimately exit the trap through perforations in the end-cap electrodes and are detected 
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Figure 1.18 Quadrupole mass analyzer. Ionized species from the ion source (A) are trapped in a small 
space at the centre of the core (B) following application of an rf voltage. 
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1. 7.3 Tandem mass spectrometry 
The TUPAC Compendium of Chemical Terminology defines a tandem mass 
spectrometer as: 
"An arrangement in which ions are subjected to two or more sequential stages of 
analysis (which may be separated spatially or temporally) according to the quotient 
mass/charge. A hybrid mass spectometer is an instrument which combines analysers of 
different types, e.g. magnetic plus electric sector combined with quadrupole. The study 
of ions involving two stages of mass analysis has been termed mass spectrometry/mass 
spectrometry." 
- IUPAC Compendium of Chemical Terminology 1991, 63, 1546 
Tandem mass spectrometry involves mass-selection, fragmentation, and mass 
analysis and involves two stages of mass analysis. The first stage (MS) performs the 
mass selection of a specified ion from a mixture of ions that are produced in the ion 
source. This mass-selected ion undergoes fragmentation in the intermediate region, 
usually via collisions with neutral gas atoms 118  The mass selected ion is termed the 
"precursor ion", and the ionic fragments are called "product ions". The second stage 
(MS2) of MS/MS is used to mass analyze the product ions that are formed in the 
intermediate step. 
For reasons of brevity the tandem mass spectrometer used in this study shall be 
discussed, namely the Tandem Ion-Trap mass spectrometer (QITMS). The QITMS acts 
as a tandem-in-time mass spectrometer. Hence, all the steps of MS/MS are performed 
within the same space, but with a temporal sequence. Following ion trapping in the MS' 
stage, all ions except the precursor are ejected out of the trap with the resonance ejection 
procedure 119.  The precursor ion is then subjected to an excitation pulse to facilitate 
collisions with helium bath gas, a process termed collision induced decay (CID). The 
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MS2 step involves analysis of the fragmented ions as described in Section 1.7.6. CID is 
a two-step process, which involves collision activation and unimolecular dissociation. 
In the former, the fast moving precursor ions collide with atoms of an inert gas, and are 
excited to higher states 120  During this excitation process, a part of the initial 
translational energy of the incident ions is converted into the excitation energy to cause 
its fragmentation. 
1. 7.4 Protein identification by gel electrophoresis-mass spectrometry and 
database search 
With the development of MALDI and ESI, mass spectrometry has become a 
widely used technique in the analysis of gel separated proteins 121  Following gel 
separation the protein band of interest is excised, reduced, carboxymethylated and 
digested within the gel by a proteolytic enzyme. A variety of amino acid-specific 
enzymes are available that will yield reproducible peptide maps of a protein. Trypsin 
was used in this study because of its excellent properties as a protease. Trypsin produces 
peptides ideal for mass spectrometry analysis and since trypsin cleaves an amide on the 
C-terminal side of lysine or arginine residue, the tryptic peptides that result contain a 
basic amino acid at the C-terminus. This is particularly useful for the ESI process and 
for subsequent sequencing by tandem MS. 
Various databases exist for protein, DNA and expressed sequence tags (ESTs). 
In the single MS mode the peptide-mass fingerprints, which are generated following a 
digestion step with trypsin, are matched with theoretical peptide fragment mass values 
of each protein in the database. The theoretical mass values are created for the protease 
that was used specifically in the digestion step by applying the protease-specific 
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fragmentation rules to all of the protein sequences in the database. In MALDIMS, from 
a list of experimentally derived [M+H] values of peptides, the output of the search 
gives a ranked list of most likely candidates. The database that produces the best score 
is assumed to be the sequence of the protein. In the MS/MS mode identification of the 
protein occurs following correlation of the fragmentation patterns with the amino acid 
sequences in the protein databases 122  Following digestion of the protein, the individual 
peptides are fragmented in MS/MS mode (e.g. CID as used in this study). The observed 
pattern of the fragment ions of individual peptides are then compared with patterns of 
fragment ions that are calculated from the database sequences 
1. 7.5 CID fragmentation of peptides 
A notation has been developed for indicating peptide fragments that arise from 
an MS/MS spectrum 123  Peptide fragment ions are indicated by a, b, or c if the charge is 
retained on the N-terminus and by x, y or z if the charge is retained on the C-terminus. 
The subscript indicates the number of amino acid residues in the fragment. Although 
peptide backbone cleavage is the most useful for sequencing and peptide identification 
other fragment ions may be observed under certain conditions including side chain loss 
ions d, v, w and immonium ions. 
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Figure 1.19 Nomenclature used for the fragmentation pattern of a peptide in MS2 mode 
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1.8 Objectives of this study 
The DNA damage checkpoint network, as discussed in the above literature review, 
depends on promotional and inhibitory, synergistic and antagonistic molecular 
interactions that are investigated by an enormous experimental effort in numerous 
laboratories worldwide. To place this checkpoint network in context of tumorigenesis, it 
is useful to use Waddington's (1957) "epigenetic landscape" (Figure 1.20). Waddington 
was a prolific biologist who was interested in reconciling Lamarck's ideas on the 
inheritance of acquired characters with modem biology. The epigenetic landscape is a 
clever metaphor for the hierarchical nature of embryogenesis. The pegs at the bottom of 
the figure represent genes, and the guy ropes pulling on the landscape surface represent 
the products of genes. The different tensions produced by each peg on the ropes and the 
surface of the landscape represent (and are directly proportional to) the phenotypes that 
develop during the life of an organism. So the deeper" a groove is on the surface, the 
less variation there is on a given phenotype (i.e. the stronger the phenotype). It is clear 
to see in this fashion how every single developmental feature depends on the production 
of a myriad of genes. Intra- and extra-cellular pathways may therefore be envisaged to 
be largely redundant, analogous to the overlapping neural networks of the brain rather 
than to traffic grids of intersecting streets and interacting vehicles. Understanding the 
dynamic, non-linear interactions of individual components in these pathways is intrinsic 
to understanding the maintenance of genomic stability or conversely, when things go 
haywire, the progression into tumorigenesis. This requires the integration of genomic, 
proteomic, and bioinformatics approaches. Proteomics is a sphere of research that 
comprises the identities, quantities, structures, and biochemical and cellular functions of 
all proteins in an organism, organ, or organelle, and how these properties vary in space, 
!EI] 
time, or physiological state. Interactomics, is a recent, further elaboration on 
proteomics, and comprises the complex, dynamic and non-linear interactions between 
individual proteins, which ultimately influences the biochemistry of the cell. 
The following treatise is, primarily, an investigation on the degradation 
interactome of wild-type and mutant p53, which revolves around interactions with the 
chaperone-assisted, ubiquitin-proteasome degradation machinery. The main objective of 
this study was therefore to investigate key differences in wild-type and mutant p53 
interactomes by revealing novel key interactors through the use of standard biochemical 
techniques and mass spectrometry. 
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2.0 Materials and Methods 
2.1 Reagents and Materials 
All reagents were supplied by Sigma unless otherwise stated. p3XFLAG-myc-
CMVTM-26 plasmid was supplied by Sigma. One-STrEP-tag vector pEXPR-IBA 105 
was supplied by IBA Biotagnology. 
DNA Mini and Maxi Prep, PCR purification kits were supplied by Qiagen. 
Restriction enzymes were supplied by New England Biolabs. Oligonucleotides were 
synthesised by Sigma-Genosys. QuikChange Site-Directed mutagenesis kit was 
supplied by Stratagene. Foetal bovine serum (FBS), Dulbecco's modified eagle's 
medium (DMEM), RPMI-1640 and trypsin-EDTA solution were supplied by (Gibco-
BRL). Lipofectamine 2000 was supplied by Invitrogen. Handee Mini-Spin Columns 
were supplied by Pierce. Protein G Sepharose 4 Fast Flow and enhanced 
chemiluminescence (ECL) hyperfilm were supplied by Amersham. 
2.2 Molecular biology methods 
2.2.1 Growing Bacterial Cultures 
Luria-Bertani (LB) broth 
1% (w/v) Tryptone 
0.5 % (w/v) Yeast extract 
1% (w/v) NaCl 
Sterilized by autoclaving at 121°C for 20 minutes 
Wj 
2.2.2 Agar bacterial culture dishes and broths 
8 g of LB Agar mix (Fisher Bioreagents) were diluted in 200 mL of dH20 and 
sterilized by autoclaving at 121 °C for 20 minutes. The LB agar mix consists of- 
1 % (w/v) Tryptone 
0.5 % (w/v) Yeast extract 
1 % (w/v) NaC1 
1.5% (w/v) Agar, granulated 
LB agar was liquefied by heating in a microwave oven and allowed to cool until 
handwarm. Ampicillin was added to a final concentration of 100 tg/mL and the agar 
poured into 90 mm Petri dishes (sterilin) and left to cool. The culture plates were stored 
at 4 °C for no more than a month. Before use the plates were dried at 37 °C for 1 h. 
5-10 mL LB broth containing 100 jg/mL ampicillin selective antibiotic (Sigma) 
was inoculated with a colony of bacteria from a stock plate and incubated for 8 h at 37 
°C (225 rpm). This starter culture was then transferred to 250 mL of LB broth and 
incubated under the same conditions overnight in 2 L culture flasks. 
2.2.3 Glycerol stocks 
Glycerol stocks of bacterial cells were prepared by adding 0.15 mL of sterile 
glycerol to 0.85 mL of liquid bacterial culture in a cryotube (Nunc) and snap frozen. 
The cells were stored at -70 °C. 
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2.2.4 Preparation of heat shock competent cells 
Transforming Buffer 1 
30 mM CH3COOK 
100 mM RbC1 
10 mM CaC12 
50 mM MnC12 
15 %(v/v) Glycerol 
pH adjusted to 5.8 with dilute acetic acid 
Transforming Buffer 2 
10 mM MOPS 
75 mM CaCl2 
10 mM RbC12 
15 % (v/v) Glycerol 
Adjusted to pH 6.8 with NaOH 
2-3 mL of LB broth were inoculated with DH5a competent cells from a glycerol 
stock and grown overnight with shaking (225 rpm) at 37 °C. 250 tL of the overnight 
stock was added to 50 mL LB broth in a 250 mL culture flask and incubated at 37°C 
with shaking (225rpm) until the OD600 was approximately 0.4 (log phase). The cells 
were pelleted by centrifugation (4000 rpm, 15 mm, 4 °C) and resuspended gently in 16 
mL of ice cold Transforming buffer 1. The cells were incubated for 10 minutes on ice. 
The cells were pelleted by centrifugation (4000 rpm, 15 mm, 4 °C) and resuspended 
gently in 2 mL of ice cold Transforming buffer 2. The cells were incubated once again 
for 10 minutes on ice and 200 tL aliquots were added to pre-chilled microcentrifuge 
tubes. The aliquots were snap frozen and stored at -70 °C. 
2.2.5 KCM transformation 
An aliquot of DH5-a competent cells was thawed on ice and 100 .tL of the 
thawed cells was incubated on ice for 20 minutes with 200 ng of DNA and 100 p.L of 
KCM (100 mM KC1, 30 mM CaCl2 and 50 mM M902). The cells were then incubated 
at room temperature for 10 minutes. 400 j.tL of LB was added to the competent 
cell/DNA mixture and incubated for 1 hour at 37°C to allow growth of transformed 
bacteria. Cells were then plated onto LB agar plates with ampicillin and incubated at 
37°C overnight for colony formation. 
2.2.6 Heat shock transformation 
An aliquot of DH5-a competent cells was thawed on ice and 100 .tL of the 
thawed cells was incubated on ice for 20 minutes with 200 ng of DNA. The cells were 
subjected to heat shock by incubating at 42°C for 45 seconds and quickly returned to ice 
for 2-5 minutes. 500 pL of LB was added to the competent cell/DNA mixture and 
incubated for 1 hour at 37°C with agitation to allow growth of transformed bacteria. The 
cells were then spun at 2000 x g. The pellet was resuspended in 250 .tL of LB. 50 and 
100 jtL of the cell suspension was plated onto LB agar plates with the appropriate 
selection antibiotic for the plasmid transformed. Plates were incubated overnight at 
37°C for colony formation. 
2.2.7 DNA amplification and purification 
Single colonies were selected and allowed to grow in 5 mL LB with the 
selection antibiotic at 37°C for 8 hours. The culture was used directly in a mini-prep 
DNA purification (Qiagen) and carried out according to manufacturer's instructions. 
For maxi-prep, the culture was used as pre-culture and added to 200 mL of LB with 
ampicillin and allowed to grow overnight at 37°C before carrying out the protocol 
according to the manufacturer's protocol (Qiagen). 
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2.2.8 Quantitation of DNA by UV spectrophotometi'y 
1-5 tL of DNA was diluted to 100 tL in water. The absorbance of the samples 
was measured by a UV Powerwave XS 96 well plate reader (Bio-tek) reader at 260 nm. 
The amount of DNA was determined by the following formula: 
DNA concentration (1ug / 	
= Absorbance at 260 nm x Dilution factor x 50 
1000 
2.2.9 Agarose gel electrophoresis 
DNA loading buffer 
40% v/v glycerol 
50 mM EDTA 
0.1 % w/v bromophenol blue 
DNA samples were mixed with DNA loading buffer and loaded onto 0.8% 
agarose ethidium bromide gels. As a size reference, a 1 Kb DNA ladder (Invitrogen) 
was loaded next to the DNA samples. Electrophoresis was performed at 80 V for 1 hour 
before analysing under a UV transilluminator. 
M. 
2.3 DNA Plasmids 
2.3.1 Primer Design 
Primers were designed to achieve a melting temperature (Tm) of 55-70°C using 
the following formula': 
TM = {81.5 + 0.41(% GC content)} -16.6- (672/N) 
were N is the number total of bases in the primer 
HPLC purified oligonucleotide primers were purchased from SigmalGenosys 
and were reconstituted in nuclease-free dl-120. 
Table 2.1 Primers designed for cloning into the respective vectors. 
Gene Vector Primer Primer melting 
temperature (°C) 
CHK2 p3XFLAG-myc-CMVTM- Upstream: 70 
26 
HIND 111 	5'- 
GAT GAC A I AG CTT GGATCT 
GGA ATG TCT CGG GAG TCG 
GAT GTT-3'  
CHK2 p3XFLAG-myc-CMVTM- Downstream: 70 
26 
Xba I 
5'-CTC CGC T I CT AGA TCC 
CAC AGC AGC ACA CAC AGC 
-3,  
CHK2 pEXPR-IBA 105 Upstream: 67 
ECO-RI 
5'-G ATA ATC GCA G IAA TTC 
G TCT CGG GAG TCG GAT GTT 
G-3'  
' Sambrook, J., Fritsch, E.F., and Maniatis, T., in Molecular Cloning: A Laboratory Manual. Cold Spring 
Harbor Laboratory Press, NY, Vol. 1, 2, 3 (989). 
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CHK2 pEXPR-IBA 105 Downstream: 67 
HIND III 
5'- G AGC AGT GAC AIAG  CTT 
TCA CAA CAC AGC AGC ACA 
C-3'  
P53 pEXPR-IBA 105 Upstream: 67 
ECO-RI 
5'-G ATA TAT GTA G IAA TFC 
U GAG GAG CCG CAG TCA 
GAT CC -3'  
P53 pEXPR-IBA 105 Downstream: 67 
HIND Ill 
5'- G ATA AGT GAC AAG CTT 
TCA GTC TGA GTC AGG CCC 
TTC- 3'  
Rps3 pEXPR-IBA 105 Upstream: 67 
ECU-RI 
5'-G AGT GAC GCA G JAA TTC 
G GCA GTG CAA ATA TCC 
AAG AAG  
Rps3 pEXPR-IBA 105 Downstream: 67 
HIND III 
5'- G AGC AGT GAC AIAG  CTT 
TTA TGC TGT GGG GAC TGG 
3'  
2.3.2 Polymerase Chain Reaction (PCR) 
Reaction mixtures were set up as in thin-wall PCR tubes as following: 
dH20 40.6 iL 
1 O cloned Pfu reaction buffer 5.0 tL 
(Stratagene) 
dNTPs (25 mM each dNTP) 0.4 j.iL 
DNA template (100 ng/.tL) 1.0 	tL 
Upstream primer (100 ng/iL) 1.0 tL 
Downstream primer (100 nglj.iL) 1.0 .iL 
PfuTurbo® DNA polymerase (Stratagene) 1.0 VtL 
(2.5 U/.tl) 
Table 2.2 PCR cycling conditions. 
Segment Number of Cycles Temperature Duration 
1 1 95°C 2mins 
2 30 95°C 





3 1 72°C 1 lOmins 
4 1 4°C I forever 
2.3.3 Restriction endonuclease digestion 
Double restriction endonuclease digestions were set up by adding 1 tL of each 
enzyme (NEB) to c.a 1 tg of DNA in a final volume of 50 tL of I x NEB buffer. The 
reaction mixture was incubated for 1 hour at 37 °C. The digests were subsequently run 
on a 0.8 % agarose ethidium bromide gels. The products were excised with a scalpel 
and purified with a QlAquick gel extraction kit (Qiagen). 
2.3.4 Ligation 
Three ligation reactions were set up using molar ratios of 1:1, 1:3, or 3:1 of 
vector:insert DNA in a final volume of 10 p.L of T4 DNA ligase buffer and 1 Weiss 
units of T4 DNA ligase (Promega). The reactions were incubated overnight at 4 C. 3 
tL of reaction mixture was used to transform DH5u by heat shock (see Section 2.2.6) 
2.3.4.1 CHK2 in p3XFLAG-myc-CMVTM-26 
p3XFLAG-myc-CMVTM-26-CHK2 was subcloned from a pENTR2 1 
(Invitrogen) vector encoding the full-length human CHK2 in a HIND III and Xba I 
digested p3 XFLAG-myc-CMVTM-26 vector (Sigma). 
we 
2.3.4.2 CHK2 in pEXPR-IBA 105 
pEXPR-IBA 105-CHK2 (wild-type and mutants) were subcloned from the 
p3XFLAG-myc-CMVTM-26-CHK2 vector in an Eco RI and Hind III digested pEXPR-
IBA 105 vector (IBA Biotagnology). 
2.3.4.3 p53 in pEXPR-IBA 105 
pEXPR-IBA 105-p53 (wild-type and mutants) were subcloned from the pCDNA 
3.1 vector encoding full-length human p53 in an Eco RI and Hind III digested pEXPR-
IBA 105 vector (IBA Biotagnology). 
2.3.4.4 rps3 in pEXPR-IBA 105 
pEXPR-IBA 105-rps3 was subcloned from the pCMV6- XL5 vector encoding 
full-length human rps3 (Origene) in a Eco RI and Hind III digested pEXPR-IBA 105 
vector (IBA Biotagnology). 
2.3.5 Site directed muta genesis 
QuickChangeTM  Site-Directed Mutagenesis Kit (Stratagene) was used to create 
CHK2 mutants. Primers were designed to achieve a melting temperature (Tm) of 55-
70°C. 
HPLC purified oligonucleotides were purchased from SigmalGenosys and were 
reconstituted in nuclease-free dH20. 
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UPSTREAM PRIMER FOR CHK2RI45W 
5' -GC AAG AAA CAC TTT TGG ATT TTC AGO GAA GTG GG -3' 
DOWNSTREAM PRIMER FOR R145W 




UPSTREAM PRIMER FOR CHK21157T 
5' -  GGT CCT AAA AAC TCT TAC ACA GCA TAC ATA GAA GAT CAC -3' 
DOWNSTREAM PRIMER FOR 1157T 




UPSTREAM PRIMER FOR CHK2INSAI368 
5-CTGGGCAGAAGTCTCAGAGAAAGCTCTGGACC-31 






UPSTREAM PRIMER FOR CHK2deIC1 100 
5' -  GTC TTA TAA AGA TTA TGA TTT TGG GCA CTC C —3' 
DOWNSTREAM PRIMER FOR Cl lOOdel 




2.3.6 DNA sequencing 
Automated sequencing was carried out by the DNA analysis facility within the 
Wellcome trust clinical research facility at the Western General Hospital. 
2.4 Protein Purification Procedures 
2.4.1 Purification of antibodies (IgG) by protein G from ascites 
200 tL of a 50% slurry of protein G sepharose beads (Pierce) were pipetted into 
a Handee Mini-Spin column (Pierce). The beads were washed five times with 500 tL of 
Phosphate Buffered Saline (PBS 140 mM NaCl, 2.6 mM KCI, 10 mM Na2HPO4, 1.7 
mM KH2PO4). 
The ascites were thawed at 4°C overnight to prevent the aggregation of proteins. 
The ascites were subsequently centrifuged at 13,000 rpm at 4°C to sediment aggregates 
of degraded proteins and lipids. 
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500 tL of ascites containing approximately 5-10 mg/mL of IgG were added to 
the washed beads and the resulting slurry rotated on a rotating wheel for 1 hour at room 
temperature. The beads were washed with 500 iL of PBS and a fraction of the wash 
used to test for the presence of protein by Bradford Assay. The wash procedure was 
repeated until no protein was detectable in the wash. The beads were drained from the 
final wash of PBS and 100 tL of elution buffer (0.1M glycine p1-I 2.8) was added to the 
beads. The eluate was collected in 1.7 mL eppendorfs containing 8 tL of neutralisation 
buffer (TRIS-HC1 1.5M pH 8.8). A fraction of the eluate was used to determine the 
concentration of purified antibody. The elution procedure was repeated until no protein 
was detected in the eluate. The eluates containing the antibody were pooled and 
concentrated with ultrafree 0.5 centrifugal columns with a molecular weight cut off 
membrane of 10 kDa. The final concentration of the purified antibody was determined 
by Bradford assay. 
2.4.2 Preparation of Protein G Immunomatrix (cross-linked IgG) 
200 tL of a 50% slurry of protein U sepharose beads were pipetted into a 
Handee Mini-Spin column. The flow-through was discarded and the beads washed five 
times with 500 tL of Phosphate Buffered Saline (PBS 140 mM NaCl, 2.6 mM KC1, 10 
mM Na2HPO4, 1.7 mM KH2PO4) and resuspendend in 100 tL of PBS. 
The required amount of protein G purified antibody (typically 50-100 pg) was 
added to the beads and the resultant slurry rotated on a rotator wheel for 1 hr at room 
temperature. The columns were centrifuged and the flow through kept to determine the 
amount of antibody bound to the beads by Bradford assay (typically> 80%). The beads 
were resuspended in 400 VtL of PBS and 12.5 pL of a 25 jtg/j.iL disuccinimidyl suberate 
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(DSS) in dimethyl sulfoxide (DMSO) stock solution added. The contents of the column 
were rotated for 1 hour at room temperature. The tube was centrifuged and the flow-
through discarded. The column was washed 5 times with 500 tL of TBS (TRIS-HC1 
1 .0M pH 6.8) to remove excess and quench the DSS. 
2.4.3 Preparation of NHS-crosslinked igG to sepharose beads 
200 iL of a 50% slurry of NHS-activated sepharose beads (Amersham) were 
pipetted in a 1.0 mL column. The isopropanol was allowed to flow out of the column at 
a rate of 1 drop/sec. 200 iL of ice cold HC1 was added to the beads and allowed to flow 
out of the column at a rate of 1 drop/sec. 200 jtL of PBS was added to the column and 
allowed to flow out at a rate of 1 drop/sec. The beads were resuspended in PBS. The 
antibody was diluted in 0.2 M NaHCO3, 0.5 M NaCl, pH 8.3 so that the final volume 
was 50 VtL. An aliquot of the antibody solution was taken prior to adding to the beads. 
The antibody was added to the beads and the resulting suspension was mixed 
thoroughly on a rotator for 1 hr at room temperature. The beads were drained by gravity 
flow and an aliquot of the eluate was taken. A Bradford assay was performed on the 
aliquots taken prior to and after binding to the beads to determine the coupling 
efficiency. 
The beads were washed and excess NHS moieties deactivated by the following 
sequence of buffer additions: 
Buffer A: 0.5 M ethanolamine, 0.5 M NaCl, pH 8.3 
Buffer B: 0.1 M acetate, 0.5 M NaCl, pH 4 
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Injected 3 x  200 tL of Buffer A. 
Injected 3 x  200 tL of Buffer B. 
Injected 3 x  200 tL of Buffer A. 
Left the column for 15-30 min in room temperature. 
Injected 3 x  200 tL of Buffer B. 
Injected 3 x  200 tL of Buffer A. 
Injected 3 x  200 iL of Buffer B. 
Finally, injected 2 ml of PBS to adjust the beads to a neutral p1-I. 
2.4.4 Immunoprecipitation of ubiquitinated p53 
Cells were lysed in Triton X-100 lysis buffer containing Complete ® protease 
inhibitor mix. Lysates were centrifuged with 13000 rpm for 10 minutes at 4°C and 
filtered through 0.2 jiM button filters to remove cellular debris and lipids. Lysates were 
precleared with Sepharose CL-4b (Sigma) overnight at 4°C. The precleared lysates were 
added to 1 mL columns containing 20 tL of DO-1 NHS-conjugated sepharose beads. 
The columns were placed on a rotator at 4°C overnight. The beads were washed three 
times with 500 iL PBS-T for 5 minutes. The beads were eluted with 3 x 100 PL of 0.1 
M glycine pH 3.5 into eppendorfs containing 10 jiL of 1.5M TRIS-HCl pH 8.8.The 
eluates were combined and concentrated with ultrafree 0.5 mL spin columns MWCO 10 
kDa. The eluates were run on a on 4-12% NuPAGE® Novex precast gel (Invitrogen) 
and immunoblotted with an antibody that recognized ubiquitinated proteins (Biomol). 
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2.4.5 Immunoprecipitation of p53 R175H  from sf9 cells. 
A 15 cm plate 0fp53R75H baculovirus infected sf9 cells was lysed in 4 mL of X-
100 lysis buffer containing Complete ® protease inhibitor mix. Lysates were 
centrifuged with 13000 rpm for 10 minutes at 4°C and filtered through 0.2 tM button 
filters to remove cellular debris and lipids. Lysates were precleared with Sepharose CL-
4b (Sigma) overnight at 4°C. The precleared lysates were added to 5 mL columns 
containing 100 .tL of DO-1 NHS-conjugated sepharose beads. The columns were 
placed on a rotator at 4°C overnight. The beads were washed three times with 5 mL 
PBS-T for 5 minutes. The beads were eluted with 3 x 100 tL of 0.1 M glycine pH 3.5 
into eppendorfs containing 10 tL of 1.5M TRIS-HC1 pH 8.8. The eluates were run on a 
on 4-12% NuPAGE® Novex precast gel (Invitrogen) and stained with colloidal blue 
stain (Invitrogen) to visualize eluted proteins. 
2.4.6 Purification of One-Strep-tag fusion proteins 
The storage buffer of 0.2 mL Strep-Tactin columns was removed prior to 
equilibration with 0.4 mL of washing buffer (100 mM Tris/HC1, 150 mM NaCl, 1 mM 
EDTA, p118.0). The soluble cell extracts were added to the column and allowed to flow 
through by gravity. The flow through was re-added to the column. This step was 
repeated 5 times. The column was washed 5 times with wash buffer. The column was 
eluted with 6 x 100 pL of elution buffer (100 mM TrisIHCl, 150 mM NaCl, 1mM 
EDTA, 2 mM biotin, pH 8.0). 
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2.5. Tissue Culture 
2.5.1 Cell maintenance 
H1299 human lung carcinoma cells were incubated in RPMI 1640 (Roswell 
Park Memorial Institute), and A549 human alveolar epithelial cell line and MCF7 
human breast adenocarcinoma were incubated in DMEM (Dulbecco's Minimal 
Essential Medium). Both media were supplemented with foetal bovine serum (FBS) at 
10% (v/v). Cells were cultured in a humidified incubator (Hera) at 37°C with an 
atmosphere of 10% CO2. Cultures were seeded in 6 cm and 10 cm dishes and 
subcultured 2-3 times per week in 10 cm diameter culture dishes in sterile conditions 
and split to a maximal dilution of 1/10. The media was discarded and the cells were 
washed with sterilized PBS. 1-3 mL of lx Trypsin-EDTA solution was added per dish 
and then incubated at 37°C for 2-3 minutes. The trypsinised cells were taken up into 
media (9mL/1 0cm diameter culture dishes) and then split into new culture dishes with 
fresh media (1 OmL/1 0cm diameter culture dishes) 
Cells were kept in liquid nitrogen for long-term storage as follows. A 10 cm diameter 
culture dish with confluent cells was trypsinised and the cells collected by 
centrifugation (1000 rpm, 5 min at room temperature). The cell pellet was gently 
resuspended in 3 mL of freezing medium (90 % (v/v) Foetal Bovine serum, 10 % (v/v) 
DMSO) and transferred to cryotubes (Nunc) at lmL per tube. The cells were placed in 
NalgeneTM Cryo freezing containers and transferred to liquid nitrogen to freeze the cells 
at 1°C/mm. 
To recover the cells the cryotubes were thawed quickly in a 37°C water bath and 
transferred to a 10 mL falcon tube containing 10 mL of culture medium. The cells were 
collected by centrifugation (1000 rpm, 5 min at room temperature) and the cell pellet 
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gently resuspended in 10 mL of fresh culture medium. The resuspended cells were 
plated out in a 10 cm diameter culture dish. 
2.5.2 Cell Treatments 
Table 2.3 Cell treatments that were directly added to the cell culture medium. 
Treatment Description Diluen Concentration 
t sused 
17-AAG (17-(Allylamino)-17-demethoxy- HSP90 DMSO 10 tM 
geldanamycin inhibitor 
(Calbiochem 






















EGS (Ethylene In-vivo DMSO 2-8 mM 





2.5.3 Transient transfection 
Cells were plated in dishes and seeded for 24 hours. All transfections were 
performed using the liposome-mediated method using LipofectamineTM 2000 
(Invitrogen) based on the manufacturer's recommendations. The quantity of DNA was 
normalized in each transfection by adding the appropriate amount of empty vector. The 
amount of plasmid DNA is detailed in figure legends. For a 10 cm diameter culture dish 
the plasmid DNA was diluted in 1.25 mL of Optimem (Gibco-BRL). 12 IL of 
LipofectamineTM  2000 was added to 1.25 mL of Optimem (Gibco-BRL) and incubated 
for 5 min at RT. The diluted LipofectamineTM 2000 was added to the diluted DNA in 
equal amounts, mixed and incubated at RT for 20 min to allow DNA! LipofectamineTM 
2000 complexed to form. 2.5 mL of the mixture was added to each culture dish. Cells 
were harvested in ice-cold PBS 24 hours post transfection unless cell treatment 
followed. 
2.5.4 Stable transfection 
2.5.4.1 Determinination of G418 working concentration for H1299 cells 
Untransfected H1299 cells were plated in ten 10 cm plates in RPMI 1640. Once 
the cells reached 40-50 % confluency the medium was removed and the cells washed 
with 1 xPBS prior to adding RPMI 1640 medium containing G418 selection antibiotic at 
a concentration of 100 - 1000 tg/mL. The cells were allowed to grow and the medium 
replenished every 3 days. The concentration at which untransfected H1299 cells were 
killed in 2 weeks was used as the G418 working concentration (500 tg/mL for H1299 
cells). 
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25.4.2 Transfection and pooling of clones 
H1299 cells at 90% confluency were transfected with LipofectamineTM 2000 as 
indicated in Section 2.5.3. 24 hours post transfection the cells were split (1:10) in RPMI 
1640 containing 500 jig/mL G418. The medium was replenished every 3 days until 
stably tranfected clones were visible (approx 2 weeks). The clones were pooled by 
trypsinisation and grown in RPMI 1640 supplemented with 300 j.tg/mL G418. 
2.6 SDS-polyacrylamide gel electrophoresis (PAGE) 
2.6.1 Cell Lysis and SDS sample buffers 
Triton X-100 Lysis buffer 	 One-strep Lysis Buffer 
50 mM Tris-HC1 pH 7.4 	 50 mM Tris-HC1 pH 7.4 
1 mM EDTA pH 7.4 	 7.5 % glycerol 
15OmMNaCl 	 15OmMNaCl 
1% (w/v) Triton X-100 	 1 mM EDTA 
10 % (w/v) Glycerol 
SDS sample buffer (SB) 
5% (w/v) SDS 
25% (vlv) Glycerol 
125 mM Tris-HC1 pH 6.8 
0.02 % (w/v) Bromophenol Blue 
DTT (1M) added to buffer (1DTT : 4 SB 
prior to use) 
2.6.2 Cell harvesting and lysis 
Cells were washed in ice cold PBS, and harvested by scraping with 1 mL of PBS 
into a pre-chilled microcentrifuge tube. Cells were collected by centrifugation at 1200 
rpm for 5 min at 4 °C. The supernatant was removed and cells snap frozen and stored at 
-70 °C until required for lysis. To 10 mL of Lysis Buffer 1 Complete-Mini protease 
inhibitor cocktail tablet (Roche) was added. For cell lysis, the cell pellet was 
resuspended in 500 - 1000 p1 of lysis buffer. The cells were disrupted further with a 2.5 
mL syringe equipped with a 0.6 mm x 25 mm syringe needle (MicrolanceTM BD). 
Samples were incubated on ice for 20 mm. The cell lysate was centrifuged at 13000 rpm 
for 5 min at 4 °C to pellet insoluble cellular debris. 
2.6.3 Bradford assay 
Bradford assay dye reagent (Biorad) was diluted one in five in water to give a lx 
working solution. Bovine serum albumin (BSA) standards ranging from 0.1 - 2 mg/mL 
were prepared in water. 1 p1 of each standard was pipetted in 500 tL of lx Bradford 
reagent and the absorbance of the resultant solution determined at 595 nm with a 
Powerwave XS 96 well plate reader (Bio-tek). A standard curve was generated from the 





192 mM Glycine 
25 mM Tris-HC1 
0.1 % (w/v) SDS 
Equal volumes of SDS sample buffer were mixed with the protein samples and 
incubated at 96°C for 3 minutes before loading onto 6,8,12% polyacrylamide gel or 4-
12% NuPAGE Bis-Tris gel (Invitrogen). The samples on 6,8 and 12% polyacrylamide 
gels were resolved by electrophoresis in SDS-tris-glycine running buffer on mini-
protean 3 apparatus (BioRad) at 150 V for approximately 1 hour. The samples on a 4-
12% NuPAGE Bis-Tris gel were resolved by electrophoresis in SDS-MOPS running 
buffer (Invitrogen) on a Novex XCell SureLock (Invitrogen) gel apparatus at 200V for 
approximately 1 hour. 
2.6.5 Detection of separated protein 
2.6.5.1 Colloidal Blue Staining 
For colloidal blue staining of proteins the Colloidal Blue staining kit 
(Invitrogen) was used and the manufacturer's instructions for Nupage® Novex Bis-tris 
gels were followed. 
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2.6.5.2 Silver staining 
Fixing Solution 	 Developing solution 
50% (v/v) methanol 	 0.04% formaldehyde solution (37% v/v) 
5% (v/v) glacial acetic 	 2% Na2CO3  
The resolved proteins were incubated in fix solution for 20 minutes and washed 
in 50% methanol for 10 minutes. Gels were subsequently washed in water overnight. 
Gels were subsequently incubated in cold sensitization solution (0.02% Na2S203) for 1 
minute. Gels were subsequently washed twice in water for 1 minute. Gels were then 
incubated in cold 0.1% AgNO3 for 20 minutes and washed twice with water for 1 
minute. The gels incubated in developing solution. Staining was terminated washing the 
gel in 5% glacial acetic acid. 
2.6.5.3 Immunoblotting 
Transfer buffer 	 ECL Solution 1 
192 mM Glycine 	 100 mM Tris pH 8.5 
25 mM Tris 	 2.5 mM Luminol 
20% (v/v) Methanol 	 0.4 mM p-coumaric acid 
ECL Solution 2 	 10 x Phosphate Buffered Saline (PBS) 
100 mM Tris pH8.5 	 1.37 M NaCl 
0.02 % (v/v) H202 	 0.1 M Na2HPO4 
0.027 M KC1 
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0.0 18 M KH2PO4 
adjusted to p1-I 7.4 with HC1 
PBS-tween (PBST) 	 Blocking Buffer 
Ix PBS + 0.1% (v/v) Tween 20 	 PBST + 5 %(w/v) low fat dry Milk 
(Marvel) 
Resolved proteins were transferred onto Hybond-C nitrocellulose membrane 
(Amersham) in Transfer Buffer at 300 mA for 1 hour or 25 mA overnight. For 300 mA 
blotting, an ice pack was placed in the transfer tank to maintain a low temperature. 
Following transfer, to prevent non-specific binding of the antibody, the membrane was 
blocked in Blocking Buffer for 1 hour. The membrane was subsequently incubated with 
primary antibody, as indicated in Table 2.4, in Blocking Buffer for 1 hour at room 
temperature or overnight at 4°C. The blot was then washed 3 times for 10 minutes in 
PBST before incubating for 1 hour in horse radish peroxidase (HRP) coupled secondary 
antibody in Blocking Buffer to detect specific antibody binding (Dako). Finally, the blot 
was washed 3 times with PBST for 10 minutes prior to incubating with ECL solutions 1 
and 2 (mixed 1:1) for 1 mm. Specific bands were detected by being exposed to 
HyperfilmTM ECL (Amersham). 
Ell 
Primary antibody Species Dilution Company 
Anti-p53 (DO-1) Mouse 1:4000 Moravian Biotechnology 
Anti-ubiquitin (ND I) Mouse 1:1000 Santa Cruz (Cat # sc8017) 
Anti-eefla (CBP-KK1) Mouse 1:1000 Upstate (Cat #05-235) 
Anti-MDM2 (2A10) Mouse 1:1000 Moravian Biotechnology 
Anti-CHIP (Stub 1) Rabbit 1:1000 Abcam (Cat # ab29 17) 
Anti-Hsp/Hsc70 Mouse 1:4000 Stressgen (Cat # SPA-822) 
Anti- Hsp70 Mouse 1:2000 Stressgen (Cat # SPA-810 
Anti-Hsp40 
________________________  
Rabbit 1:250 Immunokontact (code 221-
25-Hsp4O 
Anti-p5 Mouse 1:500 BD Transduction 
Laboratories (Cat # 
610576) 
Anti-p21 Mouse 1:500 Calbiochem (Cat # 0P64) 
Anti-3-actin (AC-is) Mouse 1:5000 Sigma (Cat # A5441) 
Anti-vimentin (v9) Mouse 1:250 Sigma (Cat # V6630) 
Anti-TCPlbeta 
(F39P7F1 1)  
Mouse 1:250 Abeam (Cat # 50605) 
Anti-CHK2 (A-12) Mouse 1:500 Santa Cruz (Cat # sc5278) 
Anti-Flag (M2) Mouse 1:5000 Sigma (Cat # F3165) 
Anti-c-myc (9E10) Mouse 1:500 Sigma (Cat # M5546) 
Anti-c-myc (4A6) Mouse 1:500 Upstate (Cat # 05-724) 
Anti-ADP, ATP 
Translocator 
(5F5 1 BB5AG7)  
Mouse 1:500 Calbiochem (Cat # 
AP1034) 
Table 2.4 Primary antibodies and respective dilutions used in immunoblotting 
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2.7 Mass Spectrometry 
2.7.1 In-Gel digestion of protein samples 
Reducing Solution 	 Alkylating Solution 
10 mM DTT 	 50 mM iodoacetamide 
0.2 % EDTA 	 100 mM NH4HCO3  
100 mM NH4HCO3  
Extraction Solution 	 Destaining solution 
50 iL of 5% Formic acid 	 0.1 M NH4HCO3  
50 % Acetonitrile 	 50 % Acetonitrile 
Trypsin Solution 
0.04 jigIj.tL trypsin (Promega) in 0.1 M 
NH4HCO3/1 0% acetonitrile 
The stained protein bands were excised from the gel with a clean scalpel, cut in 
ca. lxi mm cubes and placed in a microcentrifuge tube. The colloidal blue stained gels 
were incubated with 250 tL of destaining solution at 37 C until all visible blue colour 
was removed. Samples were dried in a Gyrovap for about 15 minutes. Gels slices were 
then incubated for 30 minutes at 56 °C with 10-15 jtL reducing solution and cooled to 
room temperature. The reducing solution was removed and gel slices incubated with 10-
50 .iL alkylating solution at room temperature and in the dark for 30 minutes. 
The alkylating solution was removed and gel slices washed and dehydrated twice by 
first incubating with 200 p.L of 100 mM NH4HCO3 for 10 minutes and then with 200 
jL of neat acetonitrile for 10 minutes. The gel slices were dried in a Gyrovap for 
approximately 15 minutes. The gel slices were incubated for 15 minutes at 37°C with 5 
!L trypsin and then covered with 10-15 ,.iL of 50 mM NH4HCO3 followed by an 
incubation at 37°C for 12-16 hours. 50 tL of 20 mM NH4HCO3 were added to the gel 
slices and incubated at room temperature for 20 minutes. The free liquid was transferred 
to a new eppendorf tube. The gel slice was placed in Extraction solution twice for 20 
minutes. The extraction solution and free liquid were pooled and dried in a Gyrovap. 
The peptides were dissolved in 10 tL of 2 % formic acid prior to analysis by MALDI-
TOF or ESI-MS-MS. 
2.7.2 Online Nano LC-MS/MS 
Online separation by reverse phase nanoLC of in-gel trypsin digests was 
performed on an UltiMate 3000 (Dionex) equipped with a C18 PepMaplOO trap (C18, 
300p.m i.d. X 5mm; 5jm, boA, Dionex) and C18 PepMaplOO analytical column (C18, 
75tm i.d X 15cm; 3jtm, boA, Dionex). Each analysis was performed using 
approximately lpmol of protein. The trap column was loaded and washed with 98% 
H20, 2% acetonitrile at a flow rate of 30uL/min. Analysis was performed at a flow rate 
of 0.3il/min. A 60minute increasing gradient of 4 to 90% of solvent B (80% water + 
20% acetonitrile + 0.05% formic acid) at 0.3i.il/min was applied for the first 40min for 
the elution of peptides from the reverse phase column. This was followed by a 4% 
RIM 
solvent B wash for lOmins to recondition the column. UV absorbance was collected at 
214nm and 280nm at 0.5s steps. 
The eluent was electrosprayed directly into the mass spectrometer using a 
360tm o.d, 20m i.d, lOpm i.d tip, distally coated picotip (New Objective, MA) 
mounted on an online nanospray source (Agilent). 
The HCT ion trap was operated in positive ion mode and MS-MS was achieved 
by collision-induced fragmentation (CID). Ions with a mass range of 200-2000m/z were 
accumulated in the ion trap for a maximum time of 200ms.The Auto MS/MS function 
was used for alternating precursor ion scanning and the MS/MS of the 2 most abundant 
precursor ions. After a spectrum was collected on an ion, it was added to an exclusion 
list for 45s. Data obtained was processed in Data Analysis, Biotools software packages 
and searched using an in-house MASCOT server (Matrix science). 
2.7.3 MALDI-ToF MS 
Matrix 
3 mg/mL a-cyano-4-hydroxycinnamic acid 
75 % (v/v) ethanol 
25 % (v/v) acetone 
1 iL of matrix was mixed by pipetting with 1 iL of sample peptide digest (refer 
to Section 2.7.1 for details of sample preparation). 0.5 - 1 iL of this mixture was 
spotted onto a MALDI target. Data were collected in positive reflectron mode on a 
MALDI De-STR (ABI) using a 337nm nitrogen laser. Each spectrum was an average of 
200 spectra (200 laser shots per spot). The spectra were batch processed in Data 
Explorer with default settings of advanced background correction, noise removal, noise 
filtered and 5points Gaussian smoothing. 
2.8 Fluorometric assays 
2.8.1 Sandwich-type enzyme-linked immunosorbent assay (ELISA) 
This technique was used mainly to study the conformations of wild type and 
mutant forms of p53. 96-PVC-wells were coated with monoclonal antibodies (DO-1, 
DO-12, PAbi620 for p53) at 50— 100 ng/well in NaFIC03 pH 8.0 overnight and washed 
3 times with 18 tL of PBST (0.02% vlv) to remove non-binding antibodies. To prevent 
non-specific binding, non reactive sites were blocked with 200 LL of 3% BSA-PBST 
and incubated for 1 hour. Cell lysates from baculovirus infected insect cells or 
transfected H1299 cells at the appropriate dilution was added to the antibody-coated 
ELISA wells and incubated for 1 hour. Unbound proteins were washed away with 200 
tL of PBST (0.02 %v/v) for 3 times. p53 captured by anti-p53 monoclonal antibodies 
were incubated with anti-p53 polyclonal antibody CM-1 in 3% BSA in PBS-T (1 in 
2000) for 2 hours at 4°C. After binding of the secondary antibodies, the wells were 
washed with 200 jtL PBST (0.02% v/v) for 6 times. The amount of CM-1 captured in 
the wells was visualised by the ECL method. 50 tL of ECL solution was added to each 
well to develop chemiluminescence and the luminescence was immediately detected 
and quantitated in a Fluoroskan Ascent FL (Labsystems) luminometer. 
2.8.2 Dual-luciferase reporter assay 
111299 cells were plated in 6-well plates a day prior to transfection. The cells 
were co-transfected with p53-wild type plasmid (50 ng), p53-responsive p21 reporter 
plasmid, Renilla luciferase (pRL-CMV) for 24 hrs using Lipofectamine 2000. To assess 
the effect ribosomal protein s3 on the transcriptional activity of p53, the plasmid 
encoding the rps3 gene was titrated at the levels indicated in the experiments. The total 
amount of DNA was kept constant with empty pcDNA 3.1 and empty onestrep tag 
(pEXPRI05). The cells were lysed in lysis buffer provided by the manufacturer 
(Promega). 
The activities of Firefly luciferase expressed by the p53-responsive p21-reporter 
plasmid were measured using the Dual-Luciferase reporter assay system (Promega) and 
a Fluoroskan Ascent FL (Labsystems) and corrected according to the Renilla luciferase 
activities derived from pRL-CMV for assessment of the transfection efficiency. The 
relative luciferase activity was calculated using the formula: (Firefly luciferase 
activity)/(Renilla luciferase activity). 
2.9 In-vitro translation 
2.9.1 TNT® coupled roticulocyte transcription/translation reactions 
The plasmids used for the in vitro transcription/translation contained the T7 
RNA polymerase promoter. 
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The reagents (Promega) were removed from storage at -70°C. TNT® rabbit 
reticulocyte lysate was thawed by hand warming and immediately placed on ice. The 
following reaction components were pipetted in a 1.5 mL microcentrifuge tube. 
. 	TNT® Rabbit Reticulocyte Lysate 
RNasin® Ribonuclease Inhibitor (40 U/tL) 










. 	TNT® Reaction Buffer 
TNT® RNA Polymerase 
. Amino Acid Mixture, Minus Leucine, 1mM 
. Amino Acid Mixture, Minus Methionine, 1mM 
The reaction components were gently mixed by pipetting and the resultant 
mixture incubated at 30°C for 90 minutes. The in-vitro translated proteins were resolved 
on 4-12% Novex gels. 
2.10 Fluorescent Microscopy 
2.10.1 Cell transfections 
Transfections were performed with the Lipofectamine reagent (InVitrogen). 
H1299 cells were seeded at a density of 0.13x106 cell/ml and plated in sterile four-
chambered slides (NIJNC) until 80-90% confluency was reached. Twenty-four hours 
post-plating the medium from the cells was removed and fresh media was added. Cells 
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were transfected with 0.5tg/ml of the pCDNA 3.1 + construct encoding wild-type p53, 
53F270A or a control empty vector 
2.10.2 Immuno fluorescence for detection of trans fected p53 DAPI staining 
Twenty-four hours post-transfection H1299 cells were washed in 1xPBS, fixed 
and permeabilized in 1:1 (v/v) Methanol: Acetone for 6 min at -20°C. Following washes 
with 1xPBS, nonspecific sites were blocked for lh with 3% (wlv) BSA/PBS in room 
temperature. After 3 washes in 1xPBS, the chambers from each slide were removed and 
cells were incubated overnight with the anti-p53 (DO-1) primary antibody (1:6000) 
diluted in 1% (v/v) BSA/PBS at 4°C. Twenty-four hours post-incubation, the slides 
were washed in 0.1% (v/v) PBS-Tween and incubated with the secondary anti-rabbit 
antibody conjugated with Alexa-568 for 30min at RT. After incubation cells were 
washed thrice in 1xPBS containing 0.1% (v/v).Tween. Nuclei were counterstained using 
DAPI. Coverslips were mounted with Fluorescent Mounting Media (DakoCytomation). 
The control for non-specific binding of the secondary antibody was the 1% (w/v) 
BSA/PBS, where no primary antibody was added. Microscopy analysis was performed 
on Zeiss microscope (Zeiss Axionplan Imaging Systems, kindly provided by the 
Medical Research Council, Human Genetics Unit). Transfected and non-transfected 
cells were localized using excitation in blue light (488nm) and images were sequentially 
acquired using DAPI and TexasRed filter blocks. Captured images were analysed using 
the Limelight microscope (Zeiss) and the Photometric CoolSnap HQ camera was used 
to capture them. 
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3.0 	Destabilising mutation F270A in p53 core domain enhances its 
ubiquitination in vivo and associates with eefla 
3.1 Introduction 
p53 transcriptional activity is influenced by two pathways, namely protein 
degradation (negative regulation) and transcriptional co-activation (positive regulation). 
p53 degradation occurs by the ubiquitin/proteasome pathway and is mediated by four 
distinct proteins with E3 ubiquitin ligase activity that catalyse the final step in linking 
the ubiquitin moiety to the r-amino group of lysine residues. The p53 E3 ligases 
discovered so far are MDM2 (murine double minute clone 2 oncoprotein), PirH2 
124 
COP-1 (constitutively photomorphogenic 1) 125  TOPORS [topoisomerase I- and p53- 
binding protein] 126  ARF-BP1/Mule 127  Synoviolin 128  CARPs [Caspase 8/10-
associated RING proteins] 129  and CHIP [C-terminus of Hsc70 (heat-shock cognate 70)-
interacting protein 108 p53  is positively co-activated by p300, which is essential for p53 
protein stabilisation in response to DNA damage. MDM2 and p300 share a binding site 
on the N-terminal domain of p53 characterised by an LXXLL motif. Binding of p300 or 
p53 at this site leads to the monoubiquitination of p53 on lysine residues in the C-
terminus of p53 or acetylation catalysed by p300. Mutation of the phenylalanine residue 
at position 19 that flanks the LXXLL motif in the N-terminus of p53 can inhibit 
MDM2-dependent ubiquitination. Interestingly, monomeric p53 is not ubiquitinated by 
MDM2 despite having an intact N-terminal domain, thereby highlighting the 
importance of p53 oligomeric status as a prerequisite for MDM2-dependent 
ubiquitination. 
Apart from the p53 N-terminal binding site for MDM2, the latter also binds a 
secondary conformationally flexible loop within the S 10 13-sheet in the central DNA- 
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binding domain of p53 67 The interaction between the N-termini of p53 and MDM2 
seems to promote a conformational change in MDM2 that stabilizes the interaction 
between the MDM2 acid-domain and the ubiquitination signal located in the above 
mentioned secondary site within the DNA binding domain of the p53 tetramer resulting 
in enhanced ubiquitination 68  These studies thereby highlight the importance of p53 
conformational status in MDM2-dependent ubiquitination. 
Polypeptides emerging from ribosomes necessitate the folding into three-dimensional 
structures prior to performing their routine functions within the cell. Failure of proper 
folding leads to an enhanced probability of protein aggregation and non-specific 
interactions with cellular components leading to deleterious effects in the cell. An 
example of the damaging effects of protein aggregation can be observed in Alzheimer's 
disease (AD) which has been identified as a protein misfolding disease due to the 
accumulation of abnormally folded amyloid beta protein and tau protein in the brains of 
AD patients 130 
Heat shock proteins are chaperones that assist the proper folding of nascent and 
mis-folded proteins by lowering the activation energy of the process. On the other hand, 
the ubiquitin-proteasome system is an error-checking system that targets improperly 
and/or unnecessarily synthesized proteins for destruction. The partitioning of proteins to 
either one of these pathways has been referred to as the "protein triage" and depends on 
the unfolding state at the ribosome. In fact, a significant fraction of newly synthesized 
proteins is degraded cotranslationally. These nascent damaged proteins can be 
ubiquitinated while bound to the ribosome, demonstrating that there exists a close 
coupling between the pathways of protein synthesis and protein degradation 
131 
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The aim of the following chapter was to focus on the role of p53 substrate 
conformation in MDM2-dependent ubiquitination of p53. A link was identified between 
substrate misfolding and susceptibility to ubiquitination. An immunoaffinity approach 
coupled with mass-spectrometry was used to elucidate potential key factors that 
discriminate between folded and misfolded p53. Using this technique a pool ribosomal 
proteins and ribosome associated proteins were identified as binding to p53. Moreover, 
eukaryotic elongation factor la (eefl a) was found to bind exclusively to the misfolded 
p53 mutant. 
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3.2 	Extent of mutant p53 unfolding and oligomeric status in cells 
To determine the relative ratios of folded or unfolded p53 in cells grown at 
37°C, lysates from H1299 p53-null cells transfected with wild-type or mutant p53 
alleles were incubated in ELISA wells coated with monoclonal antibodies PAb 1620 or 
DO-12 that are specific for wild-type and unfolded p53, respectively 
132  Total p53 
levels captured by the conformation-specific antibodies were then detected using a 
polyclonal antibody to p53 (Figure 3.1 (A) and (B)). Transfection of wild-type p53 into 
cells led to the synthesis of a pool of p53 that was predominantly in the PAb 1620 
positive conformation with a minor pool of wild-type p53 in the unfolded conformation. 
The ratio of folded to unfolded wild-type p53 was approximately 9:1. In contrast, the 
transfection of p53 F270A into cells produced a pool of mutant p53 that was 
predominantly in the DO-12 conformation. The ratio of folded to un-folded wild-type 
p53 was approximately 1:9. These data indicate that p53F270A  is significantly unfolded in 
cells at physiological temperatures when compared to wild-type p53. 
p53 functions as a transcription factor in a homotetrameric form. In-vivo cross-
linking with EGS was used to determine whether the oligomeric status of mutant 
53F271A differed from wild-type p53. As seen in Figure 3.1 (C) the oligomeric status of 
wild-type p53 was very similar to that of mutant p53 F270A as similar higher-molecular-
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Figure 3.1 Extent of mutant p53F271A  unfolding and oligomeric status in cells 
Antibody capture ELISA revealed that most of the p53F271A  mutant shows an 
unfolded conformation. Expression vector encoding wild-type p53 (A), or p53F27A 
(B) (1.5 .tg of DNA) was transfected into cells, and the conformation of p53 protein 
was examined by antibody capture ELISA. p53 proteins in the lysates were 
captured by monoclonal antibodies PAb 1620 or DO-12 coated on to ELISA wells, 
followed by polyclonal antibody CM  incubation and ECL® detection. The data are 
represented as luminescence in RLU (relative luminescence units) as a function of 
the monoclonal antibody used to capture p53. (C) In-vivo cross-linking of p53. The 
indicated p53 genes were transfected into cells and treated with EGS for 1 hr prior 
to cell harvesting, lysis and immunoblotting on a 4-12% gel with anti-p53 antibody 
(DO- 1). 
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33 	p53F270A displays enhanced ubiquitination in-vivo that is MDM2 
dependent 
Transfection of the p53 F270& allele in H1299 cells resulted in enhanced 
ubiquitination when compared to wild-type p53 as determined by the higher molecular-
mass ladder of p53 positive bands (arrows, Figure 3,2 Lane 1 vs. 2). Co-transfection of 
MDM2 into cells resulted in the enhanced ubiquitination of wild-type p53 to a level 
similar of the ubiquitination of p53 '270A  (arrows, Figure 3.2 Lane 8 vs. 1). A modest 
increase in intensity of the higher molecular-mass ladder resulted following the addition 
of proteasome inhibitor MG132 to cells transfected with p53F'270A  (Figure 3.2 Lane 4 vs. 
1). Furthermore, co-transfection of MDM2 (arrows, Figure 3.2 Lane 7) and addition of 
proteasome inhibitor MG132 resulted in distinct novel bands appearing in the high 
molecular-mass ladder in cells transfected with p53 F270/ (arrows, Figure 3.2 Lane 11 vs. 
4). 
To ascertain whether the high-molecular-mass ladder was the ubiquitinated form 
of p53, genes encoding for wild-type p53 and p53F270A  were transfected in H1299 cells 
followed by precipitation with monoclonal antibody DO-1 and immunoblotting with 
anti-ubiquitin antibody. Presumably, due to the heterogeneous nature of ubiquitin 
conjugation polyubiquitinated forms of p53 could only be detected as a large molecular 
size smear. This experiment demonstrated the enhanced ubiquitination 0fp53F27OA when 
compared to wild-type p53 in the presence of MG132 (Figure 3.3 Lane 3 vs. 4). The 
transfection of MDM2 also led to increased ubiquitin-adduct formation on wildtype p53 
in the presence of MG132 (Figure 3.3 Lane 8 vs. lane 4) to a level similar to p53 F2704. 
under the same conditions (Figure 3.3 Lane 7). 
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Figure 3.2 
Lanes 	1 	2 3 	4 	5 
p53WT(I.Spg) 	- + - 	+ 
p53 270A (1.5 pg) + 	- - + 
MG132 (10 pM) 	- - - 	+ 	+ 
MDM2(3pg) - 	- - 
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- Figure 3.2 Monomeric p53 encoded by the p53'270' allele yields higher and 
lower molecular peptides when compared to wild-type p53. 
Expression vectors (pCMV 31) encoding wild-type p53 or p53F27  (1.5 .ig) were 
co-tranfected with MDM2 in H1299 cells in the presence of proteasomal inhibitor 
MG 132 or DMSO control. The expressed proteins were examined for changes in 
their steady-state levels of p53 with the amount of ubiquitination products 
determined by immunoblotting with anti-p53 antibody (DO-1). The arrows 
highlight high-molecular mass p53-positive bands. 
Figure 3.3 
p53F270A (1 .5 pg) + 	- 	+ 	- 	+ 	- 	+  
p53VVT(1.5pg) - + - + - + - 	+ 
MG132(10pM) - 	- 	+ 	+ 	- 	- 	+ + Anti-ubi uitin Blot MDM2(3pg) 	- - - - + + + 	 	 q
Heavy Chain 
Figure 3.3 Immunoprecipitation of p53F270A  in a hyperubiquitinated state 
H1299 cells were transfected with either wildtype or mutant pcDNA-p53 (1.5 .Lg)or 
pCMV-MDM2 (3 pg), as indicated. DO-1 was used to pull down ubiquitinated 
conjugates of p53. Immunoblots of the eluates with anti-ubiquitin showed that 
mutant p53F270A  exhibits enhanced ubiquitination in-vivo in the presence of MG 132 
(Lane 3 vs. 4). The transfection of MDM2 impacts on the ubiquitin-adduct 
formation on wild-type p53 (Lane 8 vs. 4).. 
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34 	p53F270A  displays enhanced proteasomal processing but not 
NEDD8 conjugation when compared to wild-type p53 
These data indicate that a large proportion of proportion of the high-molecular-
mass forms of p53-positive bands are ubiquitinated, but they do not address whether the 
lower-molecular-mass pattern of p53-positive bands arise from cleaved fragments of 
p53 or whether the high-molecular-mass bands might also stem from other adducts such 
as NEDD8 conjugation. The latter scenario was evaluated by co-transfection of NEDP1 
(a specific cysteine protease which specifically cleaves NEDD8 molecules from 
substrates 133;  a kind gift of D. Xirodimas) into cells together with either wild-type p53 
(and MDM2) or p53F270A  A proportion of wild-type p53 adducts was reduced upon 
deconjugation by NEDP1 (Figure 3.4 (A) Lanes 2-5 vs. 1), a result which is in 
agreement with Xirodimas and co-workers. Conversely, mutant p53 adducts remained 
unchanged when co-transfected with NEDP1 (Figure 3.4 (A) Lanes 7-10 vs. 6) thereby 
leading to the conclusion that the lower- and higher-molecular-mass adducts of p53 
F27QA 
do not stem from NEDD8 conjugation. 
In an attempt to elucidate whether the lower-molecular-mass pattern of bands 
arise from intermediates in polyubiquitin coupled proteolysis, cells were transfected 
with mutant p53 and incubated with increasing amounts of the proteasome inhibitor 
Ada-(Ahx)3-(Leu)3-vinyl sulphone. This resulted in an accumulation of higher-
molecular-mass adducts and also resulted in changes of some lower-molecular-mass 
bands (Figure 3.4 (B) arrows Lanes 7-9 vs. 6 and 10). The predominance of the lower-
molecular-mass banding on mutant p53 might be due to its enhanced susceptibility for 
proteolysis owing to its unfolded nature. 
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Figure 3.4 
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Fig 3.4 Mutant p53 ubiquitin adducts are not cleaved by NEDPI protease but 
are cleaved by the proteasome. 
(A) The indicated p53 allele (wild-type p53+MDM2, lanes 1-5; or p53F27A, lanes 
6-10) was transfected into cells alone or with increasing amounts ofNEDP1 (1-8 
pg, as indicated). After 24 h, cells were harvested and immunoblotted with an anti-
p53 antibody. (B) Accumulation of lower- and higher-molecular-mass adducts on 
mutant p53 using a broad-range proteasome inhibitor. The mutant-p53-specific 
ubiquitination system was assembled in vivo as described above using transfected 
genes, followed by addition of increasing amounts of Ada-(Ahx)3 -(Leu)3 -vinyl 
sulphone. Lysates were immunoblotted to quantify changes in mutant p53 adducts, 
and higher-molecular-mass accumulation and production of lower-molecular-mass 
adducts are highlighted with arrows 
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3.5 	Mutant p53F271A  and p53 R175H display caspase cleavage- 
dependent polypeptides 
To investigate the possibility that the lower-molecular mass p53-derived 
peptides could arise from caspase cleavage, H1299 cells were transfected with empty 
vector, wild-type p53, p531175H  (a structural mutant, found in the zinc binding regions of 
the DNA binding domain 33)  or p53' 270', with or without MDM2, incubated with either 
caspase inhibitor (Z-VAD (OMe)-FMK (20tM)) or DMSO control and harvested at 
incremental time-points. Generation of some of lower-molecular-mass bands on mutant 
53F271A (Figure 3.5 (A) Lanes 6-8 vs. 5 and (B) Lanes 14-16 vs. 13) and p53 1U75 
(Figure 3.5 (C) Lanes 2-4 vs. 1 and lanes 6-8 vs. 5) is caspase dependent since it was 
blocked by Z-VAD (OMe)-FMK. Nonetheless, some of the p53 fragments were not 
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Figure 3.5 Mutant p53 is susceptible to caspase-dependent cleavage. 
H1299 cells were transfected with (A) wild-type p53 (lanes 1-4) or p5327A  (lanes 
5-8), (B) wild-type p53 (lanes 9-12) or p53F271A  (lanes 13-16) and MDM2, (C) 
p53RI75H (lanes 1-4) or p53R175I  and MDM2 (lanes 5-8), or (D) empty vector (lanes 
9-12) or empty vector and MDM2 (lanes 13-16). 24 hrs post transfection the cells 
were treated with 20 4M Z-VAD (OMe)-FMK (A, B, C and D lanes 2-4, 6-8,10-
12, 14-16) or DMSO (A, B, C and D lanes 1, 5, 9, 13). Lysates were immunoblotted 
to quantify changes in p53 adducts. 
3.6 	Mutant p53 is more susceptible to ubiquitination in vitro on 
lysine residues outside the C-terminus 
The previous studies, demonstrating a connection between p53 conformation 
and ubiquitination is somewhat limiting since the assays are based in vivo, thereby, the 
link between unfolded p53 conformation and its ubiquitination might be indirect. For 
example, the mutant unfolded p53 might be mis-localised in a cellular compartment 
different from wild-type p53, leading to an enhanced ubiquitination that is indeed 
unrelated directly to the degree of folding. In this respect, an in vitro protein-synthesis 
system was used that resolves p53 into folded or unfolded conformational variants. 
MDM2 protein was synthesized by co-translation in vitro with wild-type p53, 
53F270A 53F19A (mutation of the critical Phe residue of the p53 a-helix, that binds to 
the hydrophobic cleft of MDM2, to an Ala residue, thereby resulting in the disruption of 
the MDM2:p53 N-terminal domain interaction 134)  and p53 F270A/F19A (double mutant). 
53F270A displayed high molecular-mass adducts in the absence of MDM2 co-translation 
in contrast to wild type p53 (Figure 3.6 (A) Lane 3 vs 1). Both wild-type p53 and 
53F270A demonstrated enhanced high-molecular-mass adducts after co-translation with 
MDM2 (Figure 3.6 (A) Lanes 4 and 2). Additionally, although p53''9" was not 
ubiquitinated by MDM2 co-translation (Figure 3.6 (A) Lane 8) a high molecular-mass 
adduct appeared upon re-introduction of the F270A allele into the F19A genetic 
background, which was further augmented by co-translated MDM2 in vitro. (Figure 
3.6(A) Lanes 9 and 10). 
An attempt to confirm the identity of the high-molecular-mass adducts resulting 
from in-vitro translated mutant-p53 as ubiqutin by immunoprecipitation with a p53 
antibody (DO-1) and subsequent immunoblotting with anti-ubiquitin antibody proved 
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elusive, probably due to the inefficiency of the anti-ubiquitin antibody to cross-react 
with the rabbit ubiquitin immunogen. 
In this respect a different approach was adopted, namely, the use of small 
peptides that inhibit the E3 ligase activity of MDM2 (summarized in Table 3.1). 
Table 3.1 Small peptide inhibitors of MDM2 E3 ligase activity 
Peptide Name Peptide-Sequence Effect on MDM2- 
___________________  p53 interaction 
Retinoblastoma SGSGDQIMMCSMYGICKVKNIDLK Inhibits p53 
Peptide 1 (Rb 1) degradation by 
binding the acidic 
domain of MDM2 
IC0, 5 in the range of 
0.2-0.3 iM 
BOX V domain of SGSGRNSFEVRVCACPGRD Domain that forms 
p53 	(s9-slO 	linker part 	of a 	binding 
in the core DNA surface for MDM2 
binding domain of that is involved in 
p53) signalling 	p53 
ubiquitination. 	The 
peptide inhibits p53 
degradation 	by 
MDM2 	with an 
IC0.5 in the range of 
20-30 iM 
BOX Vc276A SGSGRNSFEVRVCAAPGRD Increase 	inhibition 
domain of p53 of p53 degradation 
(BOX V276) by MDM2 when 
compared to BOX 
V 
Constructs encoding wild-type p53, p53F270\  and p53 
F270AI6KR were in-vitro translated. 
The latter construct consists of the introduction of the F270A mutation in a 6KR 
background, a mutant form of p53 that can enter the nucleus similarly to wild-type p53 
and which has all six ubiquitin conjugation target, C-terminal lysine residues (at 
positions 370, 372, 373, 381, 382 and 386) replaced by arginine 65  The in-vitro 
r1 
translations of the above mentioned constructs were performed with Rb I (5mM), Box 
V (5mM) and Box V276 (5mM) in the presence or absence of proteasome inhibitor Ada-
(Ahx)3-(Leu)3-vinyl sulphone. p53F270A/6KR  displayed high-molecular-mass adducts 
similar to that obtained with p53 F270A The addition of proteasome inhibitor did not have 
an effect on the high-molecular-mass banding of mutant p53. Addition of 
retinoblastoma peptide I resulted in an attenuation of the high-molecular-mass adducts 
of in-vitro translated p53 F270A (Figure 3.6 (C) Lanes 12 and 17 vs Lane 16 and 21) and 
also, but to a lesser extent, of in-vitro translated p53F270A16  (Figure 3.6 (E) Lane 12 vs 
16). No significant reduction was observed with Box V or Box v276.  These results 
indicate that the majority of mutant p53 ubiquitination in-vitro occurs on lysine residues 
that are not in the C-terminus since 53F270A/6KR  displayed similar adducts to 
To further confirm that mutant and wild-type p53 are not present in different cell 
compartments an immunohistochemical approach was adopted. H1299 cells transfected 
with wild-type p53 or p53 F270A were permeabilized 24 hours post transfection and 
incubated with anti-p53 antibody (DO-1), anti-PDI endoplasmic reticulum marker 
antibody followed by DAPI staining. Mutant p53 F270A was also incubated with caspase 
inhibitor (Z-VAD (OMe)-FMK (204M)) for 6 hours prior to permeabilization. No 
significant difference was observed in cellular location of p53F271A  (Figure 3.7 as 
indicated) or wild-type p53 (Figure 3.7 as indicated) with the protein found to be 
overexpressed heterogeneously throughout the cell. Interestingly, however, addition of 
caspase inhibitor to p53 F270A (Figure 3.7 as indicated) expressing cells resulted in an 
enhanced signal of p53 observed at the periphery of the cell outside the nucleus and 
outside the endoplasmic reticulum. 
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Figure 3.6 Mutant p53 is susceptible to ubiquitination in vitro. 
(A) Co-translation of MDM2 with mutant p53 in reticulocyte lysates stimulates 
ubiquitination in vitro. Reticulocyte lysates containing co-translated MDM2 (+) or vector 
control (-) and p53 protein isoform (as indicated) were incubated at 30CC. After 90 mm 
the reactions were quenched and the material was processed for immunoblotting to reveal 
p53 protein (arrow) and high-molecular-mass modifications of the indicated p53 protein 
isoforms. (B), (C), (D) and (E) In vitro translation of p53 and peptide inhibition of 
ubiquitination. Reticulocyte lysates containing p53 WT (B), p53F270A (C), empty vector 
(D), or p53F270A16K (E) were incubated with retinoblastoma peptide 1 (5mM), Box V 
(5mM) and Box V276 (5mM) in the presence or absence of proteasome inhibitor Ada-
(Ahx)3 -(Leu)3 -vinyl sulphone (as indicated). RB peptide I attenuated the high-molecular 
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Figure 3.7 Cellular localization of wild-type and mutant p53. 
H 1299 cells were transfected with wild-type or p53F270A  as indicated. 24 hrs post 
transfection, cells were fixed, permeabilized, and probed with DO-1 antibody. The 
nucleus was stained with with 4,6-diamidino-2-phenylindole (DAPI) and anti-PDI 
endopiasmic reticulum. No significant difference was observed in cellular location 
of p53F270A  or wild-type p53 with the protein found to be overexpressed 
heterogeneously throughout the cell with predominant nuclear staining. Addition of 
caspase inhibitor results in p53F270A  localising to the cell periphery. 
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3.7 	Immunoprecipitation coupled mass-spectrometry identifies a 
ribosomal pool of proteins associated with p53 
An immunoaffinity coupled to mass-spectrometry approach was employed to 
identify novel factors that discretely discriminate between mutant and wild-type p53. 
53RI75H expressing baculovirus was used to infect insect Spodopterafrugiperida cells 
followed by precipitation with DO-1 antibody cross-linked to sepharose beads. 
Immunoblotting with anti-p53 antibody (DO-1) of the protein eluates confirmed the 
successful immunoprecipitation of p53 along with the high and low-molecular-mass 
adducts associated with the mutant form (Figure 3.8 B). Protein eluates were resolved 
on a 4-12 % gradient gel and stained with colloidal-blue stain. Uninfected insect cells 
were used as a control to eliminate false positives. Protein bands stained in the p53 R75H 
infected cell eluates but absent in the uninfected control eluates were cut out with a 
scalpel for identification with nano-spray-LC-MS/MS. 
The use of sepharose beads that directly cross-link the antibody via an NHS-
ester moiety significantly reduced the background from control un-infected 
immunoprecipitation (Figure 3.8 (A) and data not shown). Nonetheless, despite the 
antibody being cross-linked to the sepharose beads, a small amount of antibody bled 
into the eluates from uninfected cells. 
Table 3.2 summarizes the significant protein hits obtained from the colloidal 
blue stained gel slices. It is important to point out that the top hits for most of the 
proteins identified were not from the protein database of the species used in this study, 
namely Spodoptera frugiperida, possibly because the genome of this species has not 
been completely sequenced. In this respect, the high scoring matches from other closely 
related species are of interest because they are likely to be homologous to the unknown 
ME 
protein in Spodoptera frugiperida. Interestingly, all the gel slices resulted in the p53 
protein having the highest significance according to the Mowse ion score. This data 
corroborates the immunoblotting data showing that indeed all the DO-1 positive high 
and low-molecular mass bands are p53 peptides. Furthermore, all the other proteins 
identified, with the exception of ADP/ATP translocase and proteasome subunit alpha 
type 5, were ribosomal or ribosome-associated proteins. It is however, puzzling that no 
co-eluting chaperones were identified in this study. A possible explanation for this 
observation is that maximal expression of exogenous p53 by the baculovirus impedes 
the expression of host molecular chaperones. In fact a study by Yuri and co-workers 
showed that there is indeed a rate-limited expression of endoplasmic reticulum 
molecular chaperones that is strongly associated with the maximal expression of 
exogenous proteins obtained from baculovirus expression vector systems 135 
Ribosomal proteins L5 and L23 have been previously shown to bind MDM2 and 
activate p53 by inhibiting MDM2-mediated p53 degradation 136  It is tempting to 
suggest that a feedback loop exists were interaction of ribosomal proteins with MDM2 
and p53 modulates the ribosome filter '' thereby altering cellular growth and 
proliferation. 
3.8 	Identification of eukaryotic elongation factor 1  as a factor that 
discriminates between wild-type and hyperubiquitinated p53 
Eukaryotic elongation factor la (eefi a) can bind nascent polypeptide chains 
following their release from the ribosome 138  Furthermore, eefi a having a central role 
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in translation elongation, has been demonstrated to bind damaged nascent proteins that 
are ubiquitinated and facilitate their delivery to the proteasome 131 
Gel Band B from the colloidal blue stained gel depicted in Figure 3.8 (A) 
resulted in the identification of eefla. The MS/MS spectrum of tryptic peptide with 
sequence IGGIGTVPVGR from eefla is shown in Figure 3.9 (B). Alignment of 
Spodoptera frugiperda eefla with human eefial by clustalW protein alignment 
program showed that the protein was highly conserved between the two species (Figure 
3.9 (A)). Thereby, to confirm the identity of eefla in the eluates from DO-1 
immunoprecipitation of sf9 cells infected with p53R111H, immunoblotting with anti-
human eefla was carried out (Figure 3.8 (D). This experiment, indeed confirmed an 
eefla positive band being present in the eluate from p53 R175H cells but not in the eluate 
of un-infected cells. The lower molecular mass of the eefla positive cells from the 
insect eluate when compared to the marker of human cell-lysate might be due to the 
shorter length of the insect protein compared to the human protein, 413 amino acids vs. 
462 amino acids respectively (Figure 3.8 (D) as indicated). 
In order to verify the interaction between eefla and mutant p53, 111299 cells 
were transfected with p5311711 536KR  and p53F11A  and clones stably expressing the 
constructs were selected with geneticin (Invitrogen). Although multiple clones for the 
above mentioned mutants were created, generation of wild-type p53 clones in this cell 
background proved elusive, a result which is in agreement with findings of Dumont and 
co-workers who were "consistently unable to generate stably transfected clones for the 
Arg72 [polymorphic form of p53] variant" 139  An immunoblot with anti-p53 antibody 
(DO-1) of cell lysates from H1299 cells that stably express mutant forms of p53 
demonstrated that p53F270A  protein displayed similar low and high-molecular-mass 
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adducts to lipofectamine 2000-mediated transfection of the same construct (Figure 3.9 
(C) as indicated). These high and low-molecular mass adducts were absent in p536KR 
and p53 19A clones (Figure 3.9 (C) as indicated). H1299 cell lysates stably expressing 
53F270A 	53F19A or p536KR  were immunoprecipitated with anti-eefla antibody 
crosslinked to sepharose beads and eluates were immunoblotted with anti-p53 (DO-1) 
antibody. This experiment demonstrated that eefla specifically interacts with the 
unfolded and hyperubiquitinated form of p53, namely p53F270A  (Figure 3.9 (B), Lanes 5 
and 6), while no interaction could be observed with non-ubiquitinated and wild-type-
similar p536KR  and p53 E'19 (Figure 3.9 (B) Lanes 7 and 813 and 4). eefia should 
therefore be investigated more thoroughly as a potential player in the degradation 
pathway of mutant p53, especially in view of the recent finding that eefla also interacts 
with MDM2 140 
In corroboration with the previous finding that mutant p53 is degraded by the 
proteasome, it is interesting to note that the proteasome subunit alpha type 5 was 
identified in the mass-spectrometry approach. The proteasome subunit alpha type 5 
from Plasmodium yoelii yoelii has a high sequence homology with human proteasome 
subunit zeta (data not shown). This result is not surprising since the enzymes involved 
in ubiquitin metabolism are highly conserved among eukaryotes, particularly since 
mutation of the yeast homolog DOA5 (also known as PUP2) results in the accumulation 
of multi-ubiquitinated proteins 141• 
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Figure 3.8 Co-immunoprecipitation of Sf9 infected with p53 7511. 
(A) Colloidal blue stain of eluates from DO-1 immunoprecipitated p531U75H 
infected Sf9 cells. Sf9 cells were infected with p5375H baculovirus. Cells were 
harvested and lysed in Triton X-100 lysis buffer followed by DO-1 precipitation 
and 3 sequential glycine (0.1 M, pH 2.5) +10% SDS elutions. Gel Bands labelled 
A-E were excised with a scalpel, trypsinized and subjected to nano-spray-LC-
MS/MS. Proteins identified are listed in table 2.1. (B), (C), (D) Immunoblots of 
p53R1751-1 eluates with DO-i (B), anti-ubiquitin (C) and anti-human eefla (D) (I = 
input p53R175H infected sf9 cells; U = input uninfected sf9 cells; El = eluate 
p53R175H infected sf9 cells; EU= eluate uninfected sf9 cells; M = Marker for human 
eEFla). Arrows indicate gel-migration size for human and insect eefla. 
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Figure 3.9 Co-immunoprecipitation of p53 F27 with eefla 
(A) ClustaiW alignment of Spodopterafrugiperida eefla with human eefla shows 
high sequence conservation between the two proteins. (B) MS/MS spectrum of 
trpytic peptide from insect eefla. (C) DO-I immunoblot of H 1299 stably expressing 
p53F271A, p536KR and p53FI9A  (as indicated) under geneticin selection. (D) eefla 
immunoprecipitation followed by 2 sequential glycine elutions (0.1 M, pH 2.5) of 
H1299 cells stably expressing p53FI9A  (lanes 3 and 4), p53F271A  (lanes 5 and 6) and 
p536KR (lanes 7 and 8). Control immunoprecipitation with rabbit anti-mouse 
antibody crosslinked to sepharose beads are also shown for p536 (lane 2) and 
p53F271A (lanes 9 and 10). HC = DO-1 Heavy chain; LC = DO-1 Light chain. 
3.9 Discussion 
Tumour suppressor protein p53 functions as conformationally flexible 
transcription factor that is allosterically regulated by post-translational modifications 
(phosphorylation, acetylation, sumoylation, neddylation and ubiquitination) and protein-
protein interactions. MDM2 has been well characterized as a binding partner to p53 
with an idiosyncratic negative regulatory role on p53 stability by catalysing 
ubiquitination that results in the 26 S proteasome-dependent degradation of p53. 
Concomitantly, MDM2 itself, is also conformationally flexible and its binding to its 
substrates is regulated by additional cofactors such as zinc and RNA 142 
MDM2 forms a tight interaction with the p53 N-terminal domain and catalyses 
its monoubiquitination. In fact, mutation of a critical phenylalanine residue in the N-
terminus of p53 blocks ubiquitination. Although most studies of the p53:MDM2 
interaction are focussed on the N-terminal docking of MDM2 previous work from our 
lab has demonstrated the location of a second binding site for MDM2 in the DNA-
binding domain of p53 67, 68 using phage display of RNA-bound MDM2. This 
secondary site was confirmed by NMR spectroscopy of MDM2 peptides from the acidic 
domain and part of the zinc finger domain 143  Furthermore, by deconstructing the 
MDM2 mediated ubiquitination of p53 in vitro, it has been shown that interaction of 
MDM2 with the N-terminus of p53 induces a conformational change in MDM2 that 
stabilizes the interaction of the acid-domain of MDM2 with a ubiquitination signal in 
the DNA binding domain of p53 68  
The intrinsic instability of p53 and such a complex dual interaction with MDM2 
might be important when considered from an evolutionary perspective. This allows for 
tight regulation of the tumour suppressor protein but also allows for a certain degree of 
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flexibility which is central in importance to a nodal protein at the core of numerous 
cellular networks. 
The mutants analysed in this study, namely p53F270A  and p53R175H  can be 
classified as structural mutants since these residues play a role in maintaining the 
structural integrity of the DNA binding surface and are found in the 13-  sandwich and 
zinc binding regions of the DNA binding domain respectively 33.  Joerger and co-
workers have determined that mutation of the phenylalanine residue at position 270 to a 
leucine created an internal cavity with a capacity of 51 A3 in the hydrophobic core of 
the 13-sandwich without collapse of the surrounding structure 144  In this study antibodies 
were used to characterize the degree of folding of mutant p53 vs wild-type. The 
PAb1620 antibody is specific for the 'wild-type' or folded conformation but does not 
bind to denatured, unfolded p53 132 DO-12 binds to denatured, destabilized mutants at 
amino residues 256-270 which is cryptic in wild-type p53 and becomes accessible upon 
denaturation. Denaturation is not necessarily accompanied by complete unfolding of a 
protein, but rather results in the appearance of new conformations. It is important to 
stress that this conformational assay has no predictive value for the conformation of a 
mutant in the folded state. In fact, whilst p53 R175H and p53F270L  significantly destabilize 
the core domain by 3 kcal/mol and 4.1 kcal/mol as shown by urea denaturation, the 
former mutation could not bind gadd45 DNA (a transcriptional target of p53) at the 
permissive temperature of 20 °C (a temperature at which all mutants adopt an 
intrinsically folded structure) whereas the latter could bind gadd45 DNA at a level 
similar to wild-type 	The finding that mutant p53 was unfolded with respect to the 
wild-type as defined by 'conformational' antibodies is due to the marginal 
thermodynamic stability of p53 at body temperature. 
In this study the use of in-vivo cross-linking demonstrated that mutant and wild-
type p53 have similar oligomeric status which is an important prerequisite when 
comparing ubiquitination levels of p53, since, remarkably, p53 in a monomeric, rather 
than tetrameric conformation is not ubiquitinated by MDM2 145 
This study showed that transfected mutant p53 is ubiquitinated to a higher 
degree by endogenous MDM2 than wild-type p53. Comparable ubiquitination levels of 
wild-type p53 are obtainable only upon ectopic transfection of MDM2 suggesting that 
mutant p53 has a higher sensitivity to small amounts of MDM2. These results together 
with the observation of high level of expression of MDM2 in primary breast cancers 
with mutant p53 suggest that MDM2 might have a role in mutant p53 conformation 146 
Furthermore, the finding that MDM2 stabilizes the p53:DNA interaction in a 
chaperone-like way 147  suggests that MDM2 might function differently depending on 
whether the p53 substrate is native or non-native. In this light, the finding that MDM2 
catalyses the neddylation of wild-type p53 77  but not mutant p53 further points to the 
idea that the difference in p53 processing by MDM2 may be related to the native or 
non-native nature of p53. 
The finding that mutant p53 transfection also leads to proteasome and caspase 
cleavage- dependent low-molecular mass adducts in contrast to wild-type p53 also 
points to a cellular detection system that discretely discriminates between mutant and 
wild-type p53. 
One surprising finding in this study was the data acquired using p5361< as a 
substrate for ubiquitination in the in-vitro translation system showing that introduction 
of the F270A mutation in a 6KR background leads to ubiquitination levels comparable 
to p53F27OA  This suggests that ubiquitination of mutant p53 occurs on lysine residues 
that are not the widely reported C-terminal lysines. The data demonstrating that the 
level of mutant p53F270161<1  ubiquitination is not different in vitro from that of the 
53F271A mutant further points to ubiquitination sites that are not in the C-terminus, 
since p536KR  has all C-terminal lysine residues mutated to arginine residues. In fact a 
key report on the ubiquitination of p53 using a method involving in vitro proteolytic 
cleavage at specific sites after ubiquitination found that the lysines in the NH2-terminal 
and DNA-binding domains of p53 are important for ubiquitination 148  In this respect, it 
was found that the COOH-terminal lysine residues are not essential for p53 regulation 
but may contribute to a fine-tuning mechanism in vivo 149  This study thereby suggests 
that mutant p53 ubiquitination is operating along a control pathway different from that 
followed by wild-type p53 and that transfected HIS-tagged ubiquitin and MDM2 cannot 
necessarily be employed to dissect out mutant p53 ubiquitination mechanisms. 
Moreover, although specific residues are normally ubiquitinated (lysines in the C-
terminus and the DNA binding domain) in wild-type p53, native structure-disrupting 
mutations may allow other cryptic sites to be ubiquitinated. 
Although Drosophila p53 and human p53 share much sequence and biochemical 
homology, one major difference between Drosophila p53 and human p53 is that 
Drosophila p53 lacks the consensus box I sequence found in all vertebrate p53 proteins 
which is located in the p53-MDM2 interaction region. Moreover, genome-wide 
searches in Drosophila have failed to identify an MDM2 homolog. Therefore, MDM2-
mediated p53 degradation could be a later evolutionary event. In this study human 
53R175H mutant was used to infect sf'9 cells. Intriguingly, this experiment resulted in 
p53 high and low-molecular-mass peptides as seen in human H1299 cells transfected 
with mutant p53. In experiments to identify a eukaryotic cell component that associates 
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with human mutant p53 in insect cells, it was found that many proteins that co-eluted 
were associated with the ribosome. Previously, Marcheal et al. identified a 
ribonucleoprotein complex composed of 5S RNA, L5 ribosomal protein, MDM2 and 
p53 covalently linked to 5.8S rRNA 63  Furthermore, it has been previously shown that 
L5 ribosomal protein, 5S rRNA, and 5.8S rRNA form a ternary complex in solution 150 
The occurrence of these complexes suggests that p53 may be involved in one or more of 
the following mechanisms: (i) regulation of the transcription of rRNA genes; (ii) 
processing of rRNA precursors; (iii) transport of ribosomes from the nucleus to the 
cytoplasm; and (iv) translational control. In fact, a cytoplasmic fraction of p53 as the 
mature protein rather than the nascent form was demonstrated to bind to a small fraction 
of ribosomes in which 5.8S rRNA is covalently linked to the protein '' Ribosomal 
protein L13 as identified in this study to bind p53 also binds 5.8S rRNA 152  Moreover, 
probably the best characterised p53 activation involves expression of the ARF gene 
product 153  When induced, p14ARF disrupts the interaction between p53 and MDM2 and 
sequesters the latter to the nucleolus 71 153 Sherr and Webber postulated that since the 
nucleolus transcribes ribosomal RNA and processes pre-ribosomes for nuclear export, 
the p53-MDM2 complex exits the nucleus via the nucleolus, and that ARF binding to 
MDM2 interferes with this transport which is described as p53-MDM2 complexes 
'riding the ribosome'. Rubbi and Milner described nuclear-bound p53 being readily 
detectable in the nucleoli of cells grown under non-stressed conditions 154  Furthermore, 
Klibanov and co-workers have demonstrated accumulation of nucleolar p53 after 
proteasome inhibition 155  In light of this bibliographic background supporting the 
nucleolar export model of p53, it is interesting to point out that ribosomal protein L7 
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identified in this study is in fact not a ribosomal protein but a nucleolar protein that 
plays a critical role in processing of precursors to the large ribosomal subunit RNAs 156 
Another possible reason for the observation of p53 bound to a ribosomal pool is that 
ribosomes tether molecular chaperones as the first line of defence against protein 
misfolding. In this light, it is interesting to point out that the ribosomal protein L23a 
identified as one of the p53 interacting partners in this study has some degree of 
homology with the Escherichia coil ribosomal protein L23. In Escherichia coil 
ribosomal protein L23 acts as a docking site on the ribosome for trigger factor (TF) 
which acts as a chaperone of nascent polypeptide chains 157  Moreover the exposed 
glutamine residue at position 18 that is involved in the interaction with TF is conserved 
in the insect homolog 	The role of corresponds to the role played by Hsc70 and 
Mppl 1 TF in mammalian cells as proteins recruited to the ribosomes to chaperone 
nascent polypeptide chains. DnaK is a chaperone found in the cytosol of Escherichia 
coil that assists folding of newly synthesized proteins to their native states 158  DnaK 
requires ATP and its co-chaperones DnaJ and GrpE to refold a large variety of 
misfolded proteins through repeated cycles of substrate binding and release 
92  In a 
study using peptide libraries, Escherichia coil TF was shown to bind elongation factor 
Tu (EF-Tu) at sites buried within the hydrophobic interior 	Moreover, TF and DnaK 
have been shown to bind similar hydrophobic and basic residues on EF-Tu 
160 
Intriguingly, EF-Tu has been demonstrated to possess chaperone-like properties with 
nascent polypeptide chains 161, 162 The authors of this study argue that since two EF-Tu 
molecules might be involved per translation cycle, there might be some interaction 
between one EF-Tu molecule and the nascent peptidyl chain probably via the C-
terminal 2 amino acids in the nascent chain at the ribosomal P site, which influences 
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efficiency of EF-Tu-dependent read-through of stop codons. Furthermore, a separate 
study has shown that mitochondrial EF-Tu (EF-Tumt) binds to nascent polypeptides 
under stress conditions, prevents thermal aggregation of proteins while promoting their 
refolding and also recruits damaged unfolded proteins to the mitochondrial proteasome 
complex post-translationally 162 
Another consequence of the binding of mutant p53 R17511  to ribosomal proteins, 
even though speculative, is that such binding promotes the oncogenic function of 
mutant p53. This stems from a study in zebra fish (Danio rerio) showing that many 
ribosomal genes act as tumour suppressors. Despite the fact that ribosomal proteins 
have been implicated in a wide range of biological functions independent of their role in 
the ribosome, the authors of the study suggest that it is a shared ribosome-associated 
function that allows them to be tumour suppressors 163  Therefore by sequestering 
ribosomal proteins, mutant p53 might lead to reduced protein synthesis leading to a 
reduction of a positive regulator of apoptosis or differentiation, either of which could 
favour growth. Alternatively, a reduction in the number of ribosomes might alter the 
identity of the messages recruited to ribosomes—similar to the way that modulation of 
the translational capacity of mammalian cells by oncogenes such as Ras or Akt is known 
to alter the identity of mRNAs recruited to polysomes—changing the translation rate of 
growth-promoting genes 164 
In eukaryotes, the homolog of EF-Tu termed eukaryotic elongation factor la 
(eefl a) has been demonstrated to bind damaged proteins that are ligated to 
polyubiquitin chains and mediate the transfer to the proteasome 
131  Hence, eefla has 
been shown to play an important role in protein degradation. This study demonstrated 
that eefl a binds selectively to hyperubiquitinated, unfolded mutant p53 ' 27o" but not the 
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folded, mutant p53 6KR  which is not ubiquitinated by endogenous levels of MDM2. 
Hence, this study identifies a key player in a cellular detection system that exists to 
discriminate between folded and unfolded proteins and interacts exclusively with 
mutant unfolded but not wild-type folded p53. 
Intriguingly, a recent proteomic study on binding partners of MDM2 revealed an 
interaction with eefl a. Moreover, the binding of MDM2 to eefl a did not alter the 
translation function of eefla 140  Collectively, these results and results from the present 
study, suggest that eefl a might cooperate with MDM2 for the ubiquitination-mediated 
degradation of mutant unfolded p53. A striking study by Chen and Madura reports 
elevated levels of eefl a in primary human breast cancer tissues indicating a failure in 
the fidelity of protein synthesis resulting in the accumulation of damaged proteins in 
neoplastic cells 165  Hence, further studies are warranted to biochemically characterise 
the interaction between MDM2, p53 and eefla, its influence on neoplastic growth and 
the consequential development of novel cancer therapeutics. 
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4.0 Mutant and wild-type p53 chaperomes 
4.1 	Introduction 
In the post-genomic era elucidation of protein function remains an important 
challenge in biological sciences. In this respect, protein-protein interactions are a key 
element in deciphering the intricate cellular networks, recently referred to as the 
'interactome'. Mapping the interactome may better define the organization of individual 
molecular machines and their dynamic nature in the cells. While genetic methods like 
yeast two hybrid screens allow large scale systematic analysis, they also yield a 
substantial amount of false results. In addition, interactions requiring more than two 
partners or cofactors e.g. the authentic cellular environment for human proteins are not 
found in yeast. To overcome these limitations, pull-down assays in mammalian cells 
have been used. However, they require a tedious optimization of binding and washing 
conditions because of the high purification background they produce. 
An improvement to this method was the tandem affinity purification (TAP) which 
requires two successive purification steps, but this method has the disadvantage of 
missing some transient interactions.In order to prevent loss of transient but nonetheless 
important proteins that interact with p53 in the mutant and/or wild-type conformation 
the One-STrEP purification system was employed. 
MDM2 oncoprotein plays a central role in the regulation of p53 tumour 
suppressor protein. MDM2 binds to p53, blocks its activity as a tumour suppressor and 
promotes its degradation in many tumour cells. The p53 E3 ligases discovered so far are 
MDM2 (murine double minute clone 2 oncoprotein), PirH2 124,  COP-i (constitutively 
photomorphogenic 1) 125  TOPORS [topoisomerase I- and p53-binding protein] 
126 
ARF-BP1/Mule 127  Synoviolin 128  CARPs [Caspase 8/10-associated RING proteins 
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129 and CHIP [C-terminus of Hsc70 (heat-shock cognate 70)-interacting protein 108.In 
H1299 cells, overexpression of CHIP appeared to reduce the levels of co-expressed 
mutant p53 U75H  and to a lesser extent wild-type p53 while ablation of CHIP by siRNA 
resulted in an increase in endogenous p53 levels in U20S cells. Moreover, in vitro 
CHIP appears to co-operate with UbcH5b and Hsc70 to mediate ubiquitination of 
mutant 53R175H 108 Recent data by K. Vousden's laboratory, which are in contrast with 
findings reported in this study (cf Chapter 3) suggest that the MDM2 function as a 
ubiquitin ligase is less important in the degradation of mutant p53, which is heavily 
ubiquitinated in an MDM2 independent manner. The same group suggest that CHIP is 
the main ubiquitin ligase of mutant p53 and not MDM2 166  Further proteomic studies 
are therefore warranted to identify all ubiquitin ligases responsible for mutant p53 
ubiquitination. 
Molecular chaperones are a class of proteins that interact with diverse protein 
substrates to assist in their folding; with a critical role during cell stress to prevent the 
appearance of folding intermediates that lead to misfolded or otherwise damaged 
molecules. Consequently, heat shock proteins assist in the recovery from stress either by 
repairing damaged proteins (protein refolding) or by degrading them, thus restoring 
protein homeostasis and promoting cell survival 167  The interaction between Hsp70 or 
Hsc70 and mutant p53 has been widely reported. In mammary tumour cell lines, both 
Hsc70 and Hsp90 were found associated with mutated 53sh143A  in the cytoplasm 168 
Mutant p53Y205C  appears to form a complex with Hsp40 169  An elegant study by 
Whitesell et al. demonstrates a shift in a Hsc70, Hsp90, p23 and cyclophylin 40 
chaperone complex which formed with temperature sensitive mutant murine p53 A135V at 
37° C (p53 adopting a mutant conformation at this temperature) but was absent at 30° C 
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(p53 adopting a wild-type conformation at this temperature) 170  The same authors have 
speculated that wild-type p53 may undergo highly transient interactions with molecular 
chaperones. In fact, King and co-workers have demonstrated, with the use of highly 
purified proteins, that both mutant (p53R175H)  and wild-type p53 form an in initial 
complex with Hsc70 and Hsp40 under non-stress conditions. The authors argue that 
following this initial step, wild-type and mutant p53 diverge in molecular chaperone 
associations. In the case of wild-type p53, Hsp90 is tethered to p53 resulting in 
dissociation of the p53 -Hsc7O-Hsp40 heterocomplex and ultimately Hsp90-mediated 
p53 nuclear import. Bag-1 dissociates the Hsp90-p53 complex, so p53 can be targeted 
for proteolysis. In the case of mutant p53, Hsp90 and Hop do not dissociate the p53-
I-Isc70-Hsp4O heterocomplex thereby facilitating the stabilization and cytoplasmic 
sequestration of mutant p53 by masking the p53 domains required for proteolysis and 
nuclear import 171 
Protein—protein interactions usually involve large and flat surfaces and such 
interactions are difficult to disrupt by low molecular weight compounds 172  In the case 
of the p53—MDM2 interaction, however, it has been demonstrated that a limited number 
of amino acid residues are crucial for the binding of these two proteins 134  In fact, just 
three p53 amino acids —Phe19, Trp23 and Leu26 - have been found essential for the 
binding between the two proteins and they are inserted into a deep hydrophobic pocket 
on the surface of the MDM2 molecule. The first potent and selective small-molecule 
MDM2 antagonists, the nutlins could displace p53 from MDM2 in vitro with 
nanomolarpotency (1050 = 90 nM for nutlin-3a, the active enantiomer of nutlin-3). 
Nutlins bind to the p53 pocket from MDM2 in a way that mimics the molecular 
interactions of the crucial amino acid residues from p53 173 
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The aim of this chapter was to investigate the specific interactions between the 
above-mentioned molecular chaperones and MDM2 with mutant 
(p53RI75H  and 
p53 3F27OA) and wild-type p53 ('p53 chaperome') in vivo. The effect of drug inhibition of 
Hsp90 by 17-AAG, MDM2 by nutlin-3 and X-ray induced DNA damage on the p53 
chaperome was also investigated. Finally a mass spectrometric approach was adopted to 
identify potential new chaperones of p53. 
4.2 	One-strep purification of p53F270A p53R175H and wild-type p53 
The one-strep purification strategy (Figure 4.1) was adopted to identify key 
molecular chaperones that bind to p53 mutant and wild-type in vivo ('the p53 
chaperome'). The immunoaffinity approach using anti-p53 specific antibody DO-i was 
used successfully in this work (cf chapter 3) to purify bona fide protein complexes. 
However, since DO-1 binds to the N-terminus (Box I) domain of p53 it is possible that 
any chaperones binding to this site might be competitively detached. Also, even though 
chemical crosslinking of the antibody via the Fe portion to the surface of the sepharose 
beads by an NHS-ester moiety decreased the degree of bleeding of the antibody in the 
eluate, it was not possible to eliminate this contamination completely. Taking these 
factors into consideration, the p53 '27o'\ 53RI75H and wild-type p53 alleles were 
subcloned into the one-strep vector pEXPR-IBA1 05 containing an N-terminal one-strep 
tag from the pCDNA-3.l(+) vector using Eco RI and Hind III restriction sites. 
Lipofectamine mediated transfection of the above mentioned constructs into H1299 
cells led to the expression of p53 protein, together with associated high and low-
molecular mass adducts, (Figure 4.2 Lane 1) in the case of mutant p53 in a similar 
fashion to the pc-DNA3.1 (+) vector encoding these alleles (cf Figure 3.2 Lane 1). 
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To isolate protein complexes containing one-strep tagged p53, lysates from 
mutant or wild-type one-strep-p5 3 -expressing H1299 cells and from control cells 
(empty vector transfected H1299) were subjected to affinity chromatography on strep-
tactin macroprep columns (polymethacrylate resin). Following a wash step, bait mutant 
or wild-type p53 was eluted with six sequential biotin (2mM) elutions. As shown in 
Figure 4.2 approximately 80% of the bait p53 bound to the strep-tactin resin (Figure 4.2 
Lanes 1 vs. 2) and was successively eluted in biotin elutions 2-6 (Figure 4.2 Lanes 4-8) 
with a peak in elution 3 (Figure 4.2 Lane 5). Moreover, in the case of mutant p53F270A 
and p53P175H  the high and low-molecular-mass adducts also successfully eluted (Figure 
4.2 Lanes 4-8, as indicated). 
4.3 	Effect of I7AAG on co-precipitation of MDM2 with wild-type 
and ubiquitinated mutant one-strep tagged p53 
In order to rule out the possibility that the one-strep tag interferes with the 
physical binding of MDM2 to p53, 111299 cells were transiently transfected with one-
strep N-terminal tagged p53F270\, p53 R17111,  wild-type p53 or control empty vector 
followed by strep-tactin precipitation and immunoblotting of biotin eluates with anti-
MDM2 (2A10) antibody. As expected, and as shown in Figure 4.3(A) expression of 
wild-type p53 induces MDM2 protein when compared to mutant p53 
F270A or p53 R  I  75H 
(Figure 4.3(A) Lane 1 and 5 as indicated). Moreover, higher levels of MDM2 were 
obtained in biotin eluates from wild-type p53 when compared to mutant p53 
F270A or 
p53 1175H  (Figure 4.3(A) 90 arrow Lane 2-4 and 6-8, as indicated comparing lower 3 
panels to each other). Interestingly, apart from the 90 kDa SDS-migrating form of 
MDM2 this system also precipitated a 2A 10-positive MDM2 band migrating at 60 kDa 
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with both wild-type and mutant p53. Intriguingly, mutant and wild-type p53 display 
differing binding affinities to the two forms of MDM2 with a higher 90 kDa 60 kDa 
ratio for wild-type p53 when compared to mutant p53 F270A or p53RI75H  (Figure 4.3(A) 
90 and 60 arrows Lane 2-4 and 6-8, as indicated). The 60 kDa form of MDM2 has 
been demonstrated to be a product of a p53-dependent caspase cleavage which lacks E3 
ligase activity 	By binding to mutant p53 the cleaved form of MDM2 might exert a 
dominant negative effect to stabilize mutant p53. 
1 7-AAG acts as a nucleotide mimetic that binds in the deep ADP/ATP pocket of 
the amino-terminus of Hsp90 ultimately blocking the assembly of an Hsp90-p23 
complex implicated in Hsp90-dependent protein folding 175  In order to investigate the 
effect of 17-AAG on the binding of MDM2 to mutant and wild-type p53 cells were 
incubated with 10 VtM 1 7-AAG for 2hrs prior to cell-harvesting, strep-tactin 
precipitation and immunoblotting with anti-MDM2 antibody (2A 10). As shown in 
Figure 4.3(A) addition of 17-AAG did not result in an appreciable difference in the 
binding of either the 90 kDa or 60 kDa forms of MDM2 to wild-type or mutant p53 
(Figure 4.3(A) arrows Lane 2-4 vs. 6-8, as indicated). 
As discussed in Chapter 3 mutant p53F270A  is hyperubiquitinated in cells when 
compared to wild-type. In this respect, the one-strep purification system was evaluated 
to determine whether ubiquitinated p53 could be successfully pulled-down from cell 
lysates. H1299 cells were transiently transfected with one-strep N-terminal tagged 
53F270A 53R175H wild-type p53 or control empty vector followed by strep-tactin 
precipitation and immunoblotting of biotin eluates with anti-ubiquitin antibody. Using 
the one-strep purification system the hyperubiquitinated forms of mutant p53' 270" and 
53R175H were efficiently pulled-down (Figure 4.3 (B) arrows Lanes 9-12 vs. Lane 7-8). 
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Morover, addition of 17-AAG (10 tM for 2 hrs) to the cells prior to harvesting resulted 
in a modest increase in p53-ubiquitination levels (Figure 4.3 (B) Lanes 7 vs. 8; Lanes 9 
vs. 10, Lanes 11 vs. 12). 
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Figure 4.1 Schematic representation of One-Strep purification procedure. 
Cells are transfected with the plasmid coding for the bait protein fused to the One-
STrEPtag. After an appropriate expression period, cells are lysed and the bait together 
with bound proteins are isolated using a Strep-Tactin column. Following a biotin elution 
the proteins are resolved on an SDS-gel (4a) and specifically bound proteins e.g. proteins 
not appearing in the mock control can be identified. This is done by either excising the 
protein bands form the gel and subsequent mass spectrometric analysis or, if interaction 
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Figure 4.2 One-Strep purification of wild-type p53, p53F271A  and p53R175H. 
Expression vectors (pEXPR-IBA 105) encoding N-terminus tagged One-strep wild-
type p53, p53R111H and p53F27A  (1.5 tg) or control empty vector were transfected 
in H1299 cells. The expressed proteins (Input, Lane I) were purified on macroprep 
Strep-tactin columns; the flow-through (Lane 2) from the column and biotin eluates 
(Lane 3-8) were resolved on a 10% SDS-PAGE gel prior to immunoblotting for p53 
(DO-1). Expression of N-terminus tagged One-strep mutant p53F27A or p53Rl75l 
yielded high and low molecular mass adducts in a similar fashion to the pc-
DNA3. 1(+) vector encoding these alleles. Approximately 80% of the bait p53 
bound to the strep-tactin resin and was successively eluted in biotin elutions 2-6 
(Lanes 4-8) with a peak in elution 3 (Lane 5). The high and low molecular-p53-
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Figure 4.3 No effect of 17-AAG on wild-type and mutant p53 ubiquitination 
levels and co-precipitation of MDM2 with p53 following One-strep 
purification. 
H1299 cells transfected with N-terminus one-strep tagged wild-type p53, 
mutant (p53F77A  or  p5371H)  or control empty vector (1.5 .tg) in the presence of 
Hsp90 inhibitor 17-AAG (10 iM for 2 hours) or DMSO-control. The expressed 
proteins were purified on Strep-tactin macroprep columns. Proteins from cell lysate 
(Input, Lane I and 5) and biotin eluates (Lanes 2-4 and 6-8) were resolved on 10% 
SDS-PAGE and immunoblotted for endogenous MDM2 (2A10). Wild-type p53 
induced endogenous MDM2 when compared to empty vector, p53F211A or p53RI75 
(Lane I as indicated). Mutant and wild-type p53 display differing binding affinities 
to the two forms of MDM2 with a higher 90 kDa: 60 kDa ratio for wild-type p53 
when compared to mutant p53F270A  or  p53lU75i  (90 and 60 arrows Lanes 2-4 as 
indicated). Hsp90 inhibition by 17-AAG (10 jM for 2 hours) revealed no effect on 
the binding of MDM2 to wild-type or mutant p53. (Lanes 2-4 vs. 6-8). 
H1299 cells transfected with N-terminus one-strep tagged wild-type p53, 
mutant (p53270A  or p53R1151I)  or control empty vector (1.5 .tg) in the presence of 
Hsp90 inhibitor I 7-AAG (10 .tM for 2 hours) or DMSO-control. The expressed 
proteins were purified on Strep-tactin macroprep columns. Proteins from biotin 
eluates were resolved on 4-12 % gel (MOPS running buffer) and immunoblotted for 
transfected p53 (Lanes 1-6) (DO-]) and endogenous ubiquitin (Lanes 7-12) (on 
separate gels). The hyperubiquitinated forms of p53F27O/\  (arrows Lanes 9 and 10) 
and p53R175H  (arrows Lanes ii and 12) were efficiently pulled-down. A modest 
increase in p53 ubiquitination was observed following the addition of 17-AAG 
(Lanes 7 vs. 8; Lanes 9 vs. 10; Lanes II vs. 12) 
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4.4 	Effect of I7AAG co-precipitation of CHIP, HSP70 and HSP40 
with wild-type and mutant one-strep-tagged p53 
To investigate the interaction of mutant or wild-type p53 with CHIP, Hsp70 and 
HSP40, H1299 cells were transiently transfected with one-strep N-terminal tagged 
53F270A 53R1751-1 wild-type p53 or control empty vector followed by strep-tactin 
precipitation and immunoblotting of p53-normalised (data not shown) biotin eluates 
with anti-CHIP, anti-Hsp70 and anti-Hsp40 respectively. CHIP interacted with wild-
type and mutant p53 to similar extent (Figure 4.4 arrows Lanes 2-41  as indicated) 
showing that this E3 ligase does not differentiate between p53 conformations 176  This is 
in accordance with recent findings by Tripathi and co-workers, who show that CHIP 
interacts with the N-terminus of p53 which is intrinsically unstructured in both mutant 
and wild-type p53 177  Interestingly, both mutant and wild-type p53 bind to a 51 kDa 
CHIP-positive band that may correspond to the di-ubiquitinated form of CHIP (Abcam 
anti-CHIP Cat No. PC71 1 datasheet) (Figure 4.4 arrows Lanes 2-4, as indicated). 
On the other hand, mutant p531'270A  or p53R175H  forms a more stable complex 
with the Hsc/Hsp70 than wild-type p53 (Figure 4.5(A) Lanes 2-5 and 7-10, as 
indicated). Using an Hsp70 antibody to immunoblot the biotin eluates, further 
demonstrated the conformation-specific interaction of the Hsp70 molecular chaperone 
with p53 (Figure 4.5 (B) Lanes 2-4 and 6-8). Transient transfection of H1299 thus 
reiterates the findings obtained in p53-expressing cell lines and tumour specimens that 
conformational mutants but not wild-type p53 form stable complexes with molecular 
chaperones 170, 178, 179 (3739) 
Protein complexes between mutant and wild-type p53 and molecular chaperone 
Hsp40 were readily detectable following one-strep purification. However, as for Hsp70, 
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Hsp40 bound with higher affinity to the unfolded conformations of p53 (Figure 4.5 (C) 
Lanes 2-5 and 7-10, as indicated) 
The effect of Hsp90 inhibition by 17AAG on the binding affinity of CHIP, Hsp 
40 and Hsp70 to mutant and wild-type p53 was evaluated by incubating the cells with 
the inhibitor (10 tM for 2 hrs) prior to harvesting and precipitation with strep-tactin 
columns. Addition of 1 7AAG did not statistically change on the binding of CHIP (both 
full-length and di-ubiquitinated) or inducible Hsp70 to mutant or wild-type p53 (Figure 
4.5 (B) Lanes 2-4 and 6-8). On the other hand, however, a modest decrease in binding 
to constitutive Hsc70 and Hsp40 were observed upon addition of the 1 7-AAG (Figure 
4.5 (A) and (C) Lanes 2-5 vs .7-10, as indicated). Further analyses are warranted to 
confirm or refute this observation, preferably by direct knockdown experiments on 
Hsp9O. 
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Figure 4.4 Effect of 17-AAG on on co-precipitation of CHIP with wild-type and 
mutant p53 following One-strep purification. 
H1299 cells transfected with N-terminus one-strep tagged wild-type p53, mutant 
(p53F270A or p53U75H) or control empty vector (1.5 g) in the presence of Hsp90 
inhibitor 17-AAG (10 1tM for 2 hours) or DMSO-control. The expressed proteins 
(Input, Lane 1 and 6) were purified on macroprep Strep-tactin columns and biotin 
eluates (Lane 2-8 and 7-10) were resolved on a 4-12% precast gel (MOPS running 
buffer) prior to immunoblotting for CHIP (Calbiochem). Both wild-type and mutant 
p53 bound to CHIP and di-ubiquitinated CHIP (arrows Lanes 2-4 as indicated) to a 
similar extent. The effect of Hsp90 inhibition by 17-AAG (10 [IM for 2 hours) 
revealed no effect on the binding of CHIP or di-ubiquitinated CHIP to wild-type or 





EL Biotin Elution 	Biotin Elution 
- 	 C 
CD  
3 4 5 6 	3 4 5 6 
Empty 
r 1-
oil 	 Vector 
ii I-- 	 - 	p53 WT -II 0_
En 
I 	 I 
p53R175H 
p53F27OA 
Lanes  2 3 4 5 6 7 8 9 10 
DMSO 	17-AAG 
Biotin Elution 	Biotin Elution 
_ 	 C 
345 	345 
Empty 
I 	 IVector 
p53 WT 
Ii 
I 	 I p53R175H Cit I 
- 	p53F27OA 
Lanes  2 3 4 5 6 7 8 
DMSO 	17-AAG 
Biotin Elution 	Biotin Elution 
- 	 C 






__ 	 -= 	
]p53WT 
I p53R175H CI 
<I 
p53 270A 
Lanes l2 345678910 C 
120 
Figure 4.5 Co-precipitation of Hsp/Hsc70 and HSP40 with wild-type and 
mutant p53 following One-strep purification and effect of 17-AAG. 
H1299 cells transfected with N-terminus one-strep tagged wild-type p53 mutant 
(p53F270A or p53R175H)  or control empty vector (1.5 1g) in the presence of Hsp90 
inhibitor 17-AAG (10 iM for 2 hours) or DMSO-control. The expressed proteins 
were purified on Strep-tactin macroprep columns. Proteins from cell lysate (Input, 
Lane I and 5 or 6) and biotin eluates (Lanes 2-4 or 5 and 7-10 or 6-8) were 
resolved on 10% SDS-PAGE and immunoblotted for endogenous Hsp/Hsc70 
(Stressgen) (A); Hsp70 (Stressgen) (B); and Hsp40 (Stressgen) (C). Mutant 
p53F270A and p53R175FI  bound to Hsc70 (A Lanes 2-5 and 7-10 as indicated) and 
Hsp40 (C Lanes 2-5 and 7-10 as indicated) with a higher affinity when compared to 
wild-type p53. Inducible Hsp70 (B Lanes 2-4 and 6-8) bound mostly to mutant p53 
and not wild-type p53. A modest decrease in binding affinity to Hsc70 and Hsp40 
was observed following the addition of I 7-AAG (A and C Lanes 2-5 vs. 7-10 as 
indicated) 
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4.5 	Identification of novel interaction between Hsp 90AN isoform 
and conformational mutants of p53 
To investigate the transient interaction of Hsp90 with p53 in the folded or 
unfolded conformation the p53 null human lung cancer cell line H1299 was used. In an 
initial experiment, the interaction of wild-type p53 and the conformational mutants 
53F270A and p53R175F1  with Hsp90 was investigated following transient transfection of 
the p53-deficient cell line with the corresponding one-strep plasmid. Immunoblotting of 
biotin eluates with anti-Hsp90 antibody specific to an epitope mapped to amino acids 
604-697 of human Hsp90, surprisingly revealed no distinguishable interaction between 
wild-type or mutant p53 and Hsp90 when compared to mock, empty vector control pull-
down (Figure 4.6 (A) Hsp90 arrow Lanes 2-4 and 6-8 as indicated). The presence of 
Hsp90 in the empty vector biotin eluates probably arises from the interaction between 
Hsp90 and the streptactin-column matrix. This result is not surprising since the 
interaction between Hsp90 and wild-type or mutant p53 is a transient one and possibly 
disrupted by cell lysis (cf.Section 4. 1), hence, future work should address this problem 
by in-vivo protein cross-linking prior to precipitation with strep-tactin beads. 
Intriguingly, however, the antibody used for assaying Hsp90 also recognized a 
faster migrating band at approximately 75 kDa in the wild-type and mutant p53 cell 
lysates (Figure 4.6 (A) bottom 3 panels compared to top panel, AN arrow Lane 1 and 5). 
There are two major cytoplasmic forms of Hsp90, Hsp90u and Hsp 903 which are the 
inducible/major form and constitutive/minor form respectively 180  A recent report 
added another isoform to the Hsp90 family, namely Hsp90AN, which is associated with 
cellular transformation 181  Other Hsp90 analogues include Grp93 in the endoplasmic 
reticulum and Hsp75/TRAP1 in the mitochondrial matrix 180  The TRAP1 and Hsp 
90AN proteins both have a molecular mass of 75 kDa, however the former lacks the 
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carboxy-terminus of Hsp90a/ l, whereas the latter lacks the amino-terminus 182  Since 
the antibody used in this assay binds to the carbox-terminal amino acid residues 604-
697, it is possible to infer that the Hsp90-positive 75 kDa migrating band is Hsp90AN 
and not TRAP 1. 
Interestingly, Hsp90AN appeared to bind preferentially to conformational 
mutants p53' 270'' and p53R175H  rather that wild-type p53 (Figure 4.6 (A) AN arrow 
Lanes 2-4 and 6-8, as indicated). The effect of Hsp 90 inhibition by 1 7AAG on the 
binding affinity of Hsp 90AN to mutant and wild-type p53 was evaluated by incubating 
the cells with the inhibitor prior to harvesting and precipitation with strep-tactin 
columns. Addition of 1 7AAG resulted in a very slight interaction between wild-type 
p53 and Hsp90N (cf Section 4.7 for better example of this interaction). A possible 
reason for the previous observation is that Hsp90a/13 may form oligomers with 
Hsp90AN, which are disrupted following the addition of 1 7AAG. Addition of 1 7AAG 
did not have an effect on the binding of Hsp90AN to mutant p53F270  or p53' 175H 
(Figure 4.6 (A) AN arrow Lanes 2-4 vs. 7-8). This surprising result arises from the fact 
that Hsp 90AN lacks the 1 7-AAG-specific binding site which is located in the amino-
terminus of Hsp 90cL/13. 
In order to further confirm the binding of Hsp 90AN to mutant p53, biotin 
eluates from strep-tactin pull-downs of one-strep mutant, wild-type p53 and empty 
vector control transfected H1299 cells were immunoblotted with an antibody specific to 
Hsp 90AN ( a kind gift of Nicholas Grammatikakis). As shown, in Figure 4.6 (B) Hsp 
90AN specifically interacted with conformationally mutant rather than wild-type p53 
(Figure 4.6 (B) AN arrow Lane 6 vs. 7-8). Furthermore, the Hsp 90AN-specific antibody 
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also recognized a faster migrating band at approximately 51 kDa in the mutant 
53F270A and p53R175H  pulldowns (Figure 4.6 (B) arrow and question marks Lanes 5-8). 
Hsp90-associated ppSO has been identified immunologically and by peptide mapping to 
be the 50-kDa gene product of the mammalian Cdc37 homologue p5 0,d,37 183 It has 
been further proposed that p50cdc37  may serve to target Hsp90 to a subset of protein 
kinases and thereby help them achieve an active conformation 184, 185 However, the 
distantly related yeast Cdc37p by itself has been shown to have chaperone activity in 
vitro 186  Moreover, Grammatikakis and co-workers have shown that p
5 0cd1c37 and Hsp90 
each interact directly with Raf-1 but that p5 O 37 is the main determinant of the 
assembly of heterotrimeric complex. Disruption of the Raf1p5OcdlC37Hsp90  ternary 
complex with the Hsp90 inhibitor geldanamycin or with a dominant negative p5 O' 37 
inhibits Raf-1 activity 187 
In this respect, to investigate the possible interaction of p50cdc37  with mutant or 
wild-type p53 biotin eluates from strep-tactin pull-downs of one-strep mutant, wild-type 
p53 and empty vector control transfected H1299 cells were immunoblotted with an 
antibody specific to p5 O37. p50cdc37  appears to interact with mutant p53 F270A 
53R175H 
and wild-type p53 (Figure 4.6 (C) doublet arrows Lanes 1-4). Moreover, p5 O 37 
appears to migrate as a doublet with non phosphorylated p50cdc37  and phosphorylated 
50cdc37 (Figure 4.6 (C) bottom and top band of the doublet respectively, (Nicholas 
Grammatikakis personal communication) appearing to bind differentially to wt p53 and 
mutant p53 (Figure 4.6 (C) doublet arrows Lanes 1-4). Wild-type p53 might be bound 
to the phosphorylated form while mutant p53 might be bound to the unphosphorylated 
form. (Figure 4.6 (C) doublet arrows Lanes 2 vs. 3-4). In order to confirm or refute the 
differential binding of p53 to phosphorylated or unphosphorylated p5 O 37 a 
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phosphoenricbment procedure ought to be adopted followed by classical 
phosphomapping and phosphosite mutagenesis. 
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Figure 4.6 Identification of p5Oc37  and Hsp90 isoform lacking the N-terminus 
that binds mutant p53. 
H 1299 cells transfected with N-terminus one-strep tagged wild-type p53, 
mutant (p53' 271 or p53 75t') or control empty vector (1.5 1g) in the presence of 
Hsp90 inhibitor 17-AAG (10 sM for 2 hours) or DMSO-control. The expressed 
proteins were purified on Strep-tactin macroprep columns. Proteins from cell lysate 
(Input, Lane I and 5) and biotin eluates (Lanes 2-4 and 6-8) were resolved on 10% 
SDS-PAGE and immunoblotted for endogenous Hsp90 (Stressgen). There was no 
distinguishable interaction between wild-type or mutant p53 and Hsp 90 when 
compared to mock, empty vector control pull-down (Hsp90 arrow Lanes 2-4 and 6-
8 as indicated). Hsp90AN bound exclusively to mutant p53 and not to wild-type p53 
(AN arrow Lanes 2-4 and 6-8 as indicated; see text for details). Addition of 17AAG 
did not have an effect on the binding of Hsp 90LiN to mutant p53127A or p53R175H 
(Figure 4.6 (A) AN arrow Lanes 2-4 vs. 6-8). 
and (C) H 1299 cells transfected with N-terminus one-strep tagged wild-type 
p53, mutant (p53F270A  or p53R175H)  or control empty vector (1.5 sg). The expressed 
proteins were purified on Strep-tactin macroprep columns. (B) Proteins from cell 
lysates (Lanes 1-4) and biotin eluates (Lanes 5-8) were resolved on 4-12 % precast 
gel (MOPS running buffer) and immunoblotted for endogenous Hsp90AN (kind gift 
from N. Grammatikakis). Hsp90AN bound exclusively to mutant p53 and not to 
wild-type p53 (LI]'l arrow Lanes 7+8 vs. 6 as indicated). (C) Proteins from biotin 
eluates (Lanes 1-4) were resolved on 4-12 % precast gel (MOPS running buffer) 
and immunoblotted for endogenous p50 37. Wild-type p53 might be bound to 
phosphorylated p5 0,d,17  whereas mutant p53 F27( or p53R175H  might be bound 
preferentially to the unphosphorylated form (arrows p5Occ37  doublet Lanes 2-4 as 
indicated; see text for details). 
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4.6 	Effect of the addition of Nutlin-3, 17-AAG and X-ray irradiation 
on transfected onestrep p53 
The effect of inhibition of MDM2 and Hsp 90 molecular chaperone activities on 
wild-type p53 was evaluated in H1299 cells transfected with one-strep wild-type p53. 
24 hours post transfection the cells were incubated with either 8 .IM Nutlin-3 and/or 10 
.tM 17 AAG; or DMSO control for 6 hours prior to harvesting (a longer treatment was 
adopted in this and following experiment when compared to previous experiments in 
this chapter in order to augment any subtle differences of Hsp90 inhibition) One plate of 
cells was also harvested 4 hours post irradiation with 5 Gy X-ray (this is the time point 
were p53 Ser'5 phosphorylation [which increases p53-transactivation via increased p300 
binding but has no effect on MDM2 binding] is maximal, Lisa Pang personal 
communication). Cells were lysed in onestrep lysis buffer and resolved on a 4-12 % 
gradient gel prior to immunoblotting with anti-p53 antibody (DO-1). Addition of single 
inhibitors nutlin-3, 1 7-AAG and a combination of nutlin-3 and 1 7AAG resulted in an 
increase in intensity of a DO-1 positive band at 90 kDa when compared to DMSO 
control (Figure 4.7 (A) Lanes 2-4 vs. 1). Moreover, this 90 kDa DO-1 positive band 
decreased following X-ray irradiation (Figure 4.7 (A) Lane 5 vs. 1). Since this band 
usually appeared predominantly with the hyperubiquitinated mutant p53 F270A rather than 
wild-type p53, a conformational ELISA using DO-1 and Pab1620 was carried out to 
investigate the folding status of ectopically transfected one-strep tagged wild-type p53. 
Lysates were serially diluted in onestrep lysis buffer and the degree of wild-type 
conformation-specific antibody Pab 1620 reactivity was normalized against the total 
levels of p53 derived from levels of DO-i binding reactivity. X-ray irradiation appeared 
to increase the wild-type conformation as indicated by the higher affinity of normalized 
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Pab 1620 affinity to X-ray treated cell lysates when compared to DMSO control cell 
lysates (Figure 4.7 (B). No appreciable difference in normalized Pab 1620 affinity was 
observed following the addition of single inhibitors nutlin-3, 17-AAG and a 
combination of nutlin-3 and 17AAG (Figure 4.7 (B). 
The effect of nutlin-3 on the conformation ectopically transfected wild-type p53 
in H1299 may not be representative of what would happen in cells expressing 
endogenous levels of p53, since subtle changes in p53 conformation might be cancelled 
out due to overexpression of the ectopically transfected p53. In this respect, the effect of 
addition of incremental concentrations of Nutlin-3 on endogenous levels of p53 and 
MDM2 was evaluated in A375 cells as well as the folding status of endogenous p53 in 
the same lysates defined by a conformational ELISA using DO-i and Pab 1620. As 
shown in Figure 4.8 (A) the level of p53 increased steadily with incremental addition of 
nutlin-3 up to a concentration of 8 tM (Figure 4.8 (A) Lanes 2-5 vs. 1) after which it 
p53 levels remained constant from 8-20 M (Figure 4.8 (A) Lanes 6 and 7). 
Interestingly, a significant steady increase was observed for p21 and MDM2 up to a 
concentration of 8 iM nutlin-3 Figure 4.8 (A) Lanes 2-5 vs. 1) after which it levelled 
off at 16 and 20 tM (Figure 4.8 (A) Lanes 6 and 7), thereby closely mirroring the levels 
of p53. The degree of p53 folding was determined by normalizing the reactivity of wild-
type specific antibody Pab 1620 against the total levels of p53 derived from levels of 
DO-1 binding reactivity. Intriguingly, a steady increase in wild-type conformation was 
observed up to a concentration of 8 jM after which it levelled off at 16 and 20 tM 
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Figure 4.7 Effect of the addition of Nutlin-3, 17-AAG and X-ray irradiation on 
transfected onestrep p53 
H1299 cells transfected with N-terminus one-strep tagged wild-type p53 (1.5 
pig). 24 hours post transfection the cells were incubated with either 8 tM Nutlin-3; 
10 1iM 17 AAG; 8 jsM Nutlin-3 and 10 jtM 17 AAG; or DMSO control for 6 hours 
prior to harvesting. One plate of cells was also harvested 4 hours post irradiation 
with 5 Gy X-ray. Cell lysates were resolved on a 4-12 % gradient gel prior to 
immunoblotting with anti-p53 antibody (DO-1) (Lanes 1-5). Addition of single 
inhibitors 17-AAG (Lane 2), nutlin-3 (Lane 3) and a combination of nutiin-3 and 
17AAG (Lane 4) resulted in an increase in intensity of a DO-I positive band at 90 
kDa when compared to DMSO control (Lane 1). X-ray irradiation resulted in a 
decrease of the 90 kDa band (Lane 5). 
An ELISA conformation assay of cell lysates (from 4.7A) ofHl299 cells 
transfected with N-terminus one-strep tagged wild-type p53 (1.5 .tg). The signal 
from wild-type conformation specific antibody Pab 1620 was normalized against 
the total levels of p53 derived from levels of DO-i binding reactivity. X-ray 
treatment led to an increase in wild-type p53 conformation when compared to 
DMSO control. No appreciable difference in wild-type conformation in cells treated 
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Figure 4.8 Effect of the addition of Nutlin-3 on endogenous levels of p53 and 
MDM2 in A375 cells 
Nutlin titration of A375 cells. Cells were treated with DMSO control (Lane I) 
or incremental amounts (I to 20 tM) of Nutlin-3 (Lanes 2-7). Cells were harvested 
follwing a 6 hr incubation. Proteins from Triton X-100 cell lysates were resolved on 
a 10% SDS-PAGE gel prior to immunoblotting with anti-MDM2 (2A 10), anti-p2 1, 
anti-p53 (DO- 1)or 3-actin (loading control). MDM2, p21, p53 and ubiquitinated 
p53 increased following nutlin-3 up to a concentration of 8 tM (Figure 4.8 (A) 
Lanes 2-5 vs. 1) after which they levelled off at 16 and 20 ISM (Figure 4.8 (A) Lanes 
6 and 7). 
An ELISA conformation assay of cell lysates (from 4.8A) of A375 cells treated 
with DMSO control or incremental amounts (1-20 jtM) ofNutlin-3. The response of 
wild-type conformation specific antibody Pab 1620 reactivity was normalized 
against the total levels of p53 derived from levels of DO-1 binding reactivity. A 
steady increase in wild-type conformation was observed up to a concentration of 8 
l.LM nutlin-3 after which it levelled off at 16 and 20 p.M. 
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4.7 	Effect of the addition of Nutlin-3, 17-AAG and X-ray irradiation 
on binding of MDM2 and Hsp 90AN with transfected onestrep 
p53 
The effect of inhibition of MDM2 and Hsp 90 molecular chaperone activities by 
nutlin-3 and/or 17-AAG on the binding of MDM2 and Hsp 90AN to mutant p53F270A 
53R175H and wild-type p53 was evaluated in H1299 cells transiently transfected with 
the corresponding N-terminal one-strep tagged constructs. 24 hours post transfection the 
cells were incubated with either 8 ptM Nutlin-3 and/or 10 tM 17 AAG; or DMSO 
control for 6 hours prior to harvesting. One plate of cells was also harvested 4 hours 
post irradiation with 5 Gy X-ray. Following a pull-down with strep-tactin columns the 
biotin eluates were normalized for p53 levels and immunoblotted with anti-MDM2 or 
anti-Hsp 90AN antibodies. 
As indicated previously (cf Figure 4.6 (A), Hsp 90AN co-precipitates with 
mutant p53F271A  (Figure 4.9 Lane 12) and p53R175H  (Figure 4.9 Lane 6) but not wild-
type p53 (Figure 4.9 Lane 1) in DMSO control treated H1299 cells. Interestingly, 
however, wild-type p53 appears to bind to Hsp 90AN upon addition of nutlin-3, 17-
AAG or a combination of nutlin-3 and 17-AAG (Figure 4.9 Lanes 2-4 vs. Lane 1). The 
same effect is also observed with mutant p53' 270' and to a lesser extent with p53R175h1  
(Figure 4.9 Lane 13-15 vs. 12 and Lanes 7,8,10,11 vs. 6). X-ray irradiation of mutant 
p53 F2711  (Figure 4.9 Lane 16), p53R175  (Figure 4.9 Lane 10) resulted in a decrease in 
binding of Hsp 90AN. In the case of wild-type p53 these modulations of Hsp 90AN 
binding correlate with the change observed in the levels of the high-molecular mass of 
p53 (Figure 4.7 (A). It is therefore possible that addition of these inhibitors and 
induction of DNA damage by X-rays modifies the p53 chaperome in cells. 
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This modification of the p53 chaperome is indeed further reinforced with the 
effect of the above mentioned inhibitors or X-ray induced damage on the binding of 
MDM2 to wild-type p53. As shown in Figure 4.10 nutlin-3 abolishes the interaction of 
p53 with MDM2 compared to DMSO control (Figure 4.10 Lane 3 vs. 1). As expected 
X-ray induced damage results in a decrease of MDM2 binding to p53 when compared 
to DMSO control (Figure 4.10 Lane 5 vs. 1). On the other hand, addition of 17-AAG 
results in an increase in binding of p53 to MDM2 when compared to DMSO control 
(Figure 4.10 Lane 2 vs. 1) and the interaction is once again reduced upon concomitant 
addition of nutlin-3 (Figure 4.10 Lane 4 vs 2). These data suggest that the p53: MDM2 
interaction is dynamic and can be altered following addition of inhibitors to MDM2 or 
Hsp90. Further studies are therefore warranted to investigate the modification of this 
and other interactions by use of highly purified proteins and in-vitro assays. As shown 
previously in Figure 4.3A, only very low levels of the 90 kDa MDM2 bound to mutant 
p53 (Figure 4.10 Lanes 6-8 and 10-16). This was unchanged following the addition of 
inhibitors or X-rays. 
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Figure 4.9 
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Figure 4.9 Effect of the addition of Nutlin-3, 17-AAG and X-ray irradiation on 
binding Hsp 90AN with transfected onestrep p53 
H 1299 cells transfected with N-terminus one-strep tagged wild-type p53, mutant 
(p53F270A or p53R175H)  or control empty vector (1.5 tg) 24 hours post transfection 
the cells were incubated with either 8 iM Nutlin-3; 10 LM 17 AAG; 8 iM Nutlin-3 
and 10 iM 17 AAG; or DM SO control for 6 hours prior to harvesting. One plate of 
cells was also harvested 4 hours post irradiation with 5 Gy X-ray. The expressed 
proteins were purified on Strep-tactin macroprep columns. Proteins from biotin 
elution 3 (Lanes 1-18) were resolved on 10% SDS-PAGE and immunoblotted for 
endogenous Hsp90N. Hsp 90LN co-precipitates with mutant p53F270A  (Lane 12) 
and p53RI75H  (Lane 6) but not wild-type p53 (Lane 1) in DMSO control treated 
H1299 cells. Wild-type p53 appears to bind to Hsp 90N upon addition of nutlin-3, 
17-AAG or a combination of nut!in-3 and 17-AAG (Lanes 2-4 vs. Lane 1). X-ray 
irradiation of mutant p53F271A  (Lane 16), p537111 (Lane JO) resulted in a decrease 
in binding of Hsp 90N. 
1- 
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Figure 4.10 Effect of the addition of Nutlin-3, 17-AAG and X-ray irradiation 
on binding of MDM2 with transfected onestrep p53 
(A) H1299 cells transfected with N-terminus one-strep tagged wild-type p53, 
mutant (p53t27A  or p53R175F1)  or control empty vector (1.5 jsg) 24 hours post 
transfection the cells were incubated with either 8 iM Nutlin-3; 10 jiM 17 AAG; 8 
lAM Nutlin-3 and 10 jiM 17 AAG; or DMSO control for 6 hours prior to harvesting. 
One plate of cells was also harvested 4 hours post irradiation with 5 Gy X-ray. The 
expressed proteins were purified on Strep-tactin macroprep columns. Proteins from 
biotin eluates (Lanes 1-18) were resolved on a 4-12 % precast gel (MOPS running 
buffer) and immunoblotted for endogenous MDM2 (2A10). The p53-MDM2 
interaction was abolished following nutlin-3 addition (arrow Lane 3) and reduced 
following X-ray irradiation (arrow Lane 5) when compared to DMSO control 
(arrow Lane 1). The p53-MDM2 interaction was augmented following 17-AAG 
(arrow Lane 2) when compared to DMSO control (arrow Lane 1). An increase in 
MDM2 interaction was observed following the concomitant addition of nutlin-3 and 
17-AAG (arrow Lane 4) when compared to nutlin-3 treatment alone (arrow Lane 3). 
4.8 	Identification of intermediate filament vimentin as a binding 
partner to p53 and TCPI beta and hnRNP-M4 that specifically 
bind to mutant p53 by mass spectrometry 
In an attempt to identify novel chaperones that bind mutant and/or wild-type 
p53, the onestrep purification system was used prior to analysis by nano-LC-MS/MS. 
Briefly, p53 null H1299 cells were transiently transfected with N-terminus tagged 
onestrep p53 F270A 53R175H wild-type p53 or empty control vector. 24 hours post 
transfection the cells were harvested and lysed in one-strep lysis buffer prior to affinity 
purification on strep-tactin columns. The biotin eluates were resolved on 4-12% 
gradient gels, colloidal blue stained and gel bands (that were present in positive 
pulldowns but absent in mock control) excised for tryptic digestion and analysis by 
nano-LC-MS/MS. As a control, gel slices that migrated at a similar molecular weight in 
the mock empty vector were also subjected to analysis by nano-LC-MS/MS to eliminate 
any false positive that might have arisen due to lack of colloidal blue staining of the 
empty control eluate (Figure 4.11 arrows). 
The results are summarized in Table 4.1. 
The colloidal blue stained gels are illustrated in Figure 4.11. As expected, Hsp 
70 was positively identified with mutant but not wild-type p53 in the gel bands 
migrating at 70 kDa (labelled A in Figure 4.11). 
Analysis of the gel bands from mutant and wild-type p53 that migrated at 
approximately 50 kDa (labelled as B in Figure 4.11) showed the presence of p53 and 
vimentin. Additionally, in the case of mutant p53F'270  but not p53
R175H  or p53 wild-type 
TCP1 beta and heterogeneous nuclear ribonucleoprotein M4 (hnRNP-M4) were also 
positively identified. Intriguingly, Gattoni and co-workers have demonstrated that 
following a 10 minute heat shock at 45°C, hnRNP-M4, which is associated with pre- 
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mRNA splicing, transiently leaves the hnRNP population and strongly binds to the 
nuclear matrix 188  Further investigations should be undertaken to investigate whether 
the hnRNP-p53 interaction is specific to mutant and not to wild-type p53. Should 
hnRNP-M4 bind to wild-type p53, this might highlight a novel way of p53-mediated 
cell-cycle-control/arrest. 
To investigate the possibility that binding of vimentin to p53 is altered following the 
addition of either 8 .iM Nutlin-3 and/or 10 tM 17 AAG or DMSO control following a 6 
hour incubation, H1299 cells were transfected with N-terminally tagged onestrep 
mutant wild-type p53. One plate of cells was also harvested 4 hours post irradiation 
with 5 Gy X-ray. Following a onestrep purification, the protein complexes were 
resolved on a 4-12% gradient gel and immunoblotted for vimentin (V9 Sigma) and anti-
p53 (DO-1). The association of vimentin with wild-type p53 was not reproducibly 
affected by any of the inhibitors or X-ray showing (Figure 4.12 Lane 2-5 vs. 1) that the 
modification on wild-type p53 protein and chaperome by these inhibitors and X-rays 
(cf Section 4.7) does not result from a shift of the p53-vimentin association. 
The above mentioned inhibitors and X-ray irradiation were also used to investigate the 
effect on TCP 1 beta binding to p53 by immunoblotting the one-strep purified eluates 
with anti-TCP1 beta antibody (Abcam). The specific association of TCP1 beta with 
p53 11711  (Figure 4.12 Lanes 12-16) and not wild-type (Figure 4.12 Lanes 1-5), p
53 R175F1 
(Figure 4.12 Lanes 6-10) or empty vector control (Figure 4.12 Lanes 9, 17 and 18) was 
thereby confirmed by this technique. Moreover, the association between TCP 1 beta and 
53F270A was not statistically affected by the addition of inhibitors or X-ray induced 
damage highlighting the stability of this interaction (Figure 4.12 Lanes 13-16 vs. 12). 
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Interestingly, p53R175H  appeared to bind to TCP1 beta only following concomitant 
addition of 17-AAG and Nutlin-3 (Figure 4.12 Lane 11). 
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Figure 4.11 
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(B)p53 IRI 75ii vimentin Homo sapiens 53710 gi)37852 5 95 
(A) p53 WT keratin 1 Home sapiens 66198 91111935049 13 525 
P53 Home sapiens 44226 gi)23491729 12 515 
(3) p53 WT vimentin Home sapiens 53710 91 )37852 3 76 
(A) Empty keratin 1 Home sapiens 1 	66198 gill l935049 11 651 
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Figure 4.11 Identification of intermediate filament vimentin as a binding 
partner to p53 and TCP1 beta and hnRNP-M4 that specifically bind to mutant 
p53 by mass spectrometry 
H1299 cells transfected with N-terminus one-strep tagged wild-type p53, mutant 
(p53F270A or p53RI75H)  or control empty vector (1.5 [tg). The expressed proteins 
were purified on macroprep Strep-tactin columns and biotin eluates were resolved 
on a 4-12% precast gel (MOPS running buffer) prior to colloidal blue staining. 
Bands A and B from biotin eluates of each construct were excised, digested with 
trypsin and the resultant peptides separated and identified on an nano-LC-MS-MS. 
Table 4.1 Mass spectrometric identification of gel slices A and B from Fig 4.11 
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Figure 4.12 
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Figure 4.12 Effect of the addition of Nutlin-3, 17-AAG and X-ray irradiation 
on binding of vimentin and TCP-1 beta with transfected onestrep p53 
H1299 cells transfected with N-terminus one-strep tagged wild-type p53, mutant 
(p5.3 17270A  or p53fl75F)  or control empty vector (1.5 jig) 24 hours post transfection 
the cells were incubated with either 8 jiM Nutlin-3; 10 jiM 17 AAG; 8 jiM Nutlin-3 
and 10 jiM 17 AAG; or DMSO control for 6 hours prior to harvesting. One plate of 
cells was also harvested 4 hours post irradiation with 5 Gy X-ray. The expressed 
proteins were purified on Strep-tactin macroprep columns. Proteins from biotin 
eluates (Lanes 1-18) were resolved on 10% SDS-PAGE and immunoblotted for 
endogenous TCP-1 beta and vimentin. The association of vimentin with wild-type 
p53 was not affected by any of the inhibitors or X-ray (Lanes 1-5 as indicated) 
TCP-1 beta interacted with p53F271A  (Lanes 12-16) but not wild-type (Lanes 1-5) or 
p53R175H (Lanes 6-10). p53RI75IT  interacted with TCP-1 beta following concomitant 
addition of nutlin and 17-AAG 
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4.9 Discussion 
Molecular chaperones associate with non-native proteins and participate in the folding 
of newly translated and damaged polypeptides. Recently, molecular chaperones have 
also been linked with protein degradation, when the chaperone associated protein is 
directed to the degradation machinery rather than onto the folding pathway. Chaperone 
associated ubiquitin ligases, such as the CHIP, are the key component for labelling 
chaperone substrates for degradation. CHIP binds Hsp70 and Hsp90 via an N-terminal 
tetratricopeptide repeat (TPR) domain together with a highly charged region. CHIP also 
possesses a U-box that enables the co-chaperone to interact with ubiquitin-conjugating 
enzymes, such as human Ubc4/5 family members. In conjunction with Ubc, CHIP 
mediates the ubiquitination of chaperone substrates presented by Hsp70 and Hsp90. 
Therefore the chaperone/CFIIP/Ubc complex may actually be viewed as a multi-subunit 
ubiquitin ligase complex, in which the chaperone acts as the main substrate recognition 
factor 88 
This study has shown that both mutant and wild-type p53 interact with CHIP, a result 
which is in accordance with previous studies carried out in the Hohfeld and Vousden 
laboratories 108, 109 However, this study also highlights an interaction between di-
ubiquitinated CHIP with mutant and wild-type p53 189 
This study has also shown that mutant p53 interacts with a higher affinity with Hsc70 
and almost exclusively with induced Hsp70 when compared to wild-type p53. The 
binding of Hsc70 to wild-type p53 is in accordance with results obtained by King and 
co-workers 171  Moreover, Hsp40 binds with a higher affinity to mutant p53 when 
compared to wild-type, once again in agreement with findings by King and co-workers 
171 thereby adding in-cellulo evidence to the model that mutant p53 forms a stable mega- 
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complex with molecular chaperones which ultimately leads to the increased stability 
and degradation-resistance of mutant p53 within cells. 
There is substantial bibliographical information that has highlighted the 90-kDa heat 
shock protein Hsp90 as a potential target of anticancer therapy 190  Two main reasons 
warrant this. Firstly, the majority of Hsp90 substrates are signalling intermediates of 
clinical importance, which require Hsp90 for proper conformation and activity, and 
secondly, Hsp90 can be inhibited by anisamycins and radicicol, which bind the 
nucleotide-binding pocket and inhibit the ATPase activity of the molecule. Although the 
interaction between I-Isp90 and mutant or wild-type p53 has proved elusive, possibly 
due to the very transient interaction between these two proteins as suggested by King et 
al. 171  an interaction was positively identified between mutant and wild-type p53 and 
50cdc37 the specific co-factor of Hsp90 183  Furthermore, wild-type p53 might be bound 
to the phosphorylated form while mutant p53 might be bound to the unphosphorylated 
form. In this context it is relevant to add that Nicholas Grammatikakis showed that 
while p53 can be found in various kinase complexes, overexpression of 50cdc37  titres 
p53 away from such complexes. Therefore phosphorylation events (on p53 and/or 
cdc37) might also regulate the formation of p53 complexes (Nicholas Grammatikakis 
personal communication unpublished data). This study has also identified the specific 
interaction between Hsp90AN, an isoform of flsp90 lacking the N-terminus and mutant 
p53. Although wild-type p53 does not appear to interact with Hsp90AN under normal 
conditions, addition of specific inhibitors of MDM2 (nutlin-3), Hsp90 (17-AAG) or a 
combination of the two results in the formation of a complex between Hsp90AN and 
wild-type p53. Interestingly, induction of DNA damage by ionizing radiation results in 
a decreased association of Hsp90AN mutant p53. The above observations occurred in 
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conjunction with an increase in intensity of a DO-i positive band at 90 kDa when 
compared to DMSO control in wild-type p53 transfected cells. Moreover, this 90 kDa 
DO-1 positive band decreased following X-ray irradiation of wild-type p53 transfected 
cells. In the case of nutlin treated cells, an increase in wild-type conformation was 
observed with endogenous p53 in A375 cells. An increase in endogenous p53 protein 
levels was also observed in A375 cells together with a concomitant increase of p53 
transcriptional targets MDM2 and p21. Together, these results suggest an alteration of 
the wild-type p53 protein levels and conformation upon nutlin-3 addition which results 
in an alteration of the interaction between mutant/wild-type p53 and Hsp90AN. In other 
words, reduction of the Hsp90/MDM2:p53 interaction/s, results in an increase of 
mutant/wild-type p53 interaction with Hsp90AN. The above results taken together 
indicate that Hsp90AN might bind to and regulate p53 in its own right. Hsp90AN has 
been shown to interact with and activate Raf in an association that does not require 
50cdc37 and with a higher affinity than HSP90 181  Higher levels of Hsp90AN 
expression resulted in neoplastic transformation, including interruption of gap juntional, 
intercellular communication and anchorage-independent proliferation 181 
Taken together, results from this study and from Grammatikakis and co-workers 
suggest a molecular chaperone role for Hsp90AN. Backing this notion, in vitro work 
from the Buchner laboratory and in vivo work in the Hard laboratory 
191, 192 
demonstrated that the C-terminal domain of Hsp90 possesses a chaperone activity of its 
own which is independent from the activity residing at the N-terminus. In addition the 
Hsp90 C-terminal binding and release to protein substrates in vitro was unaffected by 
Hsp90 cofactors 191  Since the C-terminal chaperone activity is apparently conserved in 
Hsp90AN, it is logical to speculate that Hsp90AN also possesses the capacity to bind to 
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and chaperone its substrate(s) in a direct manner. This study, thereby calls for direct 
analysis of the Hsp90/ Hsp90AN interaction with p53 possibly via a crystallographical 
approach. Furthermore, the interaction between I-Isp90AN and mutant p53 should be 
further scrutinized to investigate whether it is responsible, at least in part, for the 
accumulation of mutant p53 to high levels in tumour cells. If this were the case, it 
would be important to design specific inhibitors for both the N-terminus and C-terminus 
of Hsp90. The recent finding of a C-terminal nucleotide binding site 193  and the 
characterisation of its differential nucleotide binding specificity '' might help 
accomplish this task. 
This study shows preliminary evidence for the interaction between chaperonin 
containing TCP 1, subunit 2 (beta) (CCT) and the conformationally misfolded mutant 
53F270A Chaperonins are the major molecular chaperones in Escherichia coil. In 
Escherichia coil, after approximately 50 residues on the nascent polypeptide chain 
interact with DnaJ (an Hsp40) and DnaK (an Hsp70), the growing polypeptide is passed 
on to the lumen of a double-ring complex formed by 14 subunits of GroEL (an Hsp60) 
- a chaperonin 190  The GroEL ring can be capped by a seven-subunit ring of GroES (an 
HsplO), transiently enclosing the nascent polypeptide within the GroEL cavity 
190 
Many models depict a folding reaction occurring within the central lumen in the 
chaperonins, thereby protecting the target protein from interaction with other proteins, 
following which, release of the native structure occurs 195-199  This model has been 
challenged by evidence that target proteins can jump between different chaperonin 
molecules during a folding reaction ("cycling") 201,211  Thus the function of chaperonins 
might be to unfold and release proteins that have been misfolded. Whereas GroEL is a 
general nascent chain factor in prokaryotes, the closest Hsp60 homologs in eukaryotes 
wt 
are in mitochondria and chloroplasts (essentially prokaryotic organelles). In the 
cytoplasmic compartment there is a family of proteins, termed T-complex polypeptides 
(TCP5) that are loosely homologous with GroEL and form toroidal structures similar to 
that of GroEL 202  TCP ring complexes are less abundant in cytoplasm than would 
appear to be necessary for general protein folding, so they may have a limited range of 
substrates. Significantly, tubulin and actin subunits are specific substrates that require 
the chaperoning of TCP ring complexes 203  Further work using a crystallographic 
approach is necessary to elucidate whether CCT binds misfolded p53 in the nucleotide-
free conformation, and whether following ATP binding, a closed structure of CCT, is 
created as observed when CCT interact to chaperone actin and tubulin 204 
This study has also highlighted a potential interaction with heterogeneous 
nuclear ribonucleoprotein M4 (hnRNP-M4). Although the effects on either mutant or 
wild-type p53 have not been investigated further studies are warranted since hnRNPs 
are known to have multiple functions related to other transcription factors. hnRNPs are 
nuclear RNA-binding proteins that form complexes with RNA polymerase II 
transcripts. They function in many cellular activities ranging from transcription and 
premRNA processing in the nucleus to cytoplasmic mRNA translation and turnover 205 
hnRNP K is involved in transcriptional activation and repression, RNA splicing and 
stability, translation activation and silencing, signal transduction, and chromatin 
remodelling 206  hnRNP U participates in regulation of transcription of several genes. It 
binds to a 65 kDa Yes-associated protein, regulating its co-activation of Bax 
transcription 207  and it regulates Kruppel-like factor 2 transcription 
207  It regulates 
initiation of transcription in general by associating with both actin and Pol 11 
208 
HnRNP F binds to TATAbinding protein, associates with RNA polymerase II, and 
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interacts with the nuclear cap-binding complex. It binds to the insulin-responsive 
element of the rat angiotensinogen gene, regulating transcription of that gene 209  A 
proteomic approach to determine protein interactions of transcription factor tonicity-
responsive enhancer/osmotic response element-binding protein (TonEBP/OREBP) also 
identified a physical interaction with hnRNP M 210 
Interestingly, a separate proteomic approach by Moumen and co-workers identified 
hnRNP K as being rapidly induced by DNA damage (via ATM and ATR) ultimately 
cooperating with p53 to elicit the activation of p53 target genes and thereby trigger cell-
cycle-checkpoint events. Moroever the same researchers show that hnRNP K is targeted 
for HDM2/MDM2-dependent proteasomal turnover in undamaged cells and that this 
degradation promptly ceases upon the creation of DNA damage 211 
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5.0 Ubiquitination status of CHK2 naturally occurring mutations 
5.1 Introduction 
The Checkpoint Kinase 2 (CHK2) regulatory amino-terminus comprises an 
SQ/TQ cluster domain (amino acid residues 19-69), that is the target for upstream 
phosphatidylinositol-3 kinase (PI-3K)-like kinase (PIKK) activities, and a 
phosphopeptide-binding Forkhead- associated (FHA) module (amino acid residues 113-
175). The carboxy-terminal catalytic domain (amino acid residues 220-486) is related to 
the 	Ca2+  /calmoduhn- dependent protein kinase (CaMK) family. The CHK2 FHA 
domain consists of an 11-stranded-13 sandwich that binds to phospho-threonine 
containing peptides 212  CHK2 is inactive in the absence of genotoxic stress but is 
activated in the presence of DNA double stranded breaks (DsBs). Activation of CHK2 
occurs via the ATM dependent phosphorylation of CHK2 on T68. Following 
phosphorylation at T68 CHK2 dimerize at the FHA domains leading to transactivation 
of other Chk2 proteins via phosphorlyation at T383/T387. Chk2 also undergoes 
autophosphorlyation at S516 and T68 6  Two oncogenic mutations reside within the 
FHA domain, namely R145W and 1157T. These mutations have been shown to reside 
on one face of the FHA 3 sandwich domain, remote from the site of peptide binding. 
The R145 residue is located on the 35 and forms the core of a network of hydrogen 
bonding, nonpolar, and van der Waals interactions involving constellation amino acids 
on the neighbouring J3 strands 212  Other CHK2 inactivating, cancer-associated 
mutations involve the common frameshift deiC 1100 and delT1422 mutations which 
encode premature stop codons within the catalytic domain, and the resulting truncated 
mutant proteins are both inactive and unstable 213  A novel breast cancer-derived CHK2 
frameshift mutant insA1368 encodes a premature stop codon within the kinase domain, 
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resulting in expression of a stable protein that is mislocalized to the cytoplasm. 
Interestingly, the breast cancer expressing the insA1368 mutant was found to be 
resistant to the chemotherapeutic agent doxorubicin, a characteristic normally associated 
with mutated p53 in these tumours. Thus, cytoplasmic localization of CHK2 may be a 
novel marker for breast cancers that are drug resistant 214 
Protein phosphatases comprise several families of enzymes that catalyse the 
dephosphorylation of intracellular phosphoproteins, thereby reversing the actions of 
protein kinases. This critical property of the reversibility of intracellular protein 
phosphorylation allows for great sensitivity of control and integration of cellular 
regulation. Protein phosphatases, however, must not be considered simply as passive 
'off-switches', since they are intricately regulated, particularly in response to 
extracellular stimuli [ix]. Protein phosphatase 2C (PP2C) exists as two isoforms, with 
catalytic subunits of 42 and 44 kDa, It is completely dependent on magnesium ions for 
activity. The amino acid sequence of PP2C is unrelated to its other family members 
PP1, PP2A or PP213. The best candidates for PP2C mediated dephosporylation are: 
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (IKKbeta), 
mitogen-activated protein kinase kinase kinase 7 (MAP3K7), cyclin-dependent kinase 2 
(CDK2), AMP-activated protein kinase and p53 215-218 
CHK2 is critical for DNA-damage induced apoptosis, since the CHK2 null cells 
from knockout mice showed remarkable resistance to ionizing radiation 
219 
Consequently, it is important to understand how CHK2 is degraded in cells. Therefore, 
the aim of the following chapter was to elucidate the ubiquitination status of wild-type 
and mutant CHK2 in a cellular system in vivo. An immunoaffinity approach coupled 
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with mass-spectrometry was used to identify PP2C as a potential novel binding partner 
of CHK2. 
5.2 	Wild-type and mutant CHK2 are degraded by the proteasome 
To investigate whether mutant or wild-type CHK2 protein expression was 
affected by proteasome mediated degradation, A549 cells were transfected with 
p3XFLAG-myc-CMVTM-26 vector encoding wild-type CHK2, CHK2""', CHK2II57T, 
CHK2IA1368 or CHK2deICII00 (8j.ig). 24 hours post transfection the cells were treated 
with proteasome inhibitor MG132 (20 LM) or DMSO control for 6 hours. The steady-
state levels of CHK2 proteins were evaluated by resolving the cells lysates on a 4-12% 
gradient gel (MOPS running buffer) followed by immunoblotting with anti-CHK2 
antibody (Al2). Wild-type C1-1K2 and CHK2 571 are expressed at high levels under 
DMSO control conditions (Figure 5.1 bottom panel, arrows Lane 7 and 9). Addition of 
proteasome inhibitor resulted in a modest increase in expression of wild-type CHK2 
protein and CHK2 delCi 100 (Figure 5.1 bottom panel, arrows Lane 2 vs. 7 and Lane 6 vs. 
11) with a concomitant increase in high-molecular-mass adducts (Figure 5.1 top panel, 
bracket Lane 2 vs. 7 and Lane 4 vs. 9). A more pronounced effect was observed with 
mutant CHK2' 115W  protein (Figure 5.1 bottom panel, arrow Lane 3 vs. 8) with a 
concomitant increase in high-molecular-mass adducts (Figure 5.1 top panel, bracket 
Lane 3 vs. 8). No significant change was observed with CHK2 
1151T  or CHK21AI368  
protein (Figure 5.1 bottom panel, arrows Lane 4 vs. 9 and botton panel, bracket Lane 5 
vs. 10, respectively), however, an increase in high-molecular-mass adducts could be 
clearly observed (Figure 5.1 top panel, bracket Lane 4 vs. 9 and top panel, bracket Lane 
5 vs 10, respectively). 
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Figure 5.1 
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Figure 5.1 Effect of proteasome inhibition on transfected CHK2 wild-type and 
mutant 
Expression vector (p3XFLAG-myc-CMVTM-26) encoding wild-type CHK2, 
CHK245W, CHK257T, CHK2iflSAI368 or CHK2deICII00 (8jig) were transfected in 
A549 cells and 24 hours post-transfection incubated in the presence ofMGl32 
(20ttM) or DMSO control. 6 hours post-treatment the expressed proteins were 
examined for changes in steady-state levels of CHK2 (bottom panel, ¶ arrows Lanes 
2-11). Addition of MG 132 resulted in an increase of protein levels for wild-type 
CHK2 (bottom panel, ¶ arrows Lane 2 vs. 7), CHK241\v (bottom panel, ¶ arrows 
Lane 3 vs. 8)and CHK2deICII00 (bottom panel, ¶ arrows Lane 6vs. 11). MG 132 also 
resulted in an increase in high molecular mass adducts for wild-type CHK2 and 
mutant CHK2RI 41W, CHK2II57T, CHK2iflSAI368 and CHK2deICIIOO when compared to 
DMSO control (top panel, bracket, Lanes 2-6 vs Lanes 7-11) as determined by 
immunoblotting with anti-CHK2 antibody (Al2). 
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5.3 	CHK2RI45W  exhibits a shortened half-life and enhanced 
ubiquitination when compared to wild-type CHK2 and 
CHK2II57T 
The half-lives of wild-type CHK2, CHK2RI45W  and CHK2' 57T  were examined to 
determine whether the low protein level of CHK2RI45W  stemmed from a high 
degradation rate when compared to wild-type C1-1K2 and CHK2II57T.  A549 cells were 
transfected with p3XFLAG-myc-CMVTM-26 vector encoding wild-type CHK2, 
CHK2RI45W or  CHK2II57T.  24 hours post transfection the cells were treated with 
cycloheximide (10 jiM) at 0.5, 1, 2, 4, 6, 8 and 10 hrs. An untreated, but transfected, 
control was included. The proteins from cell lysates were examined for turn-over rate by 
immunoblotting with anti-Flag (M2) antibody. Transfection of wild-type CHK2 and 
CHK2' 157T  alleles resulted in the expression of stable proteins with a half-life (t172) 
greater than 10 hrs (Figure 5.2 top and middle panels Lanes 1-16). In contrast 
CHK2RI45W exhibited a high turn-over rate 41,2  approx. 2 hrs Figure 5.2 bottom panel 
Lanes 25-32). 
To elucidate whether the high turn-over rate of CHK2RI45W  resulted from 
enhanced ubiquitination levels, A549 cells were transfected with p3XFLAG-myc-
CMVTM26 wild-type CHK2, CHK2RI45W, CHK2 57T,  CFIK2deICI 100 or CHK2IAI368 and 
immunoprecipitated with anti-Flag antibody followed by competitive elution with 
3xFlag peptide. Although, CHK2 could be efficiently pulled-down with this procedure 
(cf Figure 5.7), a high background in the high-molecular-mass range interfered with the 
interpretation of ubiquitination levels. Due to this hindrance, wild-type CHK2, 
CHK2RI41 i, CHK2U57T, CHK2deICII00 and CHK2IA1368 alleles were subcloned into one -
strep vector pEXPR-IBA105 containing an N-terminal one-strep tag from the 
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p3XFLAG-myc-CMVTM-26 vector using Eco RI and Hind III restriction sites. To 
isolate one-strep tagged CHK2, lysates from MG132 treated, mutant or wild-type one-
strep-CHK2-expressing A549 cells and from control cells (empty vector transfected 
A549 cells) were subjected to affinity chromatography on strep-tactin macroprep 
columns (polymethacrylate resin). Following a wash step, bait mutant or wild-type 
CHK2 was eluted with six sequential biotin elutions (2mM). As shown in Figure 5.3 all 
proteins were efficiently eluted in elution fractions 1-3 (Figure 5.3 Lanes 2-4). The 
same biotin eluates (following normalization of CHK2 protein level by densitometry) 
were resolved on a 10% SDS-PAGE gel and immunoblotted with anti-ubiquitin 
antibody. Due to the heterogeneous nature of ubiquitin conjugation polyubiquitinated 
forms of CHK2 could only be detected as a large molecular size smear. This experiment 
demonstrated the enhanced ubiquitination of CHK2RI45W  when compared to wild-type 
CHK2 and other mutants in the presence of MG132 (Figure 5.4 Lanes 2-5 as indicated). 
This observation might arise due to the inherent nature of the amino acid residue 
substitution; although arginine and tryptophan are sterically similar, a charge difference 
might disrupt the hydrophobic interactions with constellation amino acid residues in the 
n-sandwich that maintain the structure of the FHA, potentially making it more 
susceptible to proteolysis by the ubiquitinlproteasome pathway. 
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Figure 5.2 
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Figure 5.2 The half-life of mutant CHK2R175  is reduced when compared to 
wild-type CHK2 or mutant CHK2' 117T 
Expression vector (p3XFLAG-myc-CMVTM-26) encoding wild-type CHK2, 
CHK2I 45W, CHK2II57T, (81g, as indicated) were transfected in A549 cells. 24 
hours post transfection, cycloheximide was added to the cells and harvested at time 
points 0 hrs (no cycloheximide addition), 0.5, 1,2,4, 6, 8 and 10 hrs. The examined 
proteins were examined for steady-state levels of CHK2 by immunoblotting with 
anti-Flag antibody (M2). Transfection of wild-type CHK2 and mutant CHK2II57T 
led to the expression of a stable protein with a half-life> 10 hrs. CHK2RI45W  mutant 
displayed a much reduced half-life ( approx 2 hrs) when compared to wild-type 
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Figure 5.3 One-Strep purification of wild-type CHK2, CHK2RI45', CHK2II57T, 
CHK2deICII00 and CHK2 flSAI368 
Expression vectors (pEXPR-IBA 105) encoding N-terminus tagged One-strep wild-
type CHK2, CHK2RI45W, CHK21117T, CHK2deICII00 and CHK2IflSAI368(8  1g) or 
control empty vector were transfected in A549 cells and 24 hours post-transfection 
incubated in the presence ofMGl32 (20tM). The expressed proteins (Input, Lane 
1) were purified using macroprep Strep-tactin resin (microcentrifuge tube format) 
and biotin eluates (Lane 2-7) were resolved on a 10% SDS-PAGE gel prior to 
immunoblotting with anti-strep tag antibody. The CHK2 proteins were successively 
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Figure 5.4 Ubiquitination levels of wild-type CHK2, CHK2RI45W,  CHK2 157T, 
CHK2 MCI 100 and CHK2 IflSA!368 
Expression vectors (pEXPR-IBA 105) encoding N-terminus tagged One-strep wild-
type CHK2, CHK2RI45W,  CHK21157 , CHK2deICII00  and CHK2iflSAI368  (8 jtg) or 
control empty vector were transfected in A549 cells and 24 hours post-transfection 
incubated in the presence of MG 132 (20MM). The expressed proteins (Input, Lane 
1) were purified using macroprep Strep-tactin resin (microcentrifuge tube format) 
and biotin eluates (Lane 2-7) were resolved on a 10% SDS-PAGE gel prior to 
immunoblotting with anti-ubiquitin antibody. CHK2RI 45W exhibits enhanced 
ubiquitination when compared to wild-type CHK2, CHK2iI1SAI3681 CHK21I57T or 
CHK2deICI 00 
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5.4 	Identification of protein phosphatase 1  as a binding partner 
to CHK2 by mass spectrometry 
Repeated attempts to identify CI-1K2 binding partners following one-strep 
purification procedure proved elusive. Therefore, MCF7 cells were transfected with 
p3XFLAG-myc-CMVTM-26 wild-type, mutant CHK2 or empty vector. As seen in 
Figure 5.5 ectopic transfection of these constructs results in similar levels as when the 
same proteins are expressed following the transfection of the same alleles cloned in the 
one-strep vector. Due to frameshifi mutations in CHK2deICIIOO and CHK2I sA 1368  result in 
premature stop codons the c-myc epitope on the C-terminus of these constructs was 
truncated from these proteins (Figure 5.5 bottom 2 panels, Lanes 4 and 5 vs. Lanes 1-3). 
In addition, incremental amounts of in-vivo cross-linking agent EGS (1-8 mM) to 
ectopically transfected MCF7 cells with wild-type 3xflag-c-myc-CHK2 resulted in 
effective cross-linking of CHK2 as a dimer (Figure 5.6 Lanes 1-5 vs. 7). In light of 
these results MCF7 cells were transfected with p3XFLAG-myc-CMVTM-26 wild-type 
CHK2 or empty vector and immunoprecipitated with anti-Flag antibody followed by 
competitive elution with 3xFlag peptide. The 3xFlag-eluates were then 
immunoprecipitated with anti-c-myc antibody crosslinked to sepharose beads followed 
by a competitive elution with c-myc peptide. As shown in Figure 5.7 incubation of cell-
lysate containing wild-type 3xflag-c-myc-CHK2 for 15 minutes resulted in maximal 
binding of CHK2 to the Flag-sepharose beads (Figure 5.7 (A), top panel, lack of band, 
Lane 2 vs. 1). As shown in Figure 5.7, 3xFlag peptide eluates required an overnight 
incubation for a maximal binding of protein to the c-myc-sepharose beads (Figure 5.7 
(A) bottom panel, Lane 5 vs. 1). Overnight incubation with c-myc peptide was required 
for maximal elution of CHK2 (Figure 5.7 (A) bottom panel, Lane 9 vs. 6). Following 
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the above mentioned optimization procedure, c-myc peptide eluates from CHK2 wild-
type and empty vector control were resolved on a 12 % SDS-PAGE gel, silver stained 
and gel bands (that were present in positive pulldowns but absent in mock control) 
excised for tryptic digestion and analysis by MALDI-TOF-MS. As a control, gel slices 
that migrated at a similar molecular weight in the mock empty vector were also 
subjected to analysis by MALDI-TOF-MS to eliminate any false positive that might 
have arisen due to lack of silver staining of the empty control eluate (Figure 5.7 (B) 
arrows (i) and (ii) ). Analysis of gel band (i) resulted in the positive identification of 
CHK2 protein (Figure 5.7 (C). Analysis of gel band (ii) resulted in the positive 
identification of protein phosphatase 1B1 also known as PP2C beta (Figure 5.7 (D). 
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Figure 5.5 
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Figure 5.5 Ectopic transfection of Flag-c-myc dual-tagged wild-type CHK2, 
CHK2R145W, CHK2' 157T, CHI(2deICllOO and CHK2IflSAI368 
Expression vector (p3XFLAG-myc-CMVTM-26) encoding wild-type CHK2, 
CHK2 45'”, CHK2II57T, CHK2IflSAI368 or  CHK2deICII00 Ng) were transfected in 
MCF7 cells. The expressed proteins were examined by immunoblotting with anti- 
CHK2 antibody (A 12), anti-Flag (M2) and anti-c-myc (clone 4A6 or 9E10). 
Frameshift mutations in CHK2deICI 100 and CHK2IISA!368  result in premature stop 
codons so the c-myc epitope on the C-terminus of these constructs was truncated 
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Figure 5.6 Cross-linking of wild-type CHK2 
Expression vector (p3XFLAG-myc-CMVTM-26) encoding wild-type CHK2 (8p.g) 
was transfected in MCF7 cells. 24 hours post-transfection, the cells were incubated 
with incremental amounts of EGS cross-linker (Lanes 1-5) or DMSO control (Lane 
7). The expressed proteins were examined by immunoblotting with anti-CHK2 
antibody (A 12) whereas the expressed CHK2 monomer protein decreases with 
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Figure 5.7 Two-step purification of dual-tagged wild-type CHK2 and binding 
partners 
Expression vector (p3XFLAG-myc-CMVTM-26) encoding wild-type CHK2 or 
empty vector control (8tg) were transfected in A549 cells. 24 hours post 
transfection cell lysates were incubated with anti-flag sepharose beads and the flow 
through from the column taken at 0.25, 1, 1.5, 2, 2.5 and 3 hours to determine the 
degree of binding of CHK2 to the column. 
Top panel: Anti-flag immunoblot of degree of binding of bait wild-type CHK2 
protein with time shows that a 15 minute incubation results in maximal binding to 
the flag-sepharose-resin (Top panel, Lane 2 vs. 1). 
Bottom panel: Anti-flag immunoblot of 3xFlag-peptide elution from (A) shows that 
an overnight incubation results in maximal binding to the c-myc-sepharose-resin 
(Bottom panel, Lane 5 vs. I). Overnight incubation with c-myc peptide results in 
maximal elution of bait CHK2 protein (Bottom panel, Lane 9 vs. 6). 
Expression vector (p3XFLAG-myc-CMVTM-26) encoding wild-type CHK2 or 
empty vector control (8ig) were transfected in A549 cells. 24 hours post 
transfection the cell lysates were incubated with anti-flag sepharose beads for 30 
minutes followed by 3xFlag peptide competitive elution. The 3x-flag peptide 
eluates were incubated overnight with anti-c-myc resin and competitively eluted 
overnight with c-myc peptide. The protein eluates were resolved on a 12% SDS-
PAGE gel and silver-stained. Gel slices were excised from wild-type CHK2 and 
empty control eluates (i and ii arrows) 
MALDI-TOF-MS spectrum of gel slice (i), resulted in positive identification of 
CHK2 bait protein using MASCOT and Profound Search engines 
MALDI-TOF-MS spectrum of gel slice (ii), resulted in positive identification of 
protein phosphatase I B I (also known as PP2C beta) using MASCOT and Profound 
Search engines. 
5.5 Discussion 
Although most cases of classic Li-Fraumeni syndrome (LFS) and a subset of 
variant-LFS harbour germ-line mutations in p53, a small number of cases have 
mutations in CHK2 220,  The similar phenotype conferred by germ-line mutations in p53 
and CHK2, and the fact that tumours arising in CHK2-mutant family members may not 
carry somatic TP53 mutations, are consistent with CHK2 encoding a kinase responsible 
for the phosphorylation of p53 on Ser2° and its stabilization after DNA damage. 
The mutants analysed in this study fall under two catagories. Firstly, structural and 
include mutations in the fork-head associated domain (FHA) which are CHK2RI45W  and 
CIIK21I57T and secondly, frameshift mutations leading to the truncation within the 
catalytic kinase domain which are CI-1K2d1c 1100  and CHK2IA1368. 
This study has highlighted that the inherent instability of CHK2RI45W,  CHK2I SAI368 and 
CHK2deICI 100 when compared to wild-type and CHK2 57T was at the protein level and 
was partially blocked by addition of proteasome inhibitor MG132 in the case of 
CHK2' 141W  and CIIK2de1c1IOO but not CHK2jflAI368. In corroboration with this 
observation, transfected CHK2 RI45W  had a shorter half-life (approx. 2 hrs) when 
compared to the more stable wild-type CI-1K2 or CHK2" 17T (> 10 hrs). This study also 
demonstrated that CHK2RI45W  is hyperubiquitinated when compared to wild-type CHK2 
and the other mutants, as defined by one-strep precipitation and immunoblotting with 
anti-ubiquitin, thereby confirming that CHK2 is degraded in a ubiquitin-proteasome 
dependent manner and that CHK2RI41W  may be susceptible to increased levels of 
proteasome degradation when compared to wild-type CHK2. As indicated in Figure 5.8, 
CHK2RI45W and CHK2, 157T  are located on one face of the FHA 3 sandwich domain, 
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remote from the site of peptide binding. Ile 157  is located at the C-terminal end of the I 5-
36 loop, some 25 A distant from the pThr site, and is largely solvent exposed. Arg'45 is 
located on P5 and forms the core of a network of hydrogen bonding, nonpolar, and van 
der Waals interactions involving Asti 112  Trp' , and Glu'6' from adjacent f3 strands 3 
and 6 together with Phe147 located on J35 212 
' .> 
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Figure 5.8 Structure of CHK2 and Fork Head Associated Domainxhl 
In view of this structural information and the above findings it is plausible to conclude 
that the deleterious effects of the CHK2 45W mutation which result in a higher level of 
ubiquitination and shorter half-life when compared to wild-type CHK2 and CHK2II57T 
are a result of a disruption of the FHA domain folding. 
XII Figure 5.8: Bartek, J. and J. Lukas, Chkl and Chk2 kinases in checkpoint control and cancer. Cancer 
Cell, 2003. 3(5): p. 421-9. and Li, J., etal., Structural and functional versatility of the FHA 
domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mo! Cell, 2002. 9(5): p. 
1045-54. 
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Zhang and co-workers have demonstrated that downregulation of CHK2 kinase 
expression in response to cisplatin was at the protein level and the degradation of CHK2 
can be partially blocked by adding proteasome inhibitor MG132. The same authors 
conclude that proteasome inhibitors would be more potent when combined with 
cytotoxic agents such as cisplatin and MG132 for the killing of the H69 small cell lung 
cancer cells and A2780 ovarian cancer cells (wild-type CHK2)221. Such a dual pronged 
approach is likely, in theory, to have a significant approach in treatment of tumours 
bearing a wild-type CHK2 background but not necessarily for CHK2" "'-bearing
tumours since CHK2RI45W  cannot form a complex with p53 and both are defective in 
JR-induced p53 phosphorylation 222  It is therefore important to genetically screen 
patients for CHK2 background before proceeding with such a therapeutic approach. 
This study has also highlighted an interaction between CHK2 and protein 
phosphatase lB isoform 1 (PPM1B; previously named protein phosphatase 2C beta 
isoform PP2Cbeta). Dozier et al. have shown that CHK2 interacts with the B' 
regulatory subunit of protein phosphatase 2A (PP2A) and this interaction allows the 
association of the checkpoint kinase (whatever its state of phosphorylation) with the 
fully assembled PP2A holoenzyme. Moreover, the same authors show that CHK2 can 
phosphorylate B' and, in so doing, increase PP2A activity. However, a negative 
feedback loop enables PP2A to dephosphorylate and inactivate CHK2 223  In another 
study, Cheng and co-workers demonstrate that PP2C-like enzymes specifically 
dephosphorylate Cdc28p (the major budding yeast CDK) at residue Thr'69 and this 
dephosphorylation was inhibited by cyclin binding. The same authors showed that 
PP2C-like enzymes were the predominant human phosphatases acting on Thr'6° of Cdk2 
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(a downstream target of CHK2) in a HeLa cell extract, indicating that the substrate 
specificity of PP2Cs against Cdks is evolutionary conserved 224 
Although the identification of substrates of PP2C in vivo has been hindered by the 
absence of specific inhibitors, PP2C exhibits a 20-fold preference for phosphothreonine-
containing substrates compared with phosphoserine substrates in vitro 
225  and substrates 
of PP2C in vivo have been proposed to be phosphorylated on threonine residues 
226  The 
FHA domain of CHK2 appears to bind phosphothreonine-containing peptides in vitro 
212 Taken together, the results from these studies and the novel PP2C:CI-1K2 interaction 
presented in this study might highlight a trimeric complex composed of CHK2, Cdk2 
and PP2c. Under basal conditions, PP2C may serve to keep the CHK2 and Cdk2 kinases 
inactive and to CHK2 autophosphorylation impaired. In response to DNA damage, the 
buffering action of PP2C may be readily overcome allowing activation of CHK2 and 
Cdk2. 
Another possible function of the CHK2:PP2C interaction involves the downstream 
target of CHK2, namely p53. Ofek and co-workers have shown that PP2Cu 
overexpression specifically activates p53 and stimulates its transcriptional activity 
218 
The authors argue that PP2C might remove inhibitory phosphorylation sites in response 
to ionizing radiation thereby contributing to the DNA damage-induced stabilization of 
218 Therefore, the CHK2:PP2C interaction discovered in this study may act in 




6.0 	Preliminary data on novel interactions of p53 with rps3, a DNA 
repair enzyme and ANT a mitochondrial pore protein 
6.1 Introduction 
In addition to many external agents that produce repairable DNA lesions, normal 
processes such as oxidative phosphorylation, lipid peroxidation, single carbon 
metabolism, and DNA replication errors directly produce DNA damage and damaging 
agents. These changes in DNA base chemistry include such modifications as 
methylation, oxidation, deamination, or the complete loss of bases. The cell's major line 
of defense is provided by the base excision repair (BER) system 227  There are two main 
enzymes used, DNA glycosylases and AP (apurinic and apyrimidinic) endonucleases. 
The DNA glycosylase is used to break the 3-N glycosidic bond to create an AP site. The 
AP endonuclease recognizes this site and nicks the damaged DNA on the 5' side 
(upstream) of the AP site creating a free 3-OH. DNA polymerase, Pol I, extends the 
DNA from the free 3'-OH using its exonuclease activity to replace the nucleotide of the 
damaged base, as well as a few downstream, followed by sealing of the new DNA 
strand by DNA ligase. 
Besides its ability to induce cell-cycle arrest and apoptosis via sequence-specific 
transcriptional activity, p53 has also been shown to physically interact with the BER 
multiprotein pathway 228  Ref-1, also known as APE-i/Hap-i/APEX, is a DNA repair 
(AlP) endonuclease that plays a central role in the process of BER. Ref-1 functions by 
cleaving the DNA 5' to abasic sites, as well as to load DNA polymerase ' onto DNA 
229 The crystal structure of Ref-1 shows strong homology with two other DNA 
nucleases, DNase I from Bos tauri and exonuclease III from Escherichia coil 
230  In 
addition to its roles in BER, Ref-i was shown previously to activate the AP-1 
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heterodimeric fos-jun transcription complex by changing the redox state of its DNA-
binding-domain 231  Gaiddon and co-workers have shown that Ref-i interacts with p53 
in vitro and in vivo and overexpression of the former leads to increased ability of p53 to 
stimulate endogenous p21 and cyclin G expression 232  Moreover, Hanson and co-
workers have shown that Ref-i promotes tetramerization of p53 thereby enhancing p53 
binding to target DNA 233 
On the other hand, mutant p53 has recently been shown to interact with key 
proteins involved in the DNA repair mechanism of double stranded breaks (DSB5). 
Song and co-workers showed that novel gain-of-function oncogenic mutant p53 
R248w 
and p53R27311  interact with the nuclease Mreil and suppress the binding of the Mreii-
Rad5O-NBSi (MRN) complex to DSBs, leading to ATM activation 
234 
p53 exerts its apoptotic and cell-cycle effects in a transcription-independent 
manner in addition to transcription-dependent means. Some transcriptional products of 
p53 include Bcl-2-associated X protein (BAX), NADPH oxidase activator i (NOXA), 
p53 acetate-induced protein 1 (p53AIP1) and p53-upregulated modulator of apoptosis 
(PUMA) which act directly on mitochondria and induce apoptosis 
235-239  In addition, in 
some cell types, a fraction of stabilized p53 rapidly translocates to mitochondria in 
response to a death stimulus. Mihara and co-workers have shown that exogenous p53 
targets the mitochondria in p53 null cancer cells, and p53 was shown to be sufficient to 
launch apoptosis and suppress colony formation in a transcription-independent way. 
Moreover, endogenous mitochondrial p53 forms inhibitory complexes with anti-
apoptotic Bcl-X and Bcl-2 proteins, resulting in cytochrome c release from 
mitochondria, thereby contributing to apoptosis by direct signalling at the mitochondria 
and amplifying transcription-dependent apoptosis also mediated by p53 
240 
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The following preliminary data identify two potential p53-interactors that have a 
role in DNA repair and mitochondrial-dependent release of cytochrome C, namely 
ribosomal protein s3 and ADP/ATP translocase respectively. 
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6.2 	Ribosomal protein s3 and ATP/ADP translocase identified as 
new binding partners to p53 
DO-i immunoprecipitates of p53R75H-infected uninfected Spodoptera 
frugiperda were run on a 4-12% gradient gel (MOPS running buffer) and stained with 
colloidal blue stain. As shown in Figure 6.0 (A) low background was obtained in the 
empty vector (mock). All the visible bands in the gel were excised and subjected to 
analysis by LC-MS/MS., p53 was positively identified in all bands (data not shown) 
with the exception of the arrowed band Analysis of the arrowed band resulted in the 
identification of ATP/ADP translocase (ANT) (Figure 6.0 (B)) and ribosomal protein s3 
(rps3) (Figure 6.0 (C)). 
ANT is a component of the mitochondrial permeability transition pore (MPTP) 
which, in turn, is implicated in the release of pro-apoptotic factors such cytochrome C in 
response to intra or extra-cellular insults. ANT interacts with either Bax or Bcl-2, which 
influence ANT function in opposing manners. Bel-2 maintains the translocase activity at 
high levels, whereas Bax inhibits the translocase function of ANT leading to release of 
cytochrome c after MPTP opening 241  Since a fraction of p53 has been shown to localize 
with the mithochondria and specifically interact with Bcl-2 240  further analysis should be 
carried out to investigate the interaction identified in this study, particularly, to elucidate 
whether it is specific to wild-type (promoting transcription-independent apoptosis via 
MPTP opening) or mutant p53 (gain-of-function by preventing apoptosis via MPTP 
blockage and possibly aided by ANT). 
Alignment of human rps3 with human ref-i by ClustaiW protein alignment 
program revealed an identical GYSGV peptide motif in both proteins (Figure 6.01)). 
Interestingly the tyrosine residue in ref-i (also conserved in DNase I (Bos Taurus)) has 
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been shown to be implicated in binding to the scissile phosphate group, adjacent to the 
extra-helical base 230  Since Ref-i has been shown to bind and transcriptionally activate 
p53 and rps3 has been associated with DNA repair activity, these observations coupled 
with the identification of the GYSGV motif in rps3 and Ref-1, prompted an 
investigation to see whether rps3 could activate p53 in a similar fashion as Ref-1. A 
p2i-reporter dual luciferase assay was therefore employed. Briefly, H1299 cells were 
transfected with constant levels of p53 (50p.g/well) (Figure 6.0 (E) left panel) or empty 
vector (50tg/well) (Figure 6.0 (E) right panel) and incremental amounts of rps3 DNA 
(0-2500 ng). The p21-reporter levels were normalized with internal standard Renilla-
luciferase (cf Section 2.8.2). No significant effect on p53 transcriptional activity was 
observed following the addition of rps3. Furthermore no significant increase in p21 or 
BAX protein levels were observed following the titration of incremental amounts of 
rps3 (Figure 6.0 (F) left panel Lanes 1-4 vs. 5-12). Further studies should be performed 
to investigate whether an induction of base excistion repair (BER) by methyl 
methanesulfonate (MMS) activates p53 in an rps3 dependent way. 
Interestingly, apart from its role in the ribosome rps3 has been identified as an 
N-glycosylase that liberates the modified or nonconventional base from DNA forming 
in its place an apurinic/apyrimidinic (AP) site 242  Moreover, human rps3 interacts with 
BER enzymes N-glycosylase/AP lyase OGG1 promoting its activity and that of Ref-1. 
Since Ref-i has been shown to interact with p53 (cf Section 6.0), the finding presented 
in this preliminary data might suggest a mega-DNA-repair-complex including rps3-
OGGi-Ref-1-p53, which should be further elucidated. 
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Figure 6.0 Identification of rps3 and ANT binding to p53l&75H 
Colloidal blue stain of eluates from DO-i immunoprecipitated p53R175H 
infected Sf9 cells. Sf9 cells were infected with p53R175H baculovirus. Cells were 
harvested and lysed in Triton X-100 lysis buffer followed by DO-] precipitation 
and 3 sequential glycine (0.1 M, pH 2.5) elutions. All bands were excised for 
analysis by LC-MS/MS. All bands were p53 positive except for the one indicated 
with an arrow. 
and (C) CID MS/MS spectra of single peptides from ANT and rps3 respectively 
showing b and  series of fragmentation. 
Clustal W alignment of rps3 with REF 1 showing identity of GYSGV peptide in 
the two proteins. 
Dual luciferase p21-reporter assay. H 1299 cells (24 well plates) were 
transfected with p53 (50 pg) (left panel) or equivalent amount of empty vector 
(right panel), incremental amounts of rps3 (500-2500 jtg) , p2 1-consensus-
luciferase and rinella-luciferase. Levels of p21 luciferase were normalised with 
levels obtained from internal standard renilla-luciferase. 
H1299 cells were transfected with p53 (50 jig) (left panel) or equivalent amount 
of empty vector (right panel), incremental amounts of rps3 (0.021-2.5 jig). 24 hrs 




7.0 Conclusions and future perspectives 
In this thesis, primary focus was directed towards degradation of wild-type and 
mutant p53. Succinctly, and as illustrated in Figure 7.0, the following points were 
identified: 
Destabilizing, structural, missesense mutations in the DNA binding 
domain of p53 led to unfolding when compared to wild-type as defined 
by conformational antibodies. 
S 10 n-sheet mutant p53 1270A was hyperubiquitinated in vivo and in an in 
vitro translation assay which is MDM2 dependent. 
Mutant p53 interacted with a myriad of ribosomal proteins. 
Eefla bound specifically to mutant p53. 
The molecular chaperone interactomes; "chaperomes" of mutant and 
wild-type p53 differed in that wild-type p53 bound preferentially to 
MDM2, Hsp40 and CHIP while mutant p53 bound Hsp70, CHIP and 
Hsp40 (with higher affinity than wild-type). 
A novel isoform of Hsp90 lacking the N-terminus (Hsp90AN) and TCP-
1 beta (a chaperonin) were identified to specifically bind mutant p53. 
Wild-type p53 can be induced to bind to the Hsp90AN containing 
complex following the addition of Nutlin-3, 17-AAG. 
As a side project, wild-type and naturally occurring mutations of the CHK2 gene 
were investigated. The following three points were been identified: 
(1) CHK2RI45W  had a shorter half-life when compared to wild-type CHK2 and 
CHK2II 57T 
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	Protein phosphatase 1 B 1 (also known as PP2c beta) was identified as a 
binding partner of CHK2. 
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7.1 The mutant p53:MDM2:eefla interaction 
A specific interaction between eefl a and mutant p53 was identified in this study. 
Furthermore, in a recent proteomic study MDM2 was found to bind eefla without 
altering its translation function 140  Elevated levels of eefla have been found in primary 
human breast tissues 165  while high levels of MDM2 were found in a significant number 
of soft tissue sarcomas, osteosarcomas, gliomas and aggressive breast cancers 243-248  It 
would therefore be interesting to perform a screen on these tumour types, particularly 
breast cancer, to investigate any correlation between gene amplification of eefla and 
MDM2 and whether, a clinopathological significance exists for tumour progression 
(neoplasia) which is dependent on the p53:MDM2:eefla interaction. 
Biochemically, the interaction should be further characterised by knockdown of 
eefla by siRNA. Current research efforts in Cathy Abbot's laboratory are directed 
towards the stable knockdown of eefl a in breast cancer cell lines. Once available, these 
cells (should they be viable) will be a useful tool for elucidating the role of 
eefla:MDM2 in p53 degradation. 
Moreover since eefl a has been shown to interact with the Rptl lid protein of the 
proteasome 131  it would be interesting to investigate the possible role of eefla as a 
molecular chaperone that interacts with ubiquitinated p53 and directs the latter to the 
proteasome machinery for degradation. This study could be accomplished using specific 
mutant forms of eefla, namely eEF1AE2S6I(  that shows poor interaction with the 
proteasome and eEF1A' 56' which is hyperresistant to translation inhibitors but is more 
effective at eliminating damaged proteins 131 
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7.2 Mutant and wild-type p53 interaction with Hsp9OAN and p50Ic37 
In this study a specific interaction between Hsp90AN and mutant p53 was 
identified. Additionally, specific inhibitors designed for MDM2 and Hsp90, namely, 
Nutlin and 17-AAG appeared to enable WT p53 to form a complex with Hsp90AN. 
Current efforts in the laboratory are directed at disrupting the Hsp90AN:p53 complex by 
adding drugs that specifically inhibit the C-terminal ATPase activity of Hsp90 such as 
novobiocin. Briefly the experiment consists of transfecting H1299 cells with one-strep 
mutant and wildtype p53, following which the cells would be lysed and incubated with 
Novobiocin or excess ATP. The lysates would then be precipitated on strep-tactin 
columns and eluates immunoblotted for Hsp90AN, MDM2, Hsp70, Hsp90 and p5 0cdc37 
An siRNA approach to knockdown Hsp90AN could also be adopted and the effect of 
this silencing on ubiquitination of mutant/wild-type p53 ought to be investigated. A 
time-point experiment where cells are treated with 10 tM 17-AAG for incremental 
durations, i.e. 3, 10, 15, 30, 60 mins and 2, 5, 10 hours followed by analysis of 
Hsp90AN:p53 interaction would also be very informative. Treatment of cells for short 
periods of time would be enough to break hsp90 dependent complexes (including p53 
chaperomes) without degrading the various hsp90-dependent clients substantially 
(Grammatikakis personal communication). 
An interaction between p53 and the Hsp90 co-factor, p50 37 was also identified 
in this study. Grammatikakis' laboratory kindly supplied us with a GST-fusion 
construct 0f50cdc37  in which the GST moiety has been modified by mutagenesis so that 
it does not bind p53, chaperones or other proteins specifically (Grammatikakis personal 
communication). This will hopefully prove to be a useful tool in further assessing the 
50cdc37. Hsp90AN:p53 complex and its effect on p53 ubiquitinationldegradation. 
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Borek Votjesek's laboratory is currently preparing Hsp90AN specific antibodies 
for immunohistochemistry. These will be used to screen a wide array of primary human 
tumour samples (with p53 wild-type or mutant status) to assess the cellular sub-
localization of H5p90AN. Furthermore, Hsp90AN protein levels will also be screened in 
the same primary tumor samples. 
7.3 p53 interaction with rps3 
Ribosomal protein s3 (rps3) is a Janus-type protein with roles in polypeptide 
synthesis and DNA repair via the Base Excision repair pathway (BER). A specific 
interaction between rps3 and p53 was identified in this study. Recently work carried out 
by Deutsch's laboratory demonstrated that rps3 translocates from the cytoplasm to the 
nucleus following genotoxic stress. The translocation of rps3 is dependent on ERK1/2-
mediated phosphorylation of a threonine residue (T42) of rps3. Moreover, rps3 was 
shown to co-localize with 7,8-dihydro-8-oxoguanine residues in DNA lesions 
associated with BER 249  The rps3:p53 interaction should therefore be further 
investigated by observing the effect of specific rps3 knockdown by siRINA on BER and 
p53 activity in cells treated with BER inducing agents such as hydrogen peroxide and 
methyl methane sulphonate. 
The Ref-1, DNA repair protein, has been shown to interact with p53 in vitro and 
in vivo and overexpression of the former leads to increased ability of p53 to stimulate 
endogenous p2i and cyclin G expression 232  Ref-i has also been shown to activate the 
AP-1 heterodimeric fos-jun transcription complex by changing the redox state of its 
DNA-binding-domain 231  Current efforts in our laboratory are directed at elucidating 
186 
whether Ref-i has a similar effect on key cysteines within the DNA-binding domain 
that bind zinc and are important residues for p53 conformation. If this were the case and 
since Ref-i binds rps3 242  it would be interesting to investigate whether rps3 has any 
effect on altering the ability of Ref-1 to modify the redox state of target DNA-binding 
domains. 
Initial efforts to identify binding partners to rps3 by trypsin digestion of onestrep 
eluates obtained from cells transfected with onestrep rps3 have proved elusive due to 
low recovery yields. Current efforts are directed to scale up the amount of recovered 
proteins. 
In the post-genomic era, advances in tools and technologies have provided an 
excellent opportunity to better understand the complex nature of carcinogenesis. 
Interactomics is an emergent, exciting field of systems biology which is a shift from the 
so called reductionist paradigm and to quote Denis Noble it 
"is about putting together rather than taking apart, integration rather than 
reduction. It requires that we develop ways of thinking about integration that 
are rigorous as our reductionist programmes, but different. It means changing 
our philosophy, in the full sense of the term". 
In my modest opinion, the complexity of biological systems is better tackled by 
investigating multiple components simultaneously and collating data from different 
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